

## Self-Sustained Regulation or Self-Perpetuating Dysregulation: ROS-dependent HIF-YAP-Notch Signaling as a Double-Edged Sword on Stem Cell Physiology and Tumorigenesis

Chin-Lin Guo\*

Institute of Physics, Academia Sinica, Taipei, Taiwan

### **OPEN ACCESS**

#### Edited by:

Cheng Ming Chuong, University of Southern California, United States

#### Reviewed by:

Sayan Chakraborty, Institute of Molecular and Cell Biology (A\*STAR), Singapore Che-Chang Chang, Taipei Medical University, Taiwan

> \*Correspondence: Chin-Lin Guo guochin@phys.sinica.edu.tw

#### Specialty section:

This article was submitted to Stem Cell Research, a section of the journal Frontiers in Cell and Developmental Biology

> Received: 26 January 2022 Accepted: 29 April 2022 Published: 14 June 2022

#### Citation:

Guo C-L (2022) Self-Sustained Regulation or Self-Perpetuating Dysregulation: ROS-dependent HIF-YAP-Notch Signaling as a Double-Edged Sword on Stem Cell Physiology and Tumorigenesis. Front. Cell Dev. Biol. 10:862791. doi: 10.3389/fcell.2022.862791 Organ development, homeostasis, and repair often rely on bidirectional, self-organized cell-niche interactions, through which cells select cell fate, such as stem cell self-renewal and differentiation. The niche contains multiplexed chemical and mechanical factors. How cells interpret niche structural information such as the 3D topology of organs and integrate with multiplexed mechano-chemical signals is an open and active research field. Among all the niche factors, reactive oxygen species (ROS) have recently gained growing interest. Once considered harmful, ROS are now recognized as an important niche factor in the regulation of tissue mechanics and topology through, for example, the HIF-YAP-Notch signaling pathways. These pathways are not only involved in the regulation of stem cell physiology but also associated with inflammation, neurological disorder, aging, tumorigenesis, and the regulation of the immune checkpoint molecule PD-L1. Positive feedback circuits have been identified in the interplay of ROS and HIF-YAP-Notch signaling, leading to the possibility that under aberrant conditions, self-organized, ROS-dependent physiological regulations can be switched to self-perpetuating dysregulation, making ROS a double-edged sword at the interface of stem cell physiology and tumorigenesis. In this review, we discuss the recent findings on how ROS and tissue mechanics affect YAP-HIF-Notch-PD-L1 signaling, hoping that the knowledge can be used to design strategies for stem cell-based and ROS-targeting therapy and tissue engineering.

Keywords: ROS, HIF, YAP, notch, tissue mechanics

### INTRODUCTION

The ability to self-renew and the potential to differentiate, at least, into one type of mature cell have made stem cells an essential element at various stages of development and a promising tool for regenerative medicine. In general, the selection of stem cell fate depends on the interplay of intracellular signaling and extracellular niche factors. These niche factors can be specified into two groups: chemical molecular factors and physical-mechanical factors. The chemical factors include molecular oxygen ( $O_2$ ), reactive oxygen species (ROS), cell metabolites, morphogens, cytokines,

growth factors, and extracellular matrix (ECM) molecules. The physical factors contain passive elements (e.g., stiffness, plasticity, viscoelasticity, and 3D topology) and active mechanical forces (created by the cells and the surrounding environment, e.g., compression, stretching, hydrodynamic flow, hydrostatic pressure, and gravity). The responses to these mechanochemical factors, such as hypoxic responses, cell mechanotransduction, and ROS signaling, have gained growing interest, as accumulating lines of evidence indicated that their interplay is involved in the regulation of stem cell homeostasis and development. Furthermore, the interplay of these responses can lead to tumorigenesis in the presence of genomic instability and aberrant cell signaling. In particular, ROS, the byproduct of energy production that has once been considered harmful due to their ability to damage DNA and proteins, are now recognized as an important signaling factor for the regulation of pathways involved in stem cell physiology and tumor progression.

ROS can spontaneously be created in the natural environment. For living systems, ROS are mainly produced by the mitochondria (Murphy, 2009; Juan et al., 2021) and the membrane-bound NADPH oxidases (NOX) (Bedard and Krause, 2007; Ushio-Fukai, 2009). The production of ROS is primarily controlled by cell metabolism, O2, ROS themselves, and several signaling events of niche factors. Examples of these signaling events include the signaling for transforming growth factor- $\beta$  (TGF- $\beta$ ) (Hiraga et al., 2013; Yan et al., 2014; Watson et al., 2016; Yazaki et al., 2021), epidermal growth factor (EGF) (Azimi et al., 2017; Dustin et al., 2020), insulin (Besse-Patin and Estall, 2014), insulin-like growth factor-1 (IGF-1) (Kang et al., 2016), inflammatory and immune-regulatory cytokines such as angiotensin II and tumor necrosis factor-alpha (TNF-a) (Anilkumar et al., 2008), calcium (Gorlach et al., 2015; Feno et al., 2019), mechanotransduction (Sauer et al., 2008; Brandes et al., 2014a), integrin-ECM interactions (de Rezende et al., 2012; Eble and de Rezende, 2014), and cell-cell adhesions (Lim et al., 2008). Conversely, ROS modulate the activities of several cell fatedecision factors. These factors include the oxygen sensor hypoxiainducible factor (HIF) (Gerald et al., 2004; Saito et al., 2015; Kobayashi et al., 2021), the mechano-transducer Yes-associated protein (YAP) (Cho et al., 2020), the transducer for the cell differentiation transcription factor Notch, Notch intracellular domain (NICD) (Cai W.-X. et al., 2014; Caliceti et al., 2014; Yan et al., 2014; Sprouse et al., 2019; Yazaki et al., 2021), and the immune suppressor programmed death ligand-1 (PD-L1) (Bailly, 2020). Herein, HIF, YAP, and NICD act as a triad in stem cell physiology and tumorigenesis, as they can physically associate to influence each other (Qiang et al., 2012; Hu et al., 2014; Manderfield et al., 2015; Totaro et al., 2018a; Zhang X. et al., 2018; Engel-Pizcueta and Pujades, 2021). These associations include the coupling between the a subunits of HIF (i.e., HIF-1α/HIF-2α) and YAP (Xiang et al., 2015; Ma et al., 2017; Zhao et al., 2020) and the coupling between YAP and Notch (Totaro et al., 2018a). As for PD-L1, it is the ligand for the immune checkpoint receptors, programmed death-1 (PD-1) (Noman et al., 2014; Janse van Rensburg et al., 2018; Mansour et al., 2020). Recent studies indicate that the expression of PD-L1 is



coupled with YAP, Notch, and HIF-1alpha signaling to potentiate the immune suppression and evasion in the progression of tumors (Barsoum et al., 2014; Noman et al., 2014; Lee et al., 2017; Miao et al., 2017; Kim M. H. et al., 2018; Zhou et al., 2019; Wen et al., 2020). Through these couplings, negative and positive feedback regulations can likely be established in the ROSdependent YAP-HIF-Notch-(PD-L1) signaling axis, leading to a differential or switch-like behavior in the decision of cell fate. Thus, the interplay of hypoxic responses, ROS signaling, and cell mechanotransduction acts as a double-edged sword at the interface of organ development, tissue homeostasis, and cancer progression.

This review discusses how ROS are involved in the HIF, YAP, and Notch signaling pathways and how their coupling leads to positive or negative feedback for stem cell physiology and tumorigenesis. Given the complexity and the abundant molecular information in the coupling of ROS, HIF, YAP, Notch, PD-L1, and cell–ECM signaling, we organize this review in the following way. We define the signaling in ROS, HIF, YAP, Notch, PD-L1, cell–ECM, and cell mechanics as separated "modules" and introduce/add their coupling one after another. Along with the introduction of the couplings, we provide "module boxes" for each component as the supporting boxes, where detailed molecular-cellular information and references can be found. Figure 1 shows that we start with a brief discussion on HIF signaling in stem cell biology and tumors (Section I), followed by a section on the roles of ROS in HIF signaling (Section II). We then add the coupling of NOX-derived ROS (X-ROS) with the hypoxia (HIF)/cytokine/ECM signaling (Section III), followed by a section on the coupling of X-ROS with cell mechanics (Section IV), where we introduce the functional significance of cell mechanics and mechanotransduction. We then add the coupling of X-ROS/ hypoxia (HIF)/cytokine/ECM signaling with YAP signaling (Section V), followed by the final section where we discuss the integrated roles of X-ROS in the HIF/YAP/Notch/PD-L1 signaling (Section VI). In the module boxes, we discuss how molecular oxygen O2 regulates HIF stability (Module Box I), how ROS regulate HIF stability (Module Box II), and the X-ROS signaling (Module Box III). A modeling section is provided to discuss the phase diagram of ROS production quantitatively (Math Box I). How cell mechanics regulate organ size and shape (Module Box IV), the molecular transducers for cell mechanics and tissue topology (Module Box V), and the coupling of HIF/YAP/Notch triad with PD-L1 (Module Box VI) are also addressed.

### MAIN TEXT

## The Roles of HIF in Stem Cell Physiology and Tumorigenesis

For stem cell applications, one important issue is to maintain the full pluripotency of stem cells, which often requires hypoxia conditions. The major cellular responses to hypoxia are primarily mediated by hypoxia-inducible factors (HIFs) which act as transcription factors (Ezashi et al., 2005). HIFs consist of one  $\alpha$  subunit and one  $\beta$  subunit. While the  $\beta$  subunit is expressed constitutively, the a subunit is regulated in an O<sub>2</sub>- and ROSdependent manner (Module Boxes I and II). Under normoxia, the a subunits are continuously ubiquitinated and targeted to degradation. Under hypoxia, the a subunit is stabilized to form a dimer with the  $\beta$  subunit. By translocating to the nucleus, the dimer regulates downstream gene expression through binding to the hypoxia-responsive element (HRE) (Harris, 2002). Three forms of a subunits, HIF-1a, HIF-2a, and HIF-3a, have been identified (Wang et al., 1995; Tian et al., 1997; Xu and Li, 2021). While HIF-1α and HIF-2α are structurally similar and share functions to a certain extent, HIF-3a contains several splice variants, some of which act as dominant-negative inhibitors of HIF-1a or HIF-2a (Majmundar et al., 2010; Xu and Li, 2021). Under hypoxia, HIF-1a induces transcription of more than 60 genes to regulate responses such as erythropoiesis, angiogenesis, cell proliferation, cell survival, and glucose and iron metabolism. By doing so, HIF-1a promotes oxygen delivery to the hypoxic region (Semenza, 2003) and switches cells to glycolytic metabolism in response to hypoxia (Lee J.-W. et al., 2004).

HIF-1a also induces the expression of genes responsible for collagen deposition and stiffening (Gilkes et al., 2013), one of which is the gene for lysyl oxidase (LOX), the enzyme crosslinking ECM (Ji et al., 2013). In addition, through the altered metabolic flux that promotes the hydroxylation of collagen, HIF-1a renders the collagen matrix more resistant to degradation (Stegen et al., 2019). ECM stiffening, in turn, further promotes metabolic reprogramming (Ge et al., 2021). It has been shown that the altered cell metabolism can potentially activate HIF-1 (Halligan et al., 2016), leading to a positive feedback cycle. Consequently, niche stiffening and niche hypoxia can act synergistically through HIF-alpha to promote a bifurcated selection of cancer cell fate between the apoptotic and the aggressive phenotypes (Lv et al., 2017). In comparison, HIF-2a primarily regulates the expression of a panel of embryonic transcription factors and stemness-related genes such as OCT4, NANOG, and SOX2 (Covello et al., 2006; Gordan et al., 2007; Hu et al., 2014; Petruzzelli et al., 2014). Nevertheless, there are lines of evidence showing that HIF-2 $\alpha$ also participates in ECM remodeling. For example, HIF-2a induces the expression of LOX to accelerate ECM deposition and crosslinking in thyroid-associated orbitopathy (Hikage et al., 2019) and the expression of laminin receptor CD49f to facilitate stem cell development in germline stem cells (GSCs), where the expression of CD49f further enhances the expression of HIF-2a, thereby forming a positive feedback loop (Au et al., 2021) (Figure 2A).

The segregation of biological functions in HIF-1a and HIF-2a signaling makes it plausible that these two factors are stabilized under different hypoxia conditions (Hu et al., 2014). HIF-1a is stabilized under severe hypoxia (niche oxygen concentrations <2%, i.e., [O<sub>2</sub>] < 20 µM) (Hu et al., 2014). In comparison, HIF-2a is stabilized in a wider range of oxygen concentrations: from physiological oxygen concentrations ( $\sim 7\%$ , i.e.,  $[O_2] \sim 70 \mu$ M) to severely low oxygen concentrations (<2%) (Hu et al., 2014). The restricted requirement for HIF-1a stabilization indicates that the upregulation of glycolysis only occurs if the niche oxygen concentration is extremely low. As a result, the cells primarily use oxidative phosphorylation as the major energy production process. In contrast, the fact that HIF-2 $\alpha$  is stabilized in a wide range of oxygen concentrations indicates that the cells can robustly maintain certain behavior such as stemness over the fluctuation of niche oxygen, a requisite to sustain cell fate in a fluctuating microenvironment. Note that the restricted conditions for the stabilization of HIF-1a might no longer exist in tumors, allowing tumor cells to use anaerobic metabolism and elicit angiogenesis even with abundant O<sub>2</sub> in the niche (Semenza, 2003; Masoud and Li, 2015). In fact, both HIF-1a and HIF-2a play important roles in tumor angiogenesis (Krock et al., 2011), survival (Chen and Sang, 2016), proliferation (Hubbi and Semenza, 2015), immune evasion (Barsoum et al., 2014), plasticity (Terry et al., 2017), invasion and metastasis (Zhong et al., 1999), chemo- and radio-therapy resistance (Moeller et al., 2004; Rohwer and Cramer, 2011), pH regulation, and metabolism (Hulikova et al., 2013). These two factors also help the emergence and the maintenance of cancer stem cells



**FIGURE 2** (A) The differential responses of HIF-1a and HIF-2a to hypoxia conditions. See the main text for details. For all the figures hereafter, red lines indicate inhibition or downregulation, green lines indicate activation or upregulation, blue lines indicate physical association or recruitment, and black lines indicate the flow of the pathways, cascades, or reaction. (B) The factor inhibiting HIF (FIH) and prolyl hydroxylase domain-containing proteins (PHD) regulate HIF-1a and HIF-2a stability and transcriptional activity in an  $O_2$  concentration-dependent manner. See Module Box II for details. (C) ROS produced by the NOX and/or the mitochondria (Mito) exhibit both positive and negative effects on the regulation of HIF-a subunits. See Module Box III for details. (D) Stem cells exhibit differential phenotypical behavior and cytoskeletal dynamics in response to the changes in ROS concentrations. (E) The phase diagrams for the separation of ROS-mediated hypoxia responses (cyan) from normal hypoxia (pink) and/or normoxia (yellow) responses at (i) high and (ii) low cytochrome C densities corresponding to the high and low critical oxygen concentrations ([O<sub>2</sub>]<sub>c</sub>) for the onset of ROS-mediated hypoxia responses, respectively. See Math Box I for details. *K*<sub>m</sub> is the *K*<sub>m</sub> value of PHD for [O<sub>2</sub>] association (-230–250 µM (Fong and Takeda, 2008)). The *x*-axis indicates the cytoplasmic oxygen concentrations (in arbitrary units). Red \* and blue \* indicate tha ROS-mediated hypoxia responses can occur at low and high (even above *K*<sub>m</sub>) oxygen concentrations, respectively, as long as the free electron generation rate *y* is sufficiently high.

(CSCs). The detailed review can be found elsewhere (Heddleston et al., 2010; Schoning et al., 2017; Tong et al., 2018).

### The Roles of ROS in HIF Signaling

In vivo, the stability of HIF- $\alpha$  subunits is primarily regulated by molecular oxygen (Module Box I and **Figure 2B**) and ROS (Module Box II and **Figure 2C**). Once stabilized, HIF-1 $\alpha$ induces the transcription of multiple genes to boost glucose and energy metabolism (**Figure 2A**). Examples include genes for glucose transporters (e.g., GLUT1 and GLUT3), hexokinase (e.g., HK1 and HK2), pyruvate conversion [e.g., lactate dehydrogenase A (LDHA), pyruvate dehydrogenase kinase (PDK), pyruvate kinase M2 (PKM2), enolase 1 (ENO1)], and mitochondrial autophagy [e.g., BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3)], the detailed review of which can be found elsewhere (Semenza, 2010). The boost of glucose metabolism leads to the accumulation of intermediatestate metabolites, among which  $\alpha$ -ketoglutarate (Duran et al., 2013), fumarate (Yang et al., 2012), and succinate (Tannahill et al., 2013), the by-products in the Krebs cycle, can regulate the stability of HIF through the positive or negative modulation on the activity of prolyl hydroxylase domain-containing proteins (PHD), the primary enzyme to destabilize HIF- $\alpha$  subunits (Module Box I and Figure 2B). Consequently, positive and/or negative feedback might exist in the interdependent regulation of HIF-1 activity and metabolic reprogramming. Metabolic reprogramming also occurs in response to ECM stiffening (Ge et al., 2021) through a YAP/TAZ-mediate upregulation of GLUT1/GLUT3 (Cosset et al., 2017; Liu et al., 2020b). The resultant stabilization of HIF-1a can further stiffen ECM (Gilkes et al., 2013), leading to positive feedback in the coupling of hypoxia responses and ECM remodeling (Figure 2A). Moreover, the activity of HIF-1a is sensitive to stressful conditions such as hypercapnia (Selfridge et al., 2016), in which the HIF-1a activity is suppressed, and the host is at the risk of opportunistic infections (Cummins et al., 2014). In fact, tissue

hypoxia has a significant impact on inflammatory signaling pathways (Cummins et al., 2016), a part of which depends on ROS (Kohchi et al., 2009; Chen et al., 2016). The term "immunometabolism" for the interdependence of HIF activity and immunity has thus been proposed (Halligan et al., 2016). Besides, ROS is an essential factor for cell functioning and a deleterious factor for mutations, tumorigenesis, and cell apoptosis (Skonieczna et al., 2017). Such a dual role of ROS has been found in the selection of stem cell fate. For example, while ROS at moderately low levels are required to maintain stem cell quiescence and self-renewal, ROS at moderately high levels lead to stem cell proliferation and differentiation (Valle-Prieto and Conget, 2010; Burtenshaw et al., 2017). Consequently, oversuppressing ROS levels impairs stem-cell functioning, and overelevating ROS levels leads to stem-cell exhaustion, premature aging (senescence), and apoptosis (Schieber and Chandel, 2014) (Figure 2D).

ROS are primarily produced in mitochondria (Murphy, 2009; Juan et al., 2021), where free electrons in the electron transport chain (ETC) are leaked to bind to O<sub>2</sub> and form superoxide O<sub>2</sub>• (or O<sub>2</sub><sup>-</sup>) instead of the water molecule. In general, the yield of ROS depends on the generation rate of free electrons (set as Y) and the intracellular oxygen concentration (set as  $[O_2]_c$ ). To see how a free electron selects to become  $O_2^-$  rather than a water molecule, we set up a simple mathematical analysis (Math Box I) and obtained a critical cytoplasmic oxygen concentration  $[O_2]_c^*$ . For  $[O_2]_c$  above  $[O_2]_c^*$ , the free electrons predominantly select to become ROS. We also obtained the critical electron generation rate  $Y^*$ . For Y above  $Y^*$ , over 50% of the free electrons select to become ROS (Figure 2E). In the absence of any feedback or transcriptional regulation, the phase diagram in Figure 2C suggests three scenarios. The first occurs when the critical oxygen concentration  $[O_2]_c^*$  (depends on the density of cytochrome c) is above the  $K_m$  of value of PHD for  $[O_2]c$ association (Figure 2E(i)), where PHD is the primary enzyme to destabilize HIF alpha subunits (Module Box I and Figure 2B). For this case, there is a region,  $K_m \leq [O_2]_c \leq [O_2]_c^*$ , in which PHD promotes the degradation of HIF-a subunits through the association with  $O_2$  and below which (i.e.,  $[O_2]_c < K_m$ ) HIF- $\alpha$ subunits are stabilized. When  $[O_2]_c > [O_2]_c^*$ , PHD is deactivated by ROS through, for example, cysteine oxidation (Module Box II and Figure 2C), and hence, HIF-a subunits are stabilized. Such a scenario leads to a "pathological" hypoxia response under conditions; in other words, hyperoxia the oxygen concentration is above normoxia, but HIF signaling is activated. The second scenario occurs when  $[O_2]_c^*$  is less than  $K_m$  (Figure 2E(ii)). In this case, PHD is always deactivated by ROS even for  $[O_2]_c > K_m$ , the region where PHD is supposed to promote the degradation of HIF-a subunits. This scenario allows cells to maintain HIF signaling over a wide range of niche oxygen concentrations, which might be used for robust control of stem cell fate or for aberrant cellular behavior (such as tumorigenesis and cancer stemness). The third is that ROS-mediated hypoxia response can always occur at extremely low and high oxygen concentrations (Figure 2E, red \* and blue \*, respectively), as long as the yield of free electrons by cell metabolism is sufficiently high (as in the case of tumor or inflammation). This scenario might contribute to the pathological hypoxia responses under normoxia or hyperoxia conditions.

The fact that not only O<sub>2</sub>, but also ROS serve as a HIF regulator might be rationalized by the observation that hypoxia responses, such as those mediated by HIF-2 $\alpha$ , are often required for the maintenance of stemness in stem cells (Ezashi et al., 2005; Covello et al., 2006; Keith and Simon, 2007; Mazumdar et al., 2009; Pervaiz et al., 2009; Heddleston et al., 2010; Abdollahi et al., 2011; Hu et al., 2014; Petruzzelli et al., 2014). Having ROS as an additional regulator might help cells to maintain a robust control on stemness against the niche oxygen fluctuation. The ability to use ROS as an additional regulator allows cells to maintain a robust control on stemness against the niche oxygen fluctuation. Regarding the interplay of ROS and hypoxia responses, we should point out that there are both positive and negative feedback regulations. To maximize the usage of O2 as the major energy resources, the yield of free electrons from cell metabolism must fit the availability of O2 in the niche. A high yield of free electrons demands more O2 from the niche. Using the leakage of electrons into ROS as a signal, this demand evokes hypoxia responses, as one consequence of HIF-1a signaling is to induce angiogenesis (Krock et al., 2011) which can enhance O2 delivery to the niche. Enhanced delivery of O2, however, might not cope with the demand of removing abundant free electrons but instead produce more ROS. In addition, hypoxia responses include upregulating the expression of oxygen carriers and glycolytic enzymes (Hu et al., 2014). Such effects lead to higher intracellular oxygen concentrations (by the abundance of carriers) and larger free-electron generation rates (by excessive glycolysis), hence creating a positive feedback loop to couple sustained ROS production and hypoxia responses into a vicious cycle. Fortunately, prolonged HIF-1a signaling increases the expression of ROS scavengers, prolyl hydroxylase domaincontaining protein 2 (PHD2), and the factor inhibiting HIF 1 (FIH-1), which promote HIF-1a degradation (Kobayashi et al., 2021) and cease HIF signaling as negative feedback control.

The existence of positive and negative feedback provides a possibility of bifurcation and suggests that ROS signaling can be a double-edged sword (Saito et al., 2015; Di Meo et al., 2016). Under normal conditions, cells use the multiplex versatility of ROS-mediated hypoxia responses to adapt to or cope with niche fluctuations (Pervaiz et al., 2009; Valle-Prieto and Conget, 2010), thereby maintaining stem cell physiology and cell fate in a robust manner. In the abnormal situations such as tumorigenesis, tumor cells take advantage of ROS-mediated hypoxia responses to promote cancer stemness, invasiveness, drug resistance, and immune evasion (Keith and Simon, 2007; Mazumdar et al., 2009; Heddleston et al., 2010; Barsoum et al., 2014; Peng and Liu, 2015; Aponte and Caicedo, 2017; Schoning et al., 2017; Yeo et al., 2017; Tong et al., 2018). ROS can also cause stem cell exhaustion and premature aging (Turrens, 2003; Schieber and Chandel, 2014; De Gaetano et al., 2021) (Figure 2D). The onset of these physiological and pathological processes is certainly cell- and tissue-context dependent and could be differential or switch-like. In fact, switch-like behavior with a multi-stability has been reported in the ROS regulation of human cells (Huang JH. et al., 2021). Elucidating how these



processes occur requires a molecular-cellular understanding of the interplay between ROS and other signaling pathways.

## The Coupling of NOX-Derived ROS (X-ROS) With Hypoxia/Cytokine/ECM Signaling

Apparently, molecular oxygen is not the only niche factor regulating stem cell physiology. Other factors include ECM molecules and cytokines such as TGF $\beta$ 1, bone morphogenic protein (BMP), angiotensin II (Ang II), platelet-derived growth factor (PDGF), EGF, and IGF-1. Similarly, mitochondria are the only source of producing ROS. Other sources include membrane-bound NADPH oxidases (NOX) (Bedard and Krause, 2007), cytochrome p450 (Veith and Moorthy, 2018), xanthine oxidase (XO) (Battelli et al., 2016b; a), and nitric oxide synthase (NOS) (Wilkinson-Berka et al., 2013; Di Meo et al., 2016). Among them, NOX are known to regulate the differentiation and self-renewal of stem cells and potentiate the self-renewal, metastasis, and drug resistance of CSCs through, for example, Notch, mitogen-activated protein kinases (MAPKs, including Erk1/2, Jun N-terminal kinase (JNK), and p38 kinase), and phosphatidyl-inositol-3-kinase- (PI3K-) AKT signaling (Skonieczna et al., 2017). Crosstalk between NOX and the signaling of TGF $\beta$ 1 (Ning et al., 2002), BMP (Sanchez-De-Diego et al., 2019), Ang II (Nguyen Dinh Cat et al., 2013), PDGF (Al-Eisa and Dhaunsi, 2017), EGF (Weng et al., 2018), and IGF-1 (Xi et al., 2013; Kang et al., 2016) has also been reported and/or reviewed. Moreover, NOX potentiate the interaction between ECM and cell surface receptors such as integrin  $\beta$ 1 (Heo and Lee, 2011), thereby facilitating cell adhesion and migration, particularly in the presence of niche cytokine factors such as IGF-1 (Chiarugi et al., 2003; Meng et al., 2008; Heo and Lee, 2011; Xi et al., 2013).

NOX can produce ROS in the extracellular space (e.g., the niche) and inside the cells. Seven members of NOX have been identified, including NOX1-5 and dual oxidase 1-2 (Duox1-2), each of which has its own NOX gp91<sup>phox</sup> homolog (Brown and Griendling, 2009; Brandes et al., 2014a; b; Fukai and Ushio-Fukai, 2020) (Module Box III and Figure 3A). The ROS produced by NOX in the extracellular space can enter or regulate nearby cells as a paracrine signal through ion exchangers and ion channels, such as anion exchange protein 2 (AEC2) (Ghio et al., 2003) and epithelial sodium channels (ENaC) (Helms et al., 2008; Liu et al., 2016b) (Figures 3B,C). Alternatively, they can liberate latent cytokines stored in the ECM reservoirs, such as TGF-B1 (Watson et al., 2016), leading to a systemic niche remodeling. On the contrary, the ROS produced in the cell can serve as an autonomous signal to induce oxidative stress (Schieber and Chandel, 2014) or hypoxia responses (e.g., through inactivating PHD to elicit HIF-1a/HIF-2a signaling (Figure 2C)). In turn, hypoxia responses mediated by HIF-1a signaling can upregulate the expression of NOX (e.g., NOX4 (Diebold et al., 2010)) and PHD (Kobayashi et al., 2021) (Figure 3B). These lines of evidence suggest that both positive and negative feedback regulations exist in the axis of NOX-ROS-HIF signaling and that NOX act both upstream and downstream of the HIF signaling.

Beyond the HIF-mediated regulation on the expression level, the activities of NOX are modulated by the assembly and the posttranslational modifications (PTMs) of their cytoplasmic and membrane subunits. In fact, almost all NOX subunits are subject to functional-relevant PTMs. Such regulation is under the crosstalk with cytokine signaling (e.g., IGF-1, TGF-β1, EGF, and PDGF signaling) and integrin/ECM signaling (including those involved in cell mechanotransduction (Brandes et al., 2014a), cell adhesion (Schroder, 2014), and cell migration (Brown and Griendling, 2009)). Further, these signaling activities are reciprocally modulated by ROS (Ning et al., 2002; Chiarugi et al., 2003; Ali et al., 2006; Block et al., 2008; Meng et al., 2008; Heo and Lee, 2011; Touyz and Briones, 2011; Xi et al., 2013; Brandes et al., 2014a; Jiang et al., 2014; Yan et al., 2014; Gau and Roy, 2018; Pietruczuk et al., 2019; Fukai and Ushio-Fukai, 2020). In the presence of cooperative or synergistic coupling in the NOX/cytokine/ECM signaling, a bistable or multi-stable switch might be established to potentiate the selection of cell fate, as observed in the regulation of ROS (Huang JH. et al., 2021). This scenario is likely to occur in the processes involving NOX1-2 and NOX4, in that NOX2 and NOX4 are reported to involve in stem cell differentiation and self-renewal, and NOX1-2 and NOX4 are found to potentiate CSC growth, survival, and drug resistance (Brandes et al., 2014b; Skonieczna et al., 2017). The regulations of NOX mainly occur through these serine/threonine phosphorylation (NOX1-3) and tyrosine phosphorylation (NOX4) (Rastogi et al., 2016; Skonieczna et al., 2017). In comparison, the regulation of NOX5 and Duox1-2 primarily depends on calcium. This difference is correlated with the fact that most cancers have dysregulated kinase/phosphatase activities. Other than cancers, NOX-derived ROS correlate with diseases such as cardiomyopathies (Prosser et al., 2011; Kerr et al., 2015). The term "X-ROS" has thus been invented to

describe the rapid and localized mechano-chemical signaling elicited by "NOX-derived ROS" (Prosser et al., 2011). A brief review of the regulation of NOX 1-4 and a short discussion on how they are coupled with cytokine and ECM signaling can be found in Module Box III.

One example of positive coupling in X-ROS/cytokine/ECM signaling is the potential feedback amplification along the NOX2-ROS-Ca<sup>2+</sup>-protein kinase C (PKC) signaling axis (Module Box III and Figure 3C). Another is the NOX4-ROS-HIF-IGF-1 signaling, which occurs through the clustering of NOX4, steroid receptor coactivator (Src) kinase, Src homology 2- (SH2-) domaincontaining protein tyrosine phosphatase (SHP) substrate-1 (SHPS-1), growth factor receptor-bound protein 2 (Grb2), integrin-associated protein (IAP), and growth factor receptors such as IGF-1 receptor (IGF-1R) (Module Box III and Figure 3D). Among them, IAP is a transmembrane protein associated with several integrins. The association of IGF-1R with IAP thus enables the crosstalk between IGF-1R and ECM/integrin signaling, thereby coupling ROS signaling and growth factor stimulation with cell-ECM adhesion and cell migration (Maile et al., 2003). To add more systemic niche effects, NOX4-derived ROS can induce HIF-1a signaling (e.g., through downregulating the PHD activity (Xu and Li, 2021), which in turn upregulates the expressions of NOX4 (Diebold et al., 2010) and IGF-1 (Poon et al., 2009; Prabhakar and Semenza, 2012; Huang et al., 2017), leading to autonomous (through NOX and IGF-1) and non-autonomous effects (through IGF-1 acting on neighboring cells) in X-ROS-HIF-IGF-1 signaling (Figure 3D).

The association of NOX4 and Src kinase within the SHPS-1 scaffold allows Src kinase to phosphorylate NOX4 and enhance ROS production (Xi et al., 2013). Reciprocally, ROS target and oxidize the cysteine residues at the catalytic domain of Src kinase, thereby activating the kinase (Giannoni et al., 2010; Ray et al., 2012; Xu et al., 2017; Heppner et al., 2018; Dustin et al., 2020; Heppner, 2021). Such mutual interplay leads to localized feedback amplification in IGF-1 and integrin/ECM signaling. A detailed review of redox regulation on, for example, IGF-1 signaling can be found elsewhere (Lennicke and Cocheme, 2021a; Lennicke and Cocheme, 2021b). Clearly, with the abundance of cysteine residues in most signaling molecules, Src kinase is not the only substrate sensitive to ROS. The MAPKs (including JNK (Santabarbara-Ruiz et al., 2015), Erk (Aikawa et al., 1997), p38 kinase (Kulisz et al., 2002; Emerling et al., 2005; Lee et al., 2012; Santabarbara-Ruiz et al., 2015), and big MAP kinase (BMK1/ Erk5) (Abe et al., 1996), the Ca<sup>2+</sup>/calmodulin-dependent kinase 2 (CaMK2) (Basu et al., 2019), the cGMP-dependent protein kinase or protein kinase G (PKG), the PI3K/AKT (Ray et al., 2012; Koundouros and Poulogiannis, 2018), the PKC (Gong et al., 2015; Steinberg, 2015), the cAMP-dependent protein kinase (PKA (Andre et al., 2013)), and the focal adhesion kinase (FAK) (Ben Mahdi et al., 2000) are redox sensitive and subject to activation by ROS. In parallel, protein serine/threonine phosphatases (PPP, including PP1 (Kim et al., 2015), PP2A (Low et al., 2014; Raman and Pervaiz, 2019), and PP2C-like partner of PIX 2 (POPX2 (Kim P. R. et al., 2020))), and protein tyrosine phosphatases (PTP), including PTP1B, the low

molecular weight PTP (LMW-PTP, the major PTP for FAK) (Chiarugi et al., 2003), PTEN (Ray et al., 2012), SHP-2 (Chattopadhyay et al., 2017), and cdc25C (Rudolph, 2005; Seth and Rudolph, 2006; Han et al., 2018)) are also redoxsensitive and can be inhibited by oxidation. Through the ROSmediated modulation of the kinase and phosphatase activity and the reciprocal phosphorylation-dependent ROS production, it is possible to have positive or negative feedback loops in the ROSdependent cytokine/ECM signaling. Moreover, the feedback regulation on the expression levels has been reported. For example, ROS-activated p38 kinase and Erk1/2, two key kinases involved in cytokine signaling, can enhance the expressions of NOX (e.g., NOX4 (Diebold et al., 2010)) and the nuclear translocation of HIF-1a (Richard et al., 1999; Sodhi et al., 2000; Flugel et al., 2007). Nuclear HIF-1a, in turn, promotes the expression of seven in absentia homolog 2 (SIAH2), one of the enzymes targeting PHDs for ubiquitin-mediated proteasome degradation (Xu and Li, 2021), in a PI3K/AKT-dependent manner (Koundouros and Poulogiannis, 2018; Perillo et al., 2020). Src and p38 kinases can further phosphorylate and activate SIAH2 (Khurana et al., 2006; Sarkar et al., 2012), thereby forming the positive feedback amplification in HIF-1 signaling (Figures 2B, 3C). In addition, HIF-1a can induce the deposition and stiffening of collagen (Gilkes et al., 2013), and ROS can upregulate the expression of integrins and ECM molecules such as laminin (Liu J. et al., 2016) and fibronectin (Lee H. B. et al., 2004). These effects reinforce the ligand-receptor interactions in the ROS-modulated cytokine and ECM signaling (Lamari et al., 2007; Liu J. et al., 2016).

The preferential coupling of NOX4 with protein tyrosine kinases (PTKs) raises an important issue in stem cell biology. From an evolutionary point of view, PTKs have a specific relation with ROS. PTKS were primarily present in multicellular organisms during the episodes of increasing atmospheric O<sub>2</sub> concentrations, which drove the use of O<sub>2</sub> as the major energy resource in multicellular organisms (Dustin et al., 2020). The emergence of NOX in multicellular organisms had evolved at the same time (Kawahara et al., 2007; Holmstrom and Finkel, 2014). Thus, it is reasonable that PTKs are related to cell differentiation and functionalization in multicellular organisms (thus linked to stem cell homeostasis) (Dustin et al., 2020) and that NOX are coupled with RTKs in oxidative phosphorylation, metabolism, and tissue remodeling, as in the case of NOX4 (e.g., through Poldip2, TGFβ, and IGF-1/insulin signaling). In fact, PTKs have been recognized as a major target for clinical treatments (i.e., through tyrosine kinase inhibitors (TKI)) of cancers (Zhang et al., 2009; Dustin et al., 2020). Likewise, NOX have been used as a target for the treatments of, for example, thrombosis, osteoarthritis, diabetes-related complications, stroke, cancers, and pulmonary fibrosis (Bonner and Arbiser, 2012; Hecker et al., 2012; Violi and Pignatelli, 2014; Morel et al., 2015; Zhang et al., 2016; Peng et al., 2019). A HIF-1a/NOX4 signal pathway has been identified to induce drug and radiation resistance in ovarian cancer (Liu W. J. et al., 2021). It would be interesting to investigate whether a combinatory target therapy on NOX and PTKs provides additive or synergistic benefits on diseases such as cancer and systemic diseases.

# The Coupling of X-ROS Signaling With Cell Mechanics

Besides cytokine/ECM signaling, other feedback amplifications in ROS responses include the mitochondria-dependent, ROSinduced ROS release, and the mitochondria-mediated crosstalk between ROS and the calcium flux, a detailed review of which can be found elsewhere (Zorov et al., 2014; Gorlach et al., 2015; Javadov, 2015; Feno et al., 2019). Herein, we focus on the coupling of NOX with cell mechanics and mechanotransduction, an emerging issue in the fields of stem cell research, cell therapy, wound healing, and cancer (Paszek et al., 2005; Kono et al., 2012; Liu et al., 2020a; Wilkinson and Hardman, 2020; Bergert et al., 2021; Hayward et al., 2021). In fact, a great deal of interest has recently been raised in the roles of cell mechanics in the key cellular processes, such as proliferation, cell death, cell differentiation, and cell migration (Chen et al., 1997; Horowitz et al., 1999; Lecuit and Lenne, 2007; Settleman and Baum, 2008; Grosberg et al., 2011), and the maintenance of stem cell pluripotency (Discher et al., 2009; Jaalouk and Lammerding, 2009; Mammoto and Ingber, 2009; Wozniak and Chen, 2009). These key processes often involve molecular-cellular interactions at the boundaries, ranging from the membrane of a single cell to the interfaces between cells and between cells and ECM. Examples include epithelial-mesenchymal interaction (EMI) in the hair follicle (Sick et al., 2006) and tooth (Mammoto et al., 2011) formation, EMI in wound healing (Chong et al., 2009; Seltana et al., 2010), endothelial cell-pericyte interaction in angiogenesis (Gerhardt and Betsholtz, 2003), and endothelial cell-hepatocyte interaction in liver development and regeneration (Inamori et al., 2009). In these examples, the importance of cell mechanics is manifested in the ability of cells to control their size and shape (i.e., 3D topology and geometry) at the interacting boundaries, which in turn profoundly influence the binary decision of cells, for example, to proliferate or differentiate (Folkman and Moscona, 1978; Spiegelman and Ginty, 1983; Piccolo et al., 2014). In line, recent experiments have shown that the fate of stem cells (e.g., self-renewal and differentiation) and the development of organs (such as branching morphogenesis in tubular organs) can be controlled by engineered geometries on the cell-cell and cell-ECM interacting boundaries (Chen et al., 1997; Nelson et al., 2006; Gomez et al., 2010; Silver et al., 2020). Conversely, abnormality or failure in the control of cell size and shape at the interacting boundaries is often found in diseases such as organ malformation, atherosclerosis, cancer, and tumor invasion (Chen et al., 1997; Paszek et al., 2005; Nelson et al., 2006), and cancerassociated fibroblast- (CAF-) aided initiation and maintenance of cancer stemness (Chen et al., 2014). A conceptual discussion on how mechanics contribute to the regulation of cell/organ size and shape can be found in Module Box IV. Reviews on the details of mechano-sensing can also be found elsewhere (Cai et al., 2021).

From the molecular signaling perspective, X-ROS and cell mechanics act both upstream and downstream of each other. This reciprocal coupling occurs through the cytoskeletal dynamics. On the one hand, X-ROS can activate Ras-related C3 botulinum toxin substrate 1 (Rac1) through, for example, the X-ROS-Ca<sup>2+</sup>-PKC



compartmentalization. Green texts indicate activation. (D) Merlin, angiomotin (AMOT), kidney and brain expressed protein (KIBRA), and protein tyrosine phosphatase non-receptor type 14 (PTPN14) act with the Hippo complex and cytoskeletons to regulate the phosphorylation, sequestration, compartmentalization, and degradation of YAP in a ROS-dependent manner. See Module Box V for details. (E) The ECM components and mechanical properties can regulate YAP signaling in a self-perpetuating manner. See Main Text and Module Box V for details.

coupling (Module Box IV and **Figure 3C**), and Ras homolog family member A (RhoA), through, for example, cysteine oxidization on the Rho GEF ARHGEF1 (MacKay et al., 2017) (Module Box IV and **Figure 3D**), by which they promote actin

filament polymerization and actomyosin contractility. X-ROSmediated cysteine oxidization also enables the association of Ras GTPase-activating-like protein or IQ motif-containing GTPase activating protein 1 (IQGAP1) with NOX2 and cytokine

Guo

receptors such as VEGF receptor (VEGFR) at the lamellipodial leading front of migrating cells (Ikeda et al., 2005; Kaplan et al., 2011) (Figure 4A). IQGAP1 is a scaffold protein that binds to microtubule plus-end binding proteins such as cytoplasmic linker associated protein 2 (CLASP2), YAP, and the regulators of YAP in the Hippo pathway, MST2, and LATS1 (Watanabe et al., 2009; Sayedyahossein et al., 2016; Quinn et al., 2021) (Module Box IV and Figure 4A). As a result, X-ROS signaling influences cell mechanics by modulating cytoskeletal dynamics and the distribution of mechano-transducers such as YAP. On the other hand, actin enhances NOX-mediated ROS production, and an actin-binding site has been identified on the subunit of NOX2, p47<sup>phox</sup> (Tamura et al., 2006) (Module Box III). p47<sup>phox</sup> is redox-sensitive, and sequential phosphorylation and S-glutathionylation of  $p47^{phox}$  leads to sustained  $O_2^{-1}$ production (Nagarkoti et al., 2018). These lines of evidence suggest a self-perpetuating amplification of the ROS-dependent cytokine/ECM signaling and cytoskeletal dynamics.

The effect of ROS on cytoskeletal dynamics appears to depend on the ROS levels. It has been shown that ROS at low (physiologically relevant) levels promote actin filament polymerization, stress fiber assembly, and microtubule selforganization, yet ROS at high levels compromise these processes (Khairallah et al., 2012; Xu et al., 2017; Loehr et al., 2018) (Figure 2D). The explicit mechanisms remain elusive (Wilson and Gonzalez-Billault, 2015). To date, the most wellstudied example of the coupling of NOX-ROS and cell mechanics microtubule-dependent X-ROS the signaling in is cardiomyocytes and skeletal muscle cells (Prosser et al., 2011; Prosser et al., 2013; Kerr et al., 2015; Limbu et al., 2015; Robison et al., 2016; Caporizzo et al., 2018; Chen et al., 2018; Caporizzo et al., 2019; Scarborough et al., 2021; Uchida et al., 2021) (Module Box IV). With the interdependence between cytoskeletal dynamics and X-ROS signaling, it is plausible that X-ROS signaling is sensitive to the mechanical modulation in cell morphogenesis and acts in part as a mechano-transducer. The integration of these effects can lead to a self-perpetuated amplification of the cellular mechanical responses, which might serve as a switch for the selection of stem cell fate (see examples in Module Box IV).

### The Coupling of X-ROS-Hypoxia/Cytokine/ ECM Signaling With YAP Signaling

One goal of cell/tissue mechanics is to shape organs and tissues into the proper form. In this process, what is needed is the control over the proliferation and differentiation of stem cells and tissuespecific progenitor cells. The fundamental question is how these cells know when and where to stop growing after the organ reaches a certain size and topology. In principle, the growth control should arise from a proper balance of three cellular processes, namely, cell division, cell differentiation, and programmed cell death (apoptosis), in a time- and spacedependent manner. The classical "chemical-driven" view on the control of organ size and topology was started by Alan Turing's famous work on the dynamic instability of interacting morphogens (Turing, 1952) and is amplified by the focus of molecular biology and genetics on regulatory mechanisms implemented by diffusive molecules. However, attempts to create organ-scale tissues by diffusive morphogens have limited success. Indeed, if organ pattern formation relies on chemical gradients only, it would be impossible to explain several remarkable examples of ordered proliferation, differentiation, and self-organization of the entire organ spontaneously emerging in vitro from naive cells cultured in media saturated with mitogens and growth factors (Sasai, 2013). Using soluble factors alone also makes it difficult to realize how fluctuating microenvironments can robustly template cell behavior in time and space with micrometer accuracy (Huang and Ingber, 1999; Discher et al., 2009). It appears that a "mechanics-driven," non-autonomous effect must exist; in other words, the tissue is endowed with a capacity to inform individual cells with certain "structure-code messengers" about its size and entire topology (Nelson et al., 2006; Piccolo et al., 2014), by which a long-range regulation can be imposed on individual cells (Guo et al., 2012), guiding them to shape the tissue in synchrony with other cells.

The transcriptional coactivators, YAP/TAZ, which boost organ growth and are suppressed by the Hippo complex (Module Box V and Figure 4B), are likely to be the "structure-code messengers" in organ development, homeostasis, repair, and tumorigenesis (Wang et al., 2009; Li et al., 2010; Lian et al., 2010; Zhao et al., 2010a; Dupont et al., 2011; Yu et al., 2015; Panciera et al., 2017). The activity of YAP/ TAZ is mainly regulated through PTMs (e.g., serine/threonine and tyrosine phosphorylation and dephosphorylation, and ubiquitination), sequestration, and compartmentalization (Figure 4C). The effectors modulating the PTMs of YAP include the Hippo pathway components such as MST1/2, SAV1, LATS1/2, MOB1, MAP4Ks, and STK25, tyrosine kinases such as Src kinase, the E3 ubiquitin ligase  $SCF^{\beta-TrCP}$ , protein phosphatase (PP), and protein tyrosine phosphatase (PTP) (Module Box V). We should point out that the consequences of serine/threonine phosphorylation and tyrosine phosphorylation of YAP are different. While the serine/threonine phosphorylation of YAP promotes YAP sequestration, compartmentalization, or ubiquitination, the tyrosine phosphorylation of YAP promotes YAP nuclear translocation and signaling (Rosenbluh et al., 2012; Smoot et al., 2018; Sugihara et al., 2018) (Figure 4C). For the sequestration of YAP, the major adaptors and scaffold molecules include 14-3-3, a-catenin, Dishevelled (DVL), angiomotin (AMOT), IQGAP1, kidney and brain expressed protein (KIBRA), Merlin, Expanded (Ex), protein tyrosine phosphatase non-receptor type 14 (PTPN14), and Switch/Sucrose non-fermentable (SWI/SNF) (Module Box V and Figures 4C,D). Among them, the association of YAP with AMOT in the cytoplasm is under competition with actin filaments, hence linking cytoskeletal dynamics to YAP regulation (Mana-Capelli et al., 2014) (Module Box V and Figures 4C,D). Likewise, in the nucleus, polymerized nuclear actin filaments (induced by, e.g., the exposure of cells to stiff ECM) bind to SWI/SNF and relieve its sequestration of YAP (Chang et al., 2018). Cell mechanics are also linked to the Merlindependent YAP regulation. Merlin phosphorylation at S518, for example, is counteracted by myosin phosphatase target subunit 1-(MYPT1-) regulated PP1c, the phosphatase for myosin light chain (MLC) (Jin et al., 2006; Kiss et al., 2019; Alvarez-Santos et al., 2020). When RhoA, Rho-associated kinase (ROCK), or both are activated (e.g., by integrin–ECM interactions), MYPT1 can be inhibited by ROCK (Kawano et al., 1999) and/or sequestered to stress fibers (Joo and Yamada, 2014), thereby maintaining Merlin at the inactive, S518-phosphorylated state (Module Box V and **Figure 4D**). The compartmentalization of YAP mainly occurs at adherens junctions (AJs, by, e.g., PTPN14, 14-3-3, and Merlin), tight junctions (TJs, by, e.g., AMOT and Merlin), and multi-vesicular body (MVB, by, e.g., axin) (Module Box V and **Figures 4C,D**).

Several mechanisms have been identified to activate YAP signaling in an X-ROS- and/or cell mechanics-dependent manner. These mechanisms are to change the PTMs, the sequestration, and/or the compartmentalization states of YAP. Examples of the processes include 1) enhancing the degradation or dephosphorylation of LATS (Kim P. R. et al., 2020; Zhao et al., 2020) (Figure 4B), 2) reducing YAP S127/S397 phosphorylation (e.g., by PP1A, PP2A, PPM1A (Schlegelmilch et al., 2011; Li et al., 2016; Hu et al., 2017; Zhou et al., 2021), or Nemo-like kinase (NLK) (Moon et al., 2017)) (Figure 4C), 3) reducing YAP-Merlin association (by, e.g., enhancing Merlin S518 phosphorylation (Morrison et al., 2001; Sherman and Gutmann, 2001)) (Figure 4D), and 4) attenuating YAP-AMOT association (by, e.g., promoting actin filament polymerization to compete for binding to AMOT (Mana-Capelli et al., 2014)) (Figures 4C,D). A mechanism similar to example 4 is to reduce YAP-SWI/SNF association by nuclear actin filament polymerization (Chang et al., 2018) (Figure 4C). The effects of X-ROS in these processes are complex, as they can be additive, synergistic, or contradicting. To demonstrate such complexity, we use ROSmediated LATS degradation and dephosphorylation as an example.

The degradation of LATS is primarily mediated by the E3 ubiquitin ligase, SIAH2 (Ma et al., 2015; Zhao et al., 2020) (Figure 4B), the enzyme targeting PHDs for degradation (Nakayama and Ronai, 2004; Qi et al., 2013) (Figure 2C), thus connecting the regulation of hypoxia responses with YAP signaling. SIAH2 can be upregulated by p38 kinase and Src kinase (Khurana et al., 2006; Sarkar et al., 2012), which are redox-sensitive and can be activated by X-ROS (Abe et al., 1996; Aikawa et al., 1997; Kulisz et al., 2002; Emerling et al., 2005; Ray et al., 2012; Xu et al., 2017; Koundouros and Poulogiannis, 2018; Basu et al., 2019; Perillo et al., 2020). This effect places X-ROS upstream of YAP activation (Figure 4B). On the contrary, the dephosphorylation of LATS is primarily mediated by POPX2, which is also redox-sensitive and can be inhibited by ROS through cysteine oxidation (Kim P. R. et al., 2020). This effect places ROS upstream of YAP suppression (Figure 4B). Thus, X-ROS exhibit contradicting effects on YAP regulation (Figure 4C).

Contradicting effects, in fact, appear in many aspects of the ROS-dependent YAP regulation. For example, ROS can activate not only Src and p38 kinases (which activates SIAH), but also Src family kinase (SrcFK) (Tominaga et al., 2000; MacKay et al.,

2017) and PKC (Xu et al., 2017) through cysteine oxidation or ROS-Ca<sup>2+</sup> coupling (Shirai and Saito, 2002) (Figures 3B,C). PKC and SrcFK, in turn, activate Rac1 (Cathcart, 2004; Brown and Griendling, 2009; Gorlach et al., 2015) and Rho guanine nucleotide exchange factor 1 (ARHGEF1) (MacKay et al., 2017) to promote p21-activated protein kinase (PAK) activation and RhoA activation, respectively. The resulting effects include actin filament polymerization (by Rac1 and RhoA), MLC phosphorylation and stress fiber formations (by RhoA) (Tominaga et al., 2000), and MYPT1 inhibition (Kawano et al., 1999) or sequestration to the phosphorylated MLC (by RhoA) (Joo and Yamada, 2014). Among them, actin filaments compete with YAP for the binding of AMOT, thus releasing YAP from the AMOT-mediated sequestration (Figure 4C). PAK catalyzes Merlin S518 phosphorylation (Shaw et al., 2001) to prevent Merlin from binding to YAP (Figure 4D). RhoAmediated inhibition and sequestration of MYPT1 prevent MYPT1 from dephosphorylating Merlin<sup>pS518</sup> (Figure 4D). These effects act additively or synergistically to promote YAP signaling. At the same time, RhoA-mediated ROCK activation at the epithelial circumferential actin belt increases intercellular tension and promotes the release of Merlin from AJs to enable Merlin-mediated YAP nuclear export (Furukawa et al., 2017), thereby suppressing YAP signaling (Figure 4C). If not exported, the nuclear YAP requires the binding of TEAD for signaling, which can be disrupted by 5' AMP-activated protein kinase-(AMPK-) mediated YAP phosphorylation at S94 (Mo et al., 2015), and elevated ROS levels were found to increase the AMPK activity (Irrcher et al., 2009) (Figure 4C). In addition, ROS can suppress not only POPX2 (which dephosphorylates LATS), but also PP1 (Santos et al., 2016) and PP2A (Rao and Clayton, 2002; Raman and Pervaiz, 2019), both of which can dephosphorylate YAP to promote YAP signaling (Schlegelmilch et al., 2011; Li et al., 2016) (Figure 4C). These inhibitory effects place ROS upstream of YAP suppression and certainly contradict the aforementioned ROS-mediated YAP activation. Moreover, ROS can activate not only Src, p38, PKC, and SrcFK, but also PKA and AKT, yet the effects of the two kinases on Merlin-YAP association are different or even conflicting (Module Box V and Figure 4D). It is thus likely that the effect of X-ROS on YAP signaling is multiplexed and dependent on the context of the niche and the cellular status.

One consistent influence of X-ROS on YAP signaling is to promote the association of YAP with IQGAP1 (**Figure 4C**), which brings YAP to the cell leading front (**Figure 4A**). Another consistency is the effect of intercellular tension on the regulation of YAP signaling. In epithelial organs, the intercellular tension is primarily determined by the contractility at the circumferential actin belt around the AJs. RhoA/ROCKmediated enhancement of tension at the circumferential actin belt has been shown to promote the release of Merlin from AJs, thereby facilitating Merlin-mediated YAP nuclear export (Furukawa et al., 2017). Consistently applying forces at E-cadherin to mimic the high intercellular tension state has been shown to activate AMPK (Bays et al., 2017), which disrupts the YAP-TEAD association and suppresses the nuclear signaling of YAP (Mo et al., 2015). Moreover, the activated AMPK reinforces the RhoA/ROCK/MLC-mediated contractility to keep the cells at a high-tension state, thereby forming a positive feedback loop for the maintenance of the epithelial barrier (Bays et al., 2017) and the suppression of YAP signaling (Figure 4C). The third consistency is the ROS-mediated activation of tyrosine kinases and suppression of tyrosine phosphates. Unlike the negative regulation of serine phosphorylation of YAP by LATS and other kinases such as AKT and JNK (Basu et al., 2003; Danovi et al., 2008), tyrosine phosphorylation of YAP (at, e.g., Y357) by the redox-sensitive Src kinase or SrcFK promotes the nuclear translocation and signaling of YAP (Rosenbluh et al., 2012; Smoot et al., 2018; Sugihara et al., 2018) (Figure 4C). ROS-activated Src kinase can also suppress LATS by upregulating SIAH2 (Figure 4B), and ROS can inhibit tyrosine phosphates (Hecht and Zick, 1992; Lewis and Aitken, 2001; Chao et al., 2011) such as PTPN14, the inhibition of which abolishes the PTPN14-mediated sequestration of YAP (Liu et al., 2013) (Figure 4C). As a result, the regulations of ROS on tyrosine kinases and phosphatases lead to a synergistic or additive effect on YAP signaling.

X-ROS can be generated in integrin-ECM signaling and cell migration (Module Box III and Figures 3B-D). In these processes, integrin-ECM signaling can promote the dephosphorylation of YAP<sup>pS397</sup>, likely through an integrin a3-FAK-Cdc42-PP1A cascade, leading to the YAP nuclear translocation and potentiating mTOR signaling in stem cellbased tissue renewal (Hu et al., 2017) (Figure 4E). Stiffening and stretching of ECM also leads to Src kinase activation (Koudelkova et al., 2021), which in turn promotes tyrosine phosphorylation and nuclear translocation of YAP (Figures 4D,E). In fact, the mechano-chemical properties of ECM, such as ECM stiffness and ECM components, exhibit a profound impact on YAP signaling. The type I collagen, for example, can stimulate YAP nuclear translocation to suppress adipogenic differentiation in preadipocytes, likely through downregulating the expressions of Hippo pathway kinases (Liu X. et al., 2020). The crosslinking of collagen by, for example, LOX and LOX-like (LOXL) enzymes (Levental et al., 2009) increases ECM stiffness to promote YAP nuclear translocation (Dupont et al., 2011; Noguchi et al., 2018) and metabolic reprogramming (Ge et al., 2021) which can potentially activate HIF-1 signaling (Halligan et al., 2016). HIF-1a signaling and YAP signaling, in turn, can induce the expression of genes responsible for collagen deposition and stiffening directly (Gilkes et al., 2013; Ji et al., 2013) and indirectly (Liu et al., 2015; Noguchi et al., 2017), leading to a self-perpetuating vicious cycle in tissue fibrosis (Noguchi et al., 2018). Another example of the influence of ECM on YAP signaling is Agrin, an ECM proteoglycan that transduces ECM stiffness and cell rigidity to YAP signaling. Agrin activates p21-activated protein kinase- (PAK-) 1 through the integrinß1-FAK-integrin-linked kinase (ILK) signaling axis, which subsequently phosphorylates Merlin at S518 (Chakraborty et al., 2017) and reduces YAP-Merlin association (Module Box V and Figures 4D,E). Reciprocally, the effect of YAP on ECM remodeling often requires the presence of other niche factors such as TGFB (Fujii et al., 2012; Noguchi et al., 2018). TGF<sup>β</sup> also enhances the association of SIAH2 with LATS2

(Ma et al., 2016) for degradation. These lines of evidence place X-ROS-coupled cytokine/ECM signaling and cell mechanics upstream of YAP signaling. Nevertheless, we should point out that ROS are generally considered an inducer of premature senescence and aging (Kodama et al., 2013; Davalli et al., 2016; Marazita et al., 2016), and YAP signaling can prevent premature senescence yet often lead to tumorigenesis (Xie et al., 2013; Xu X. et al., 2021). How to optimize their interplay to boost longevity while minimizing the risk of tumorigenesis will be an interesting subject to investigate.

YAP signaling dictates the selection of cell fate, and it is likely that YAP signaling follows switch-like behavior. For the therapeutic purpose, it will be convenient if ROS-mediated effects also act as a switch at different stages of stem cell development and tumor progression, whereby pharmaceutical interventions can be explicitly applied to turn "on" or "off" specific or unwanted effects (Kim P. R. et al., 2020). In fact, epithelialswitch-like enhancement of YAP-mediated mesenchymal transition (EMT) has been proposed in cell engineered with migration on substrates nano-scale topographic cues (Park et al., 2019). The potential coexistence of the compatible and conflicting ROS-mediated effects on YAP signaling suggests that X-ROS and cell mechanics regulate YAP activity in a multiplex, niche factor context-dependent manner and can lead to a differential rather than switch-like response. Whether there is segregation between differential and switch-like YAP responses in the variation of niche factors and how such segregation depends on the physiological or pathological niche conditions remain to be resolved.

# The Coupling of X-ROS With HIF/YAP/Notch Triad and PD-L1 Signaling

The involvement of SIAH2 in X-ROS-HIF-1a and X-ROS-YAP signaling suggests that HIF and YAP might be interdependent or connected in the regulation of cell fate and tissue responses. In fact, YAP forms complexes with HIF-1 $\alpha$  and acts as the transcription activator of HIF-1a (Xiang et al., 2015; Zhao et al., 2020), and HIF-1a was found to promote YAP activation (Li H. et al., 2018). Positive feedback thus appears in the HIF/SIAH/YAP axis, which might play an important role not only in stem cell physiology but also in tumorigenesis (Module VI and Figure 5A). Box The tumor microenvironment (TME) is often characterized by an abundance of ROS and the stiffening of ECM. From the discussion in the previous sections, we note that both HIF-1a and YAP are sensitive to the ECM stiffness and ROS and that the yield of ROS depends on the O2 concentration and the metabolic activities in the TME. An intriguing question is then how the YAP target genes are differentially regulated by ROS-independent and ROS-dependent HIF signaling in response to the change of ECM stiffness and niche O2 concentrations. Unfortunately, no quantitative data on this perspective are available to date, and studies are thus warranted.

The complexity in HIF-YAP coupling increases when Notch signaling is considered. In contrast to the regulation of organ size by the Hippo pathway (Yu et al., 2015), Notch signaling regulates





the exquisite timing and spatial programming in the organ plan, including the spatiotemporal specification of cell fate and cell differentiation, tissue patterning, and the maintenance of stem cells (Artavanis-Tsakonas et al., 1999; Lasky and Wu, 2005; Sirin and Susztak, 2012; Kessler et al., 2015; Teo et al., 2019). Notch signaling is also associated with a neurological disorder, inflammation, senescence, aging, tumorigenicity, cancer drug resistance, cancer metastasis, cancer stemness, and cancer immune evasion (Sharma et al., 2011; Liu et al., 2012; Wang et al., 2014c; Balistreri et al., 2016; Hoare and Narita, 2018; Wu et al., 2018; Liu et al., 2021a; Xiu et al., 2021). YAP/TAZ forms a complex with the Notch effector, Notch intracellular domain (NICD), to promote the transcription of Notch target genes (Manderfield et al., 2012). Recent studies suggest a coupling of YAP/TAZ and Notch signaling pathways. This coupling can be positive or negative, with YAP/TAZ acting upstream of, downstream of, or in parallel with Notch signaling (Module Box VI). Moreover, YAP/TAZ, HIF-1a, and HIF-2a can bind to NICD to promote the transcriptional activity in a mutually exclusive manner (Hu et al., 2014) (Module Box VI and Figure 5A). Such HIF-Notch coupling can be found in, for example, neurological disorder and degeneration, brain function and angiogenesis, and the maintenance of glioblastoma stem cells (Gustafsson et al., 2005; Chen et al., 2010; Qiang et al., 2012; Hu et al., 2014; Li Y. et al., 2018; Kim S. et al., 2020). Conversely, Notch signaling is required for HIF to preserve the full pluripotency of stem cells under hypoxia (Gustafsson et al., 2005), the condition wherein stem cells maintain their stemness (Ezashi et al., 2005). These lines of evidence suggest that HIF, YAP, and Notch act as a triad in the regulation of stem cell physiology and the dysregulation of cell behavior in tumorigenesis.

In addition to YAP and HIF, recent studies have shown that Notch is associated with various subtypes of X-ROS signaling and involved in oxidative stress (Zhang H.-M. et al., 2018). For example, reciprocal ROS-Notch signaling has been identified in the clusters of circulating tumor cells (CTCs) and myeloidderived suppressor cells (MDSCs), where CTCs have been considered as the bona fide precursors for metastatic tumors and MDSCs, a group of undifferentiated, bone marrow-derived heterogeneous cells with enhanced ability of immune suppression (Gabrilovich and Nagaraj, 2009; Wen et al., 2020), are known to promote neoplastic growth by inhibiting the tumoricidal activity of T cells (Aceto et al., 2014; Boral et al., 2017; Sprouse et al., 2019). Several mechanisms have been identified in X-ROS/ cytokine/ECM signaling-coupled Notch signaling. The first is to act through the coupling of TGFB1 and NOX4-derived ROS in epithelial cells, where niche factor TGFB1 induces NOX4 expression (through p38 kinase (Ning et al., 2002)), ROSdependent Nrf2 activation and expression, NOX4-derived ROS production, and Nrf2-dependent Notch signaling (Yazaki et al., 2021), which in turn induces EMT (Matsuno et al., 2012). Herein, Nrf2 stands for nuclear factor erythroid-derived 2-related factor 2, a leucine-zipper transcription factor (Moi et al., 1994). Nrf2 and its repressor Kelch-like ECH-associated protein 1 (Keap1) act as the major regulators for cell redox levels (Sporn and Liby, 2012). It has been shown that elevated ROS levels alone are sufficient to trigger Notch signaling for the homeostasis of airway basal stem cells in an Nrf2-dependent manner (Paul et al., 2014) (Figure 5B). The second is to act through the combination of the GSK3β-mediated crosstalk between Notch and Wnt/β-catenin signaling pathways (Force and Woodgett, 2009; Caliceti et al., 2014), the X-ROS-mediated activation of GSK3 $\beta$  (Wang C.-Y. et al., 2014), and the downregulation of  $\beta$ -catenin by a redoxsensitive negative regulator of Wnt signaling pathway, nucleoredoxin (NRX) (Shin et al., 2004; Funato and Miki, 2010; Funato et al., 2010). Note that GSK3 $\beta$  is also involved in the HIF-α subunit regulation (Flugel et al., 2007) (Module Box I and Figures 2B,C) and the axin-dependent YAP degradation and compartmentalization (Azzolin et al., 2014) (Module Box V and Figure 4C). The third is to act through niche mechanics- and ROS-interdependent integrin signaling (Werner and Werb, 2002; Gregg et al., 2004; Buricchi et al., 2007; Taddei et al., 2007; Zeller et al., 2013; Xu Z. et al., 2021), where the activation of ILK potentiates Notch signaling (Maydan et al., 2010) and regulates GSK3ß activity (Maydan et al., 2010).

YAP signaling can upregulate PD-L1, the ligand for the cell surface glycoprotein PD-1 that suppresses immune responses in chronic inflammation and in the tumor microenvironment (TME) (Greenwald et al., 2005; Janse van Rensburg et al., 2018), particularly in cancer cells (Lee et al., 2017; Miao et al., 2017). However, YAP is not alone. Recent studies have identified a Notch signaling pathway through the Notch3-PI3K-AKTmTOR axis to be responsible for the overexpression of PD-L1 in breast cancer stem cell-like (CSC-like) cells (Mansour et al., 2020) (Figure 5B). Under hypoxia, the common niche condition in the TME, HIF-1a but not HIF-2a, has been found to bind to an HRE in the PD-L1 promoter region to overexpress PD-L1 in myeloid-derived suppressor cells (MDSCs) (Noman et al., 2014), by which HCCs evade immune systems (Wen et al., 2020). A concomitant elevation of cell surface PD-L1 and intracellular HIF-2a expression has also been observed in solid tumors (Chang et al., 2016; Tawadros and Khalafalla, 2018; Guo et al., 2019; Zhou et al., 2019), where enhanced activities in ERK, AKT, IKBa (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha), and NF-KB were found to be involved in PD-L1 overexpression (Guo et al., 2019). Conversely, PD-L1 overexpression can promote the expression of HIF-1a and YAP-1 in a ROS-dependent manner (Tung et al., 2018), perhaps through the interaction of PD-L1 with vimentin, a major cytoskeletal element contributing to cell stiffness and EMT (Ancel et al., 2019), or through the nuclear translocation of PD-L1 and subsequent operation on a panel of immune regulation-related genes (Gao et al., 2020; Jaccard and Ho, 2020) (Figure 5B).

The coupling of PD-L1 and HIF/YAP/Notch signaling has led to a proposed idea that the targeting therapy on HIF/YAP/Notch signaling pathways, along with the conventional chemotherapy and immune therapy, might serve as a potential surrogate for cancer treatment (Janghorban et al., 2018) (Module Box VI). Given the coupling of X-ROS in HIF/YAP/Notch signaling, it is legitimate to ask whether niche ROS affect PD-L1 expression and/ or signaling. Figure 2E shows that when the yield of free electrons from the respiratory chain (i.e., ETC) exceeds a certain level with respect to the niche oxygen concentration, ROS can be created and leak to the cytoplasm. This situation is likely to occur at the TME, where tumor cells often carry enhanced glycolysis. In addition, the TME contains inflammatory cells that produce a significant amount of ROS through, for example, NOX, and modify the oxidative stress of the TME, which in turn can influence the antitumor effect of immune responses. It is, therefore, important to evaluate the impact of ROS on PD-L1 expression and functions (Bailly, 2020). This impact is complex and bi-directional. For example, X-ROS and cell mechanics can upregulate HIF and YAP signaling activities and expression levels (Abe et al., 1996; Aikawa et al., 1997; Kulisz et al., 2002; Emerling et al., 2005; Ray et al., 2012; Hu et al., 2017; Xu et al., 2017; Koundouros and Poulogiannis, 2018; Basu et al., 2019; Perillo et al., 2020), which in turn promote PD-L1 expression (Noman et al., 2014; Janse van Rensburg et al., 2018). Conversely, PD-L1 can induce HIF-1a expression in a ROS-dependent manner and, in turn, upregulate YAP1 expression (Tung et al., 2018) (Figure 5B). These lines of evidence suggest a potential self-perpetuating amplification in the ROS-HIF/YAP-PD-L1 axis. As a result, enhancing ROS production might promote the PD-L1 expression, and scavenging ROS can repress the PD-L1 expression. Nevertheless, there are contradicting examples in cancer cell lines, where applying ROS-generation drugs leads to PD-L1 downregulation and applying ROS scavengers promotes PD-L1 expression (Bailly, 2020). More studies on the interplay of ROS and PD-L1 are thus warranted.

### CONCLUSION REMARKS

Except for the anti-pathogen capacity, ROS have long been considered harmful due to the ability to damage DNA and proteins but is now recognized as an important element in regulating stem cell physiology. Exploding evidence over the past decade further indicates that ROS are intensively coupled with tissue mechanics and HIF-YAP-Notch signaling. Such coupling is manifested in organ development, homeostasis, and repair, and when things go wrong, the coupling can lead to tumorigenesis. This review discusses the interplay of ROS (particularly NOX-derived ROS (i.e., X-ROS)) and the HIF-YAP-Notch signaling. The potentiation of PD-L1 expression in response to ROS-HIF-YAP-Notch signaling is also addressed. Most importantly, we point out the existence of multiplexed positive and negative feedback couplings that occur at different times (i.e., transient or prolonged) and spatial (i.e., autonomous (within the cell) or non-autonomous (within the niche)) scales. Understanding under what niche conditions these couplings can lead to differential or switch-like tissue responses and/or change self-sustained regulation in stem cell physiology to selfperpetuating dysregulation in cancer progression will help us move into the clinical realm to design strategies for stem cellbased and X-ROS-targeting therapy.

### SUPPORTING BOXES

## Math Box I: The Estimated Phase Diagram of ROS Production

ROS are mainly produced by mitochondria (Murphy, 2009; Juan et al., 2021). In the regular energy production process, the decomposition of carbon hydrates yields CO<sub>2</sub> and H<sub>2</sub>, the latter of which forms the high-energy electron donors: nicotinamide adenine dinucleotide phosphate- (NADP-) H, and flavin adenine dinucleotide- (FAD-) H<sub>2</sub>. These donors bring electrons to the mitochondria's inner membrane electron transport chain (ETC), through which the electrons are delivered to the molecular oxygen O<sub>2</sub> in exchange for a buildup of pH gradient and an electrochemical potential across the membrane. When the proton flows back through the membrane, it drives the rotation of the membrane-bound ATP synthase and phosphorylates ADP into ATP. This process is called "chemiosmosis," a process by which oxidative phosphorylation generates ATP (Anraku, 1988; Kracke et al., 2015). Eukaryote ETC consists of NADH-coenzyme Q oxidoreductase (Complex I), succinate-Q oxidoreductase (Complex II), electron transfer flavoprotein-Q oxidoreductase, Q-cytochrome c oxidoreductase (Complex III), and cytochrome c oxidase (Complex IV) (Kracke

et al., 2015). Among them, Complexes I, III, and IV are transmembrane proteins coupling the transfer of electrons with the transport of protons. Q stands for ubiquinone, a lipid-soluble electron carrier, and cytochrome c is a watersoluble electron carrier. For an effective electron transfer, the electron donated from NADPH and FADH<sub>2</sub> should be transported between the lipid-soluble and water-soluble carriers along the membrane to reach the final target Complex IV, where it binds to O<sub>2</sub> to form H<sub>2</sub>O. In reality, however, the anionic nature of the free electron allows it to escape through the transmembrane complexes to both sides of the inner mitochondrial membrane (Murphy, 2009), where it binds to O<sub>2</sub> delivered by cytoplasmic oxygen carriers such as cytoglobin (Novianti et al., 2020). This "leakage" primarily occurs at Complexes I/III and, in turn, forms superoxide, O2• (or O<sub>2</sub><sup>-</sup>), a major form of ROS (Murphy, 2009; Bleier and Drose, 2013).

The theoretical value for the reduction of  $O_2$  to  $O_2^-$  in mitochondria was estimated as -68 to -230 mV/mole (Murphy, 2009) and thus is thermodynamically favorable (Andreyev et al., 2005). To see how the free electron selects the "leakage" over the regular path to reach O<sub>2</sub>, we considered the internal electron transfer in the catalytic cycle of Complex IV, which has been documented as the rate-limiting step (Sarti et al., 1988). Complex IV contains four electron carriers, including two heme groups, heme "a" and heme "a3," each of which contains an iron ion, and two Cu groups, the first of which contains two copper ions and is referred to as CuA/CuA and the second is formed by a single copper ion and referred to as CuB (Voet and Voet, 2011). Complex IV receives free electrons from the watersoluble carrier, cytochrome c, and passes the electrons internally through CuA/CuA to "a," "a3," and finally CuB. While the function of CuA/CuA and "a" is primarily for electron transfer, "a3" and CuB form a binuclear center not only for electron transfer but also for O2 association and reduction. Adjacent to the binuclear center is a tyrosine group (Tyr244-OH) which also participates in the process of O<sub>2</sub> reduction. To proceed, we hereafter used the label "X" to represent the binuclear center, a3(Fe)-(CuB)-(Tyr244-OH). Likewise, we used "c" to denote cytochrome c. In terms of the redox state, we used " $c^{0}$ " and "c-" to indicate the reference state and the reduced state (i.e., carrying one free electron) of cytochrome c, respectively. As for X, its catalytic cycle starts from the reference state,  $a3(Fe^{3+}OH^{-})-(CuB^{2+})-(Tyr244-O^{-})$  (referred to as  $X^{0}$ ). In each cycle, four electrons from four reduced cytochrome c molecules are used, along with the consumption of four protons from the mitochondrial matrix (equivalent to pumping four protons to the intermembrane space). The first electron and proton reduce the copper ion and restore the tyrosine group of X into  $a3(Fe^{3+}OH^{-})$ - $(CuB^+)$ -(Tyr244-OH) (referred to as  $X^-$ ). The second electron and proton reduce the  $Fe^{3+}$  of X into  $a3(Fe^{2+})-(CuB^+)-(Tyr244-$ OH) (referred to as  $X^{2-}$ ), during which the hydroxide ligand, OH<sup>-</sup>, at "a3" is protonated and lost as water, creating a void for O<sub>2</sub> association. Upon association, the oxygen is rapidly reduced by two electrons from  $a3(Fe^{2+})$ , one electron from (CuB<sup>+</sup>), and one electron and a proton from (Tyr244-OH). The reduction of  $O_2$ , in turn, transforms X into the fully oxidized state,

a3(Fe<sup>4+</sup>O<sup>2-</sup>)-(CuB<sup>2+</sup>OH<sup>-</sup>)-(Tyr244-O<sup>\*</sup>) (referred to as  $X^{2+}$ ), where Tyr244-O<sup>\*</sup> indicates a neutral tyrosine radical. Following O<sub>2</sub> reduction is the addition of the third electron and proton that reduces tyrosine radical and converts X to a partially oxidized state, a3(Fe<sup>4+</sup>O<sup>2-</sup>)-(CuB<sup>2+</sup>)-(Tyr244-O<sup>-</sup>) (referred to as  $X^+$ ), with the yield of one water molecule. The fourth electron reduces the iron ion, and with the oxygen atom picking up a proton from the matrix, converts X back to a3(Fe<sup>3+</sup>OH<sup>-</sup>)-(CuB<sup>2+</sup>)-(Tyr244-O<sup>-</sup>), that is, the  $X^0$  state (Voet and Voet, 2011; Wikstrom and Springett, 2020) (**Figure 1B**).

In the absence of protein degradation and synthesis, we set ( $c^0 + c^-$ ) =  $\rho_c$  and ( $X^0 + X^- + X^{2-} + X^+ + X^{2+}$ ) =  $\rho_{IV}$ , with  $\rho_c$  and  $\rho_{IV}$  as the densities of cytochrome c and Complex IV on the mitochondrial inner membrane, respectively. Ignoring the spatial inhomogeneity and fluctuation of free electrons and  $O_2$ , we used the following equations to address the dynamics of *X* and *c*:

$$\frac{dX^0}{dt} = k_{IET}c^{-}[\mathrm{H}^+]X^+ - k_{IET}c^{-}[\mathrm{H}^+]X^0, \qquad (1)$$

$$\frac{dX^{-}}{dt} = k_{IET}c^{-}[\mathrm{H}^{+}]X^{0} - k_{IET}c^{-}[\mathrm{H}^{+}]X^{-}, \qquad (2)$$

$$\frac{dX^{2-}}{dt} = k_{IET}c^{-}[\mathrm{H}^{+}]X^{-} - k_{O2}[\mathrm{O}_{2}]_{m}X^{2-},$$
(3)

$$\frac{dX^{2+}}{dt} = k_{O2} [O_2]_m X^{2-} - k_{IET} c^- [H^+] X^{2+}, \qquad (4)$$

$$\frac{dX^{+}}{dt} = k_{IET}c^{-}[\mathrm{H}^{+}]X^{2+} - k_{IET}c^{-}[\mathrm{H}^{+}]X^{+},$$
(5)

$$\frac{dc}{dt} = k_{ETC}[e^{-}]c^{0} - k_{IET}[H^{+}](X^{+} + X^{0} + X^{2+} + X^{-})c^{-}, \quad (6)$$

$$\frac{d[e^{-}]}{dt} = Y - \left(k_{leak}[O_2]_c + k_{ETC}c^0\right)[e^{-}].$$
(7)

 $k_{IET}$  was referred to as the internal electron transfer rate from cytochrome c to the binuclear center of Complex IV (for simplicity, we used a single entity to represent all the transfer events). [H<sup>+</sup>] was the proton concentration in the mitochondrial matrix.  $[O_2]_m$  indicated the mitochondrial molecular oxygen concentration, and  $k_{O2}$  was the association rate with Complex IV.  $[e^{-}]$  stood for the density of free electron that was generated at a rate Y and transferred through ETC to the cytochrome c at a rate  $k_{ETC}$ , or leaked at a rate  $k_{leak}$  to cytoplasmic O<sub>2</sub>, the concentration of which was set as [O<sub>2</sub>]<sub>c</sub>. These parameters and variables were tissue context- and physiology-dependent, and estimates had been made in = previous studies (Murphy, 2009; Wikstrom and Springett, 2020). In principle,  $[O_2]_m$  could be related to  $[O_2]_c$ . Using an estimate of  $[O_2]_c$  as 120 µM (Wikstrom and Springett, 2020) and  $[O_2]_m$  as 25  $\mu$ M (Murphy, 2009), we could set them at a ratio of ~0.2.

At the steady state, all of the "X" states in Eqs 1–5 could be solved in terms of  $X^0$  and used to express the steady-state solutions of  $c^-$  and  $e^-$  in Eqs 6, 7:

$$X^{0} = \rho_{IV} / \left( 4 + \frac{k_{IET} \, [\mathrm{H}^{+}] c^{-}}{k_{O2} \, [\mathrm{O}_{2}]_{m}} \right), \tag{8}$$

$$c^{-} = \rho_{C} k_{ETC} [e^{-}] / (4k_{IET} [H^{+}] X^{0} + k_{ETC} [e^{-}]), \qquad (9)$$

$$[e^{-}] = Y / (k_{leak} [O_2]_c + k_{ETC} (\rho_C - c^{-})),$$
(10)  
$$c^{-} \qquad 1$$

$$z \equiv \frac{1}{\rho_C} = \frac{4\frac{\rho_{IV}}{Y} k_{IET} [\mathrm{H}^+] \left(\frac{k_{Ieak} [O_2]_c}{k_{ETC}} + \rho_C (1-z)\right)}{4 + \frac{k_{IET} [\mathrm{H}^+] \rho_C}{k_{O2} [O_2]_m} \times z},$$
(11)

$$w \equiv \frac{k_{ETC}(\rho_C - c^-)}{k_{leak}[O_2]_c} = \frac{k_{ETC}\rho_C(1 - z)}{k_{leak}[O_2]_c}.$$
 (12)

Combining **Eqs 8–10**, we had **Eq. 11**, which defined the fraction of reduced cytochrome c with respect to all the cytochrome c on the membrane as z ( $0 \le z \le 1$ ). Examining the left-hand and the right-hand sides of **Eq. 11**, we found that there was always a solution of z between zero and one. In **Eq. 12**, we defined the ratio of electrons selecting the regular path over the leakage to reach O<sub>2</sub>. When w was less than one, most electrons selected the leakage. The critical  $z^*$  at w = 1 was found in **Eq. 12**:

$$z^{*} = 1 - \frac{k_{leak} [O_{2}]_{c}}{k_{ETC} \rho_{C}}.$$
 (13)

From Eq. 13, the maximal  $[O_2]_c^*$  for  $w \ge 1$  read as follows:

$$\left[\mathsf{O}_2\right]_c^* = \frac{k_{ETC}\rho_C}{k_{leak}}.$$
 (14)

**Eq. 14** suggests a critical cytoplasmic oxygen concentration  $[O_2]_c^*$ , which increases with the density of available cytochrome c on the mitochondrial membrane,  $\rho_C$ . For cytoplasmic oxygen concentration above  $[O_2]_c^*$ , electrons generated in ETC predominantly leaked and formed ROS. Using Eqs. **11–14**, for a given  $[O_2]_c$ , we obtained the critical electron generation rate  $Y^*$  in the ETC, and for  $Y > Y^*$ , the generated electrons predominantly selected the leakage over the regular path to reach  $O_2$ :

$$Y^{*} = \frac{8\rho_{IV}k_{IET}[\mathrm{H}^{+}]\rho_{C}\left(1 - \frac{k_{leak}[\mathrm{O}_{2}]_{c}}{k_{ETC}\rho_{C}}\right)}{4 + \frac{k_{IET}[\mathrm{H}^{+}]\rho_{C}}{k_{O2}[\mathrm{O}_{2}]_{m}}\left(1 - \frac{k_{leak}[\mathrm{O}_{2}]_{c}}{k_{ETC}\rho_{C}}\right)}$$
$$= \frac{\frac{8\rho_{IV}k_{IET}k_{leak}[\mathrm{H}^{+}]}{k_{ETC}}[\mathrm{O}_{2}]_{c}^{*}\left(1 - \frac{[\mathrm{O}_{2}]_{c}}{[\mathrm{O}_{2}]_{c}^{*}}\right)}{4 + \frac{k_{IET}k_{leak}[\mathrm{H}^{+}]}{k_{O2}k_{ETC}}\frac{\mathrm{O}_{2}]_{m}}{[\mathrm{O}_{2}]_{c}}\left(1 - \frac{[\mathrm{O}_{2}]_{c}}{[\mathrm{O}_{2}]_{c}^{*}}\right)} \text{for }[\mathrm{O}_{2}]c \leq [\mathrm{O}_{2}]^{*}$$
$$= kETC\rho C/kleak, Y^{*} = 0. \tag{15}$$

Using the estimate that  $[O_2]_m/[O_2]_c \sim 0.2$ , we obtained the maximal electron generation rate on the variation of cytoplasmic oxygen concentrations (**Figure 2E**). Below this rate, over 50% of electrons would be used for oxidative phosphorylation.

## Module Box I: $O_2$ -Dependent Regulation of HIF- $\alpha$ Stability

The cells use the oxygen-sensing regulations to regulate the stability of HIF- $\alpha$  subunits in response to niche oxygen. For HIF-1 $\alpha$ , these regulations occur at its functional motifs: proline 402 and 564 at its N-terminal activation domain (NAD) and asparagine 803 at its C-terminal transactivation domain (CTAD).

Both NAD and CTAD can recruit E1A binding protein p300 (p300)/cyclic adenosine monophosphate response elementbinding protein-binding protein (CREB-binding protein, CREBBP, or CBP) co-activators to enhance the transcriptional activity of HIF. The HIF prolyl hydroxylase domain-containing proteins (PHD or HIF prolyl hydroxylases (HPH)) 1-3 (Fong and Takeda, 2008) and the factor inhibiting HIF (FIH) (Lando et al., 2002; Sim et al., 2018) are the main enzymes responsible for the oxygen-sensing post-translational modifications (PTMs) of HIF- $\alpha$  subunits (Figure 2B). PHD is a Fe<sup>2+</sup>-dependent dioxygenase. It binds to one  $O_2$  and one HIF- $\alpha$  subunit at the same time, followed by transferring O<sub>2</sub> to the proline 402 and 564 of the HIF-1a subunit (or 405 and 531 of the HIF-2α subunit) (Hashimoto and Shibasaki, 2015), HIF-L-proline + 2-oxoglutarate (αketoglutarate) +  $O_2$   $\vec{x}$  HIF-trans-4-hydroxy-L-proline + succinate + CO<sub>2</sub>, to hydroxylate the proline residues. The reaction indicates that the accumulation of 2-oxoglutarate (or  $\alpha$ -ketoglutarate) promotes the hydroxylation of HIF, and the accumulation of succinate prohibits hydroxylation. Once hydroxylated, the proline residue not only fails to recruit p300/CBP to NAD but also becomes recognizable by von Hippel-Lindau tumor suppressor protein (VHL) E3 ubiquitin ligase, which targets the HIF- $\alpha$  subunit for ubiquitination and a rapid 26S proteasome-dependent degradation (Maxwell et al., 1999; Bruick and McKnight, 2001; Epstein et al., 2001; Ivan et al., 2001; Jaakkola et al., 2001). Consequently, PHDs serve as an oxygen sensor to regulate HIF-a subunit stability in response to the fluctuation of niche oxygen concentration [O<sub>2</sub>] (Ivan et al., 2001). In comparison, FIH is an asparaginyl hydroxylase that uses a-ketoglutarate and O2 to hydroxylate asparagine 803 of the HIF-1a (or 851 of the HIF-2a) (Schofield and Ratcliffe, 2004) and inhibits its transcriptional activity at CTAD (Lando et al., 2002; Sim et al., 2018), rather than degradation, a detailed discussion of which A detailed can be found elsewhere (Masson and Ratcliffe, 2014; Strowitzki et al., 2019). Apart from hydroxylation, the stability and the ability of HIF-1 $\alpha$  to translocate into the nucleus depends on phosphorylation, which is primarily mediated by kinases such as glycogen synthase kinase 3ß (GSK3B) and MAPKs (the common effectors involved in TGFB and IGF-1 signaling, for example, extracellular regulated kinases (Erk1/2) and p38 kinase (Richard et al., 1999; Sodhi et al., 2000; Flugel et al., 2007)) (Figure 2C). As HIF-1a promotes angiogenesis and glycolysis and HIF-2a helps the maintenance of stemness (Figure 2A), it is not surprising that HIFs are dysregulated in tumors. In fact, not only HIF but also PHDs are dysregulated in tumors. PHDs are often overexpressed in tumors by contradicting the expectations, and inhibition of PHDs can impair tumor growth, metastasis, and immune tolerance (Gaete et al., 2021). Thus, HIFs and PHDs have been proposed as therapeutic targets against cancer.

The regulation of HIF stability by FIH and PHD depends on their  $K_{\rm m}$  values for  $[O_2]$  association. The  $K_{\rm m}$  value of FIH is ~90–200 µM (Koivunen et al., 2004; Tarhonskaya et al., 2015). In comparison, the  $K_{\rm m}$  value of PHD for  $[O_2]$  association is documented as 230–250 µM (Fong and Takeda, 2008) or even higher (250 µM–1.7 mM) (Ehrismann et al., 2007; Dao et al., 2009; Tarhonskaya et al., 2015). In any case, it is above the  $[O_2]$  in air-saturated aqueous buffer at 37°C ([O<sub>2</sub>] ~21% (~210  $\mu$ M)) (Reynafarje et al., 1985; Murphy, 2009), abundantly above the physiological oxygen concentration ([O<sub>2</sub>] ~7% (~70  $\mu$ M)) (Hu et al., 2014), larger than the  $K_m$  value of other oxygenases such as collagen PHD (~40  $\mu$ M) (Hirsila et al., 2003), and far above the oxygen concentration in mitochondria ([O<sub>2</sub>] ~3–30  $\mu$ M) (Turrens, 2003). Such discrepancy reflects that FIH and PHD are designed for different purposes in response to the niche oxygen concentrations (i.e., FIH for differential activation of HIF target genes and PHD for degradation) and suggests that additional mechanisms might exist for the regulation of HIF- $\alpha$  subunits. Indeed, negative feedback mechanisms have been identified. HIF-1 $\alpha$ , for example, promotes its degradation by inducing the expression of PHD2-3 and FIH-1 (Marxsen et al., 2004; Kobayashi et al., 2021).

## Module Box II: ROS-Dependent Regulation of HIF- $\alpha$ Stability

Recent evidence suggests that ROS contribute to the regulation of HIF-α stability by modulating the activity of PHD (Gerald et al., 2004; Fong and Takeda, 2008; Lee et al., 2016) (Figure 2C). The precise mechanism by which ROS regulate PHD is complex and not fully understood. At least three inhibitory and one enhancing mechanisms have been identified. The first inhibitory mechanism is to act by oxidizing the cysteine residues of PHD into disulfide bonds, which cause homo-dimerization and inactivation of PHD (Lee et al., 2016). The second is to act through chelating and oxidizing PHD-bound Fe<sup>2+</sup> to Fe<sup>3+</sup>, by which the ability of PHD to bind to O<sub>2</sub> is abolished (Gerald et al., 2004; Fong and Takeda, 2008). The third is to act through seven in absentia homolog 2 (SIAH2), a RING finger-containing E3 ubiquitin ligase targeting PHDs for ubiquitin-mediated proteasome degradation (Nakayama and Ronai, 2004; Qi et al., 2013). SIAH2 can be phosphorylated and activated by several ROS-activated kinases, a detailed review of which can be found elsewhere (Xu and Li, 2021). In contrast, the enhancing mechanism is a long-term effect and acts through redox factor-1 (Ref-1). Prolonged ROS exposure induces Ref-1 expression in an NF-KB- (nuclear factor kappalight-chain-enhancer of activated B cells-) dependent manner and, in turn, upregulates the transcriptional activity of HIF-1a to promote PHD2 and FIH-1 expressions (Kobayashi et al., 2021), the outcome of which is to downregulate HIF-1a (Figure 2C).

# Module Box III: The NOX-Derived ROS (X-ROS) Signaling

NOX can be found on the plasma membrane (NOX1-5 and Duox1-2), endoplasmic reticulum (NOX2, NOX4, and NOX5), mitochondrial membrane (NOX4), nuclear membrane (NOX4-5), membrane microdomains such as caveolae and lipid rafts (NOX1), focal adhesions (NOX4), and invadopodia (NOX1 and NOX4) (Brown and Griendling, 2009; Brandes et al., 2014a; b; Fukai and Ushio-Fukai, 2020). The catalytic domains of NOX, homologs of gp91<sup>phox</sup>  $\beta$  subunit with six transmembrane helices, are anchored to the membrane with the cytoplasmic tails binding to NADPH for electron transfer (Brandes et al., 2014b). Upon

activation, the NOX-associated NADPH is oxidized, and electrons are transferred across the gp91<sup>phox</sup> transmembrane domain to bind to  $O_2$  in the extracellular or intracellular spaces, thereby increasing ROS levels in the niche or inside the cell (Brandes et al., 2014b).

In general, the functionality of NOX requires their catalytic units, the transmembrane  $gp91^{phox}$  homolog subunit (each NOX subtype has its own  $gp91^{phox}$  homolog), to be in a homodimer (e.g., NOX5) or in a complex with specific membrane scaffolds, namely, NOX1-4 with the membrane scaffold p22<sup>phox</sup> and Duox1-2 with membrane scaffolds DuoxA1-2, respectively (Brandes et al., 2014b; Skonieczna et al., 2017) (Figure 3A). The mechanisms by which NOX are activated vary among the subtypes. NOX5 and Duox1-2, for example, are activated by calcium binding to their cytoplasmic EF-hand calcium-binding motifs, whereas the activation of NOX1-3 requires the assembly and the PTMs of their cytoplasmic regulators (Brown and Griendling, 2009; Brandes et al., 2014b; Skonieczna et al., 2017). By contrast, NOX4 is constitutively active and does not need the association of any cytoplasmic regulators to produce ROS (Ellmark et al., 2005). Still, the activity of NOX4 is modulated by the phosphorylation on its tyrosine reside 491 (in, e.g., IGF-1 stimulation (Xi et al., 2013)) and on the threonine residues of its membrane scaffold p22<sup>phox</sup> (Regier et al., 1999). Below, we briefly review the regulation of NOX 1-4 and discuss how they are coupled with cytokine and ECM signaling.

As the first example, we use NOX2 to illustrate how the NOX multi-unit assembly is organized and how the PTMs of NOX subunits affect their assembly and functions. The details can be found elsewhere (Brandes et al., 2014b; Rastogi et al., 2016; Skonieczna et al., 2017). As aforementioned, NOX1-3 are inactive when present as a monomer (i.e., with the gp91<sup>phox</sup> homolog subunit alone) and need to form a complex with the membrane scaffold p22<sup>phox</sup> for maturation and stabilization (Nakano et al., 2007). The activation of NOX2 further requires recruiting p21<sup>Rac1/2</sup> (Rho GTPase Rac1/2), p67<sup>phox</sup>, p40<sup>phox</sup>, and p47<sup>phox</sup> into the gp91<sup>phox</sup>-p22<sup>phox</sup> complex (Brandes et al., 2014b), where gp91<sup>phox</sup> is the core subunit and each NOX subtype has its own homolog (Figure 3C). Recruiting these molecules consumes high-energy phosphate compounds. For example, the recruitment of Rac needs the Rac guanine nucleotide exchange factor (GEF) to switch Rac from the GDP- to GTP-bound form and expose its prenylated tail for membrane binding (Abo et al., 1994; Diekmann et al., 1994), whereas the recruitment of p47<sup>phox</sup> requires phosphorylation of p47<sup>phox</sup> by serine/threonine kinases such as protein kinase B (PKB)/AKT, protein kinase C (PKC), and p21-activated protein kinase (PAK) (Fontayne et al., 2002; Chen et al., 2003; Hoyal et al., 2003; Bey et al., 2004; Martyn et al., 2005). Reciprocally, the association between  $p22^{phox}$  and  $p47^{phox}$  is enhanced if  $p22^{phox}$  is phosphorylated by phosphatidic acid- (PA-) activated protein kinase or PKC (Regier et al., 1999). The phosphorylation of p47<sup>phox</sup> not only enables its binding to p67<sup>phox</sup> and p22<sup>phox</sup> but also exposes its pbox consensus sequence (PX) domain to phosphatidylinositol (4,5)-bisphosphate or phosphatidylinositol (3,4,5)-trisphosphate (PIP<sub>2</sub> or PIP<sub>3</sub>) for membrane binding (Ago et al., 2003; Groemping et al., 2003). Such PX domain is also

found in  $p40^{phox}$ , a regulator that binds to  $p67^{phox}$  and stabilizes  $p67^{phox}$ - $p47^{phox}$  complex formation (Kanai et al., 2001).

The involvement of PIP<sub>2</sub>/PIP<sub>3</sub> in NOX2 multi-unit assembly suggests that NOX2 activity is modulated by PI3K and phosphatase and tensin homolog (PTEN), the common effectors in the cytokine/ECM signaling. Likewise, the involvement of phosphorylation-mediated PTMs on the subunit assembly suggests that cytokine/ECM signaling regulates NOX2 activity. These phosphorylation-mediated PTMs are not just for potentiating NOX multi-unit assembly. PKC-mediated phosphorylation in NOX2 and p67<sup>phox</sup>, for example, has been found to maximize the yield of NOX2derived ROS (Regier et al., 1999; Raad et al., 2009; Brandes et al., 2014b), which in turn can evoke calcium influx (Gorlach et al., 2015). The binding of  $Ca^{2+}$  to the C2 domain of PKC then promotes the membrane targeting of PKC (Shirai and Saito, 2002) and the phosphorylation of p47<sup>phox</sup>, p67<sup>phox</sup>, p40<sup>phox</sup>, and Rac through calcium-activated PKC (Cathcart, 2004; Brown and Griendling, 2009; Gorlach et al., 2015; Islam et al., 2018; Tu et al., 2020), leading to a potential feedback amplification along the ROS-Ca<sup>2+</sup>-PKC signaling axis (Figure 3C).

The second example is NOX1 and NOX3, the activation of which requires the assembly of p47<sup>phox</sup> homolog Noxo1 and the p67<sup>phox</sup> homolog Noxa1 to NOX1-p22<sup>phox</sup> and NOX3-p22<sup>phox</sup> complexes, respectively (Brandes et al., 2014b). Similar to p67<sup>phox</sup>, the activity of Noxa1 is regulated by phosphorylation. Unlike p67<sup>phox</sup>, however, the phosphorylation of Noxa1 can lead to active or inhibitory effects, which involve not only serine/ threonine kinases but also protein tyrosine kinases. For example, PKC, steroid receptor coactivator (Src) kinase, and CaMK2 phosphorylate Noxa1 and enhance its association with Noxo1 and NOX1, whereas the phosphorylation of Noxa1 by cAMP-dependent protein kinase or PKA inhibits the association (Kim et al., 2007; Gianni et al., 2010; Kroviarski et al., 2010; Brandes et al., 2014b). Inhibitory phosphorylation also occurs at NOX2 (mediated by casein kinase 2 (CK2)) (Kim et al., 2009) and at p40<sup>phox</sup>, the phosphorylation of which leads to the suppression of NOX activity (Lopes et al., 2004).

The third example is NOX4 (Figure 3D). The activation of NOX4 does not explicitly require the multi-unit assembly of cytosolic regulators. Still, NOX4 interacts with several cytosolic molecules to modulate its activity. For example, NOX4 interacts with a chaperon protein, calnexin, to facilitate its maturation (Prior et al., 2016). NOX4 also interacts with a mitochondrial protein, polymerase  $\delta$ -interacting protein 2 (Poldip2), to increase its activity (Lyle et al., 2009). Poldip2 is a molecule interacting with DNA polymerase  $\delta$  p50 subunit and with the proteins constituting the mitochondrial DNA nucleoid, through which NOX4 activity is associated with the TCA cycle and metabolic reprogramming (Andjongo et al., 2021; Kulik et al., 2021). In fact, metabolism-related cytokines, such as insulin and IGF-1, are known to increase NOX4 expression (Meng et al., 2008; Schroder et al., 2009; Kim et al., 2012). Cytokine-enhanced upregulation of NOX has also been reported in the TGFβ-mediated pulmonary remodeling (Watson et al., 2016) (Figure 3B). In addition to the mitochondria, Poldip2 interacts and activates the Rho GEF,

epithelial cell transforming sequence 2 (Ect2), to enhance actin filament polymerization, thereby linking the NOX4 activity to cytoskeletal dynamics (Huff et al., 2019). As for the phosphorylation-mediated PTMs, in contrast to NOX1-3, mostly regulated by serine/threonine kinases, NOX4 is primarily regulated by protein tyrosine kinases (PTKs) such as Src kinase. The phosphorylation of Tyr-491 on NOX4, for example, promotes NOX4 association with Src homology 2-(SH2-) domain-containing protein tyrosine phosphatase (SHP) substrate-1 (SHPS-1), through an adaptor protein, growth factor receptor-bound protein 2 (Grb2) (Xi et al., 2013). SHPS-1 is a transmembrane protein that serves as a scaffold to cluster membrane receptors such as IGF-1 receptor (IGF-1R) with other signaling and adapter molecules, including protein tyrosine kinases, Src family kinase (SrcFK), focal adhesion kinase- (FAK-) related cytosolic kinase, NOX4, SHP-2, Grb2, Janus kinase 2 (Jak2), proline-rich tyrosine kinase 2 (Pyk2), and integrin-associated protein (IAP) (Oshima et al., 2002; Maile et al., 2008; Shen et al., 2009; Xi et al., 2013). Among them, IAP is a transmembrane protein associated with several integrins, including the broadly expressed RGD receptor avß3, the platelet-fibrinogen receptor aIIbß3, and the collagen receptor α2β1. In IGF-1 signaling, the SHPS-1-mediated association of IGF-1R with SHP-2 and Src kinase regulates the lifetime of phosphorylated IGF-1R and the duration of IGF-1 signaling. The association of IGF-1R with IAP enables the crosstalk between IGF-1R and integrin/FAK signaling, by which growth factor stimulation can be coupled with cell-ECM interactions (Maile et al., 2003).

NOX4 is not the only NOX family member that can bind to scaffold proteins involved in cytokine and integrin/ECM signaling. NOX2, for example, can be translocated to the cell front via the association of phosphorylated p47<sup>phox</sup> with scaffold proteins such as tumor necrosis factor (TNF) receptor-associated factor 4 (TRAF4) and Wiskott-Aldrich Syndrome protein (WASP) family verprolin homologous protein 1 (WAVE1) (Wu et al., 2003; Li et al., 2005; Anilkumar et al., 2008; Kim et al., 2017; Fukai and Ushio-Fukai, 2020). Reciprocally, TNFainduced Erk1/2 activation requires the association of phosphorylated p47<sup>phox</sup> with TRAF4 (Li et al., 2005). Likewise, vascular EGF- (VEGF-) induced JNK activation needs the interaction of p47<sup>phox</sup> with WAVE1 (Wu et al., 2003). The TRAF4-p47<sup>phox</sup> association also plays an important role in the TRAF4-mediated thrombosis, suppressed by NOX2 inhibition (Arthur et al., 2011). These lines of evidence suggest not only spatial confinement of X-ROS to the vicinity of signaling targets (as the lifetime of ROS is short (Marklund, 1976)) but also crosstalk between X-ROS and cytokine/ECM signaling that leads to feedback amplification or suppression. The feedback signal could occur at multiple levels, including genetic regulations (e.g., TGFβ, insulin, and IGF-1 are known to increase NOX4 expression (Ning et al., 2002; Meng et al., 2008; Schroder et al., 2009; Kim et al., 2012; Watson et al., 2016; Liu W. J. et al., 2021; Yazaki et al., 2021)), PTMs (e.g., phosphorylation- and oxidationmediated regulations), and ligand-receptor interactions. One example of ligand-receptor interactions is TGFB signaling, where ROS produced by NOX4 promotes the activation of latent TGF $\beta$ , an inactive form of TGF $\beta$  secreted and bound to ECM (Watson et al., 2016). The activated ligands, in turn, can stimulate not only the ROS-producing cells but also nearby non-ROS-producing cells, leading to a multi-scale (i.e., autonomous and non-autonomous) niche response in the TGF $\beta$ -ROS signaling. Another example is integrin, the most abundant receptor for cell–ECM interactions. Growing evidence suggests that integrins are redox-sensitive, and NOX4-derived ROS can activate integrins through the cleavage of integrin  $\alpha$  subunits (Wang et al., 1997; Ushio-Fukai, 2009; de Rezende et al., 2012; Eble and de Rezende, 2014).

# Module Box IV: Mechanics for the Regulation of Organ Size and Shape

To control cell shape and tissue topology, for decades, the dogma has been the interactions of diffusive extracellular cytokines and intracellular signaling molecules. It is suggested that the dynamic instability of interacting molecules can create spatiotemporal patterns to direct the assembly and remodeling of cytoskeleton and ECM, the mechanical output of which shapes cell and tissue boundaries and, in turn, determines cell fate. Conversely, little is known about whether the shape of cell and tissue boundary can spontaneously emerge through the mechanical instability of cytoskeleton and ECM and, in turn, direct the spatiotemporal patterns of signaling molecules and cytokines. Regardless of whether the chemical or the mechanical factors serve as the initial cues, cells need to continuously produce and respond to mechanical forces for the creation and maintenance of cell shape and tissue topology and often do so in synchrony with other cells (Cai D. et al., 2014). Unlike chemical signals, mechanical forces lack specificity and can be integrated, independent of the origins. Further, forces can be transmitted between and across cells through cytoskeletons, membranes, intercellular adhesions (Ragsdale et al., 1997; Vaezi et al., 2002), and ECM (Reinhart-King et al., 2008). Unlike the isotropic diffusion of cytokines, the transmission of forces within the boundary depends on the topology and structure of materials and hence can be fast, long-range, and highly anisotropic. Cells can likely take advantage of these properties to create long-range regulators and/or communicators. In fact, it has been shown that cells use membrane tension as a long-range inhibitor to regulate their polarization and morphology (Toriyama et al., 2010; Houk et al., 2012). We have also shown that epithelial cells create forces at collagen-based ECM and use them as a longrange coordinator to guide the self-assembly of tubular patterns (Guo et al., 2012).

Following the laws of thermodynamics, cell shape and tissue topology are determined by minimizing the surface free energy, which creates local forces at the boundaries, such as shear and/or normal stresses, that in turn evoke signaling activities to change cell fate. Shear stress, for example, is known to facilitate the respiratory barrier function and renal tubulogenesis, and failure in these processes leads to an abnormality such as polycystic kidney diseases (Sidhaye et al., 2008; Cattaneo et al., 2011). Similarly, normal stress that stretches the boundary between cells and ECM can lead to cell proliferation, whereas compression can lead to stem cell differentiation, as in the formation of teeth and cartilages (Terraciano et al., 2007; Mammoto et al., 2011; Aragona et al., 2013). In both cases, the forces are transduced into chemical signaling, such as the expression or nuclear translocation of transcriptional factors, Pax9, Sox-9, and/or YAP (Terraciano et al., 2007; Dupont et al., 2011; Mammoto et al., 2011). In this regard, cell mechanics and cytokine signaling appear to be both upstream and downstream of each other, with cell mechanics as a doubleedged sword to facilitate organ development and potentiate cancer progression.

From the physics perspective, cell mechanics contains the passive components and the active elements, corresponding to the mechanical structures/properties of cells and the forces created therein, respectively. In general, forces created or acting at the cell include isotropic ones, such as osmotic pressure regulated by ion channels/pumps and water channels, and anisotropic ones, such as shear stress, cytoskeletal polymerization-mediated expansion, actomyosin-mediated retraction, and adhesions at the cell-cell and cell-ECM interfaces. For osmotic pressure, one example is the NOX2mediated activation of ENaC, in which NOX2 produces ROS to activate the nearby ENaC (via cysteine oxidization) and induce sodium influx (Takemura et al., 2010; Goodson et al., 2012). A similar effect has been found in peroxynitrite (OONO<sup>-</sup>, created by NO +  $O_2^{-}$ ) mediated inhibitory cysteine glutathionylation on the sodium-potassium pump (Na<sup>+</sup>-K<sup>+</sup> ATPase), which causes intracellular sodium retention (Brown and Griendling, 2009; Figtree et al., 2009). The increment of intracellular sodium concentration, in turn, brings water into the cell through the water channels and aquaporin and induces calcium influx through the reverse mode of the sodium-calcium exchanger (NCX) (Tykocki et al., 2012; Ma and Liu, 2013; Yan et al., 2015; Chifflet and Hernandez, 2016) (Figures 3B,C). Depending on the cell type, calcium influx can activate NOX5, Duox1-2 (Brandes et al., 2014b; a), and/or PKC (Shirai and Saito, 2002), which can phosphorylate p47<sup>phox</sup>, p67<sup>phox</sup>, p40<sup>phox</sup>, Rac, and NOX2 (Cathcart, 2004; Brown and Griendling, 2009; Gorlach et al., 2015), leading to a positive feedback amplification on ROS-Ca<sup>2+</sup> signaling. Calcium and the activated Rac1 can further promote actomyosin association and actin filament polymerization, respectively, thereby connecting the feedback with cell mechanics.

Rac1 is not the only ROS-activated effector in cytoskeletal dynamics. SrcFK, for example, can be activated by ROS through cysteine oxidization to phosphorylate the Rho GEF ARHGEF1 and the Rho-associated protein kinase (ROCK), thereby promoting RhoA activation for actin filament polymerization and myosin light chain (MLC) phosphorylation for actomyosin contraction (MacKay et al., 2017). *Via* cysteine oxidization, ROS also enables the association of Ras GTPase-activating-like protein or IQ motif-containing GTPase activating protein 1, IQGAP1, with NOX2 and cytokine receptors such as VEGF receptor (VEGFR) at the lamellipodial leading edge (Ikeda et al., 2005; Kaplan et al., 2011) (**Figure 4A**). IQGAP1-3 are scaffold proteins interacting with more than 100 molecules. These molecules include CD44, Rac1, Cdc42, formin mDia1, inverted formin-2

(INF-2), WASP, microtubule plus-end binding protein CAP-GLY domain-containing linker protein 1 (CLIP1), and associated linker cytoplasmic protein 1 (CLASP1), adenomatous polyposis coli (APC), β-catenin, Mek1/2 kinase, Erk1/2, Src kinase, integrin-linked kinase (ILK), 5' AMPactivated protein kinase (AMPK), PTP, and ezrin (Brandt et al., 2007; Le Clainche et al., 2007; Watanabe et al., 2009; Malarkannan et al., 2012; White et al., 2012; Widmaier et al., 2012; Liu et al., 2014; Smith et al., 2015; Bartolini et al., 2016; Sayedyahossein et al., 2016; Hedman et al., 2021). IQGAPs also bind to CLASP2, YAP, and the regulators of YAP in the Hippo pathway, MST2, and LATS1 (Watanabe et al., 2009; Sayedyahossein et al., 2016; Quinn et al., 2021). Through these binding capacities, the cytokine-NOX2 signaling can confine microtubule plus end, ROS signals, kinase activities, and actin filament polymerization at the cell leading edge, by which it not only directs the microtubule transport-delivered surface receptors and signaling molecules to the moving front but also interferes with YAP-dependent mechanotransduction.

IQGAP1 is involved in microtubule dynamics. To date, the most well-studied system for the coupling of X-ROS and microtubule dynamics is the cardiomyocytes. These cells are huge (with cell volume  $\geq 40,000 \,\mu\text{m}^3$ ), in a rod shape packed with dense cytoskeletal networks that can be divided into two groups-the contractile actomyosin arrays organized into myofibrils and the viscoelastic microtubule bundles aligned in the longitudinal direction of the cells. Given the long persistence length of microtubules (~0.5-1.5 mm<sup>2</sup> (Gittes et al., 1993; van Mameren et al., 2009)), it is plausible that microtubules serve as the mechanical sensor to detect the conformational change of the cell as a whole. In fact, it was shown that physiologic stretch elicits a rapid activation of NOX2 in these cells, likely through the release of microtubule-bound Rac1-GTP (Best et al., 1996) by mechanical deformation to activate nearby NOX2. NOX2derived ROS then sensitize nearby sarcoplasmic reticulum (SR) calcium channels, ryanodine receptors (RyRs), by cysteine oxidation to release calcium ions in response to the mechanical stretch as a rapid and localized mechano-chemo transduction process (Prosser et al., 2011). Conversely, in muscle contraction, microtubules buckle to bear the mechanical load created by the actomyosin contraction. The buckling not only elicits X-ROS signaling but also provides resistance against the contraction (Robison et al., 2016). The amount of elicited X-ROS signals depends on the PTMs of microtubules. It was shown that detyrosinated microtubules, a stable microtubule subpopulation, are responsible for muscle stiffness and X-ROS generation during contraction (Robison et al., 2016). As a result, suppressing microtubule detyrosination provides a therapeutic strategy to treat patients with hypertrophic or dilated cardiomyopathies, both of which carry a higher amount of detyrosinated microtubules than normal (Chen et al., 2018).

With the cytoskeletal dynamics and NOX activity mutually influencing each other, it is plausible that NOX is subject to the mechanical modulation in cell morphogenesis and involved in cell mechanotransduction. Indeed, recent studies have shown that cyclic stretch increases mitochondria-released ROS, FAK phosphorylation at Tyr397, and PKC activity (Ali et al., 2006). PKC and the released ROS, in turn, activate (through phosphorylation and/or cysteine oxidization) p47<sup>phox</sup>, p67<sup>phox</sup>, p40<sup>phox</sup>, Rac, NOX2, SrcFK, and NOX4 (Shirai and Saito, 2002; Cathcart, 2004; Brown and Griendling, 2009; Xi et al., 2013; Gorlach et al., 2015) to enhance ROS production, whereas FAK recruits Src kinase to the integrin cytoplasmic tails and forms a complex therein to induce multiple responses including PI3K-AKT activation, actin filament polymerization, and focal adhesion complex formation (Bolos et al., 2010; Zhao and Guan, 2011). The cysteine-oxidized SrcFK then activates ARHGEF1 and ROCK to enhance MLC phosphorylation, stress fiber assembly, and force generation at the cell-ECM interface (Tominaga et al., 2000; MacKay et al., 2017), by which the mechanical stretch between cells and the ECM could be reinforced (Figure 2C). In addition, mechanical stretch can induce persistent calcium influx via microtubuledependent activation of NOX2 to generate ROS, which acts on redox-sensitive transient receptor potential (TRP) channels (Song et al., 2011; Taylor-Clark, 2016; Pires and Earley, 2017; Pratt et al., 2020; Singh et al., 2021) such as TRPA1, TRPM2, TRPV4, and TRPC6 to evoke or prolong calcium signaling, thereby enhancing PKC activity (Shirai and Saito, 2002) and actomyosin assembly and contractility (through, e.g., activating the CaM (calmodulin)/ MLCK-signaling pathway (Zergane et al., 2021)). The integration of these effects can lead to a self-perpetuated amplification of the cellular mechanical responses, which might serve as a switch for the selection of stem cell fate. One example is the cyclic stretchinduced cardiomyogenesis of mouse embryonic stem cells in the presence of Wnt/ $\beta$ -catenin signaling (Heo and Lee, 2011). At the genetic level, mechanical stretch can modulate NOX and HIF-1a expressions (Grote et al., 2003; Schmelter et al., 2006; Sauer et al., 2008; Zhang et al., 2015). However, the effect is exposure timeand pattern-dependent (Goettsch et al., 2009) and can lead to positive or negative feedback regulations, a detailed review of which can be found elsewhere (Brandes et al., 2014a).

### Module Box V: Merlin, YAP, and Angiomotin as Transducers for Cell Mechanics and Tissue Topology

YAP/TAZ boost organ growth and are suppressed by the Hippo pathway (Wang et al., 2009; Zhao et al., 2010a; Li et al., 2010; Lian et al., 2010; Dupont et al., 2011; Yu et al., 2015; Panciera et al., 2017; Totaro et al., 2018b). YAP is referred to as WW domaincontaining transcription coactivator Yes-associated protein (Sudol, 1994), TAZ is referred to as transcriptional coactivator with PDZ-binding motif, also known as WW domain-containing transcription regulator 1 (WWTR1) (Sarmasti Emami et al., 2020), and the Hippo pathway, also known as the Salvador-Warts-Hippo (SWH) pathway, is a pathway that controls organ size by restraining cell proliferation and promoting apoptosis (Piccolo et al., 2014). Herein, PDZ stands for post-synaptic density 95, Discs large, and Zonula occludens-1, whereas the WW domain, named after the presence of two tryptophan (W) residues and also known as the rsp5-domain or WWP repeating motif, is a modular protein domain

preferentially binding to proline-rich, for example, PPXY and LPXY, or phosphor-serine/threonine-containing (e.g., p-SP/p-TP) motifs (Chen and Sudol, 1995; Sudol et al., 1995; Macias et al., 1996; Lu et al., 1999). YAP/TAZ has a critical role in stem cell self-renewal and tissue-specific progenitor cell self-expansion (Dong et al., 2007; Zhao et al., 2011b; Anton and Wandosell, 2021), where YAP/TAZ is accumulated and active in the cell nucleus (Camargo et al., 2007; Cao et al., 2008; Schlegelmilch et al., 2011; Silvis et al., 2011; Lavado et al., 2013). Moreover, as hyperactive YAP/TAZ leads to uncontrolled cell growth, a growing interest has been raised in the roles of YAP/TAZ in cancer progression (Saucedo and Edgar, 2007; Xu et al., 2009; Pan, 2010; Johnson and Halder, 2014; Mo et al., 2014; Lee Y. A. et al., 2018). In fact, YAP/TAZ contributes not only to tumor growth but also to drug resistance (Lai et al., 2011; Zhao and Yang, 2015). Likewise, self-sustained YAP activity has been found in CAFs, through mutually enhanced cell contractility and "inside-out" ECM stiffening, to remodel the niche mechanoenvironment (i.e., the tumor microenvironment (TME)), thereby promoting tumor progression (Calvo et al., 2013; Piccolo et al., 2014). To date, the regulation of YAP/TAZ has been intensively studied. Herein, we focus on X-ROS-dependent cytokine/ECM signaling in the regulation of the Hippo pathway. In order to proceed, a short introduction of the Hippo pathway is given below. More details of this pathway can be found elsewhere (Pan, 2010; Yu and Guan, 2013; Piccolo et al., 2014; Zanconato et al., 2016a; Zanconato et al., 2016b; Meng et al., 2016; Panciera et al., 2017; Zheng and Pan, 2019; Sarmasti Emami et al., 2020; Zhao et al., 2020; Wang et al., 2021).

The Hippo pathway is processed by several serine/threonine kinases and cofactors in a multiplexed, sequential manner. These molecules include the mammalian Ste20-like protein kinase 1/2 (MST1/2), the Salvador family WW domain-containing protein 1 (SAV1), the large tumor suppressor kinase 1/2 (LATS1/2), and the Mps one binder (MOB) kinase activator-like 1 (MOB1) (Piccolo et al., 2014; Sarmasti Emami et al., 2020) (Figure 4B). The signaling starts from the association of MST1/2 with SAV1 into a hetero-tetramer complex (2 MST and 2 SAV1), by which MST1/2 perform auto-activation (at T180). Activated MST1/2-SAV1 then phosphorylate MOB1 and LATS1/2 (in a complex form) to induce LATS1/2 auto-phosphorylation and autoactivation (LATS1 at T1079 and LATS2 at T1041 (Ma et al., 2019; Sarmasti Emami et al., 2020)). Other kinases that act in parallel to MST1/2 and activate LATS1/2 include mitogenactivated protein kinase kinase kinase kinases (MAP4Ks) (Meng et al., 2015) and serine/threonine kinase 25 (STK25) (Lim et al., 2019). Once activated, LATS1/2 phosphorylate YAP at S61, S109, S127, S381, and S397 (Zhao et al., 2010b; Mo et al., 2014; Piccolo et al., 2014; Ni et al., 2015; Elisi et al., 2018; Mana-Capelli and Mccollum, 2018; Sarmasti Emami et al., 2020), which is counteracted by the protein phosphatase magnesiumdependent 1A (PPM1A or PP2Ca) (Zhou et al., 2021), PP1A (Li et al., 2016), and PP2A (Schlegelmilch et al., 2011), or the prephosphorylation of YAP at S128 by Nemo-like kinase (NLK) (Hong et al., 2017; Moon et al., 2017). YAP with phosphorylation at S127 is a target of 14-3-3 proteins, whereas phosphorylation at YAP S381 or S397 creates a phosphor-degron motif for the subsequent phosphorylation by casein kinase 1 (CK1) and binding of Skp1-Cullin-1-F-box protein (SCF) type of E3 ubiquitin ligase,  $SCF^{\beta-TrCP}$ , which catalyzes the ubiquitination and degradation of YAP (Hao et al., 2008; Zhao et al., 2010b; Liu et al., 2010; Iwasa et al., 2013; He et al., 2016). The association of YAP with 14-3-3 proteins sequesters YAP in the cytoplasm or at the adherens junctions (AJs) (via the association of AJ α-catenin with 14-3-3 proteins and YAP (through its WW-domain)) (Schlegelmilch et al., 2011; Yu and Guan, 2013). In epithelial organs, 14-3-3 protein-potentiated association of YAP with acatenin depends on the cell density and the maturation of AJs. When the cells are at low-density states or with immature AJs, αcatenin fails to sequester YAP at AJs, and the cytoplasmic 14-3-3 protein-YAP complex is subject to the PPM1A/PP2A-mediated dephosphorylation at YAP S127 (Schlegelmilch et al., 2011; Zhou et al., 2021).

14-3-3 proteins are not the only molecules to sequester YAP. Switch/sucrose non-fermentable (SWI/SWF), an ATP-dependent chromatin remodeling complex, can bind to YAP in the nucleus through AT-rich interactive domain-containing protein 1A (ARID1A), thereby inactivating the transcriptional activity of YAP (Chang et al., 2018). Dishevelled (DVL), a scaffold molecule in the Wnt pathway (Barry et al., 2013), can sequester pS127-YAP in the cytoplasm (Lee Y. et al., 2018). Angiomotin (AMOT), a PDZ domain-binding protein, can bind to and sequester YAP in the cytoplasm and/or at the tight junctions (TJs), but the association acts through the YAP WW domain without YAP S127 phosphorylation (Zhao et al., 2011a; Yi et al., 2013; Moleirinho et al., 2017; Wang et al., 2021) and depends on actin dynamics because actin filaments and YAP compete for the same binding site at AMOT (Yi et al., 2011; Li et al., 2015). Likewise, protein tyrosine phosphatase non-receptor type 14 (PTPN14) can bind to YAP through the WW domains of YAP and sequester YAP at AJs or in the cytoplasm without YAP S127 phosphorylation (Poernbacher et al., 2012; Wilson et al., 2014). Other molecules that can sequester YAP without YAP S127 phosphorylation include axin (Azzolin et al., 2014) and IQGAP1 (Quinn et al., 2021), both of which are the scaffold molecules for  $\beta$ -catenin. Axin, a scaffold that assembles APC,  $\beta$ catenin, and GSK3 $\beta$  into the destruction complex of  $\beta$ -catenin in the Wnt signaling pathway, can bind to and sequester YAP in the cytoplasm (Azzolin et al., 2014) or the multi-vesicular body (MVB) (Gargini et al., 2016; Rivas et al., 2018; Anton and Wandosell, 2021). In comparison, the association of IQGAP1 and YAP occurs through the DNA-binding domain for the transcriptional enhancer factor TEF-1, TEC1, and AbaA (TEA domain- (TEAD-)) binding domain of YAP and does not explicitly sequester YAP into the nucleus or the cytoplasm. Instead, its major effect is to block YAP-TEAD nuclear interaction (Sayedyahossein et al., 2016). A similar mechanism is AMPK-mediated phosphorylation on YAP S94, which disrupts the YAP-TEAD association (Mo et al., 2015) in metabolic and nutrient-sensing regulations (Santinon et al., 2016). Intriguingly, IQGAP1 can bind to and suppress the activity of MST2 and LATS1 (Quinn et al., 2021), and as a result, it suppresses both the Hippo pathway and YAP signaling (Figures 4B,C).

YAP sequestered by 14-3-3 proteins or β-catenin destruction complex in the cytoplasm is subject to degradation via the ubiquitin-proteasome pathway (Zhao et al., 2020). By contrast, YAP molecules sequestered in the MVB, with IQGAP1, or at the AJs/TJs are prevented from degradation or nuclear translocation. Only free YAP (with or without S127 phosphorylation) can translocate into the nucleus for the transcription of target genes (Zhao et al., 2020) such as PD-L1 (Janse van Rensburg et al., 2018), connective tissue growth factor (CTGF), fibroblast growth factor 1 (FGF1), receptor tyrosine kinase AXL, BMP4, and pro-apoptotic or pro-survival genes (Kim M.-K. et al., 2018; Sarmasti Emami et al., 2020; Quinn et al., 2021). These genes are involved in not only organ development but also tumorigenesis, including enhanced cell migration and immune evasion. The nuclear accumulation of YAP, however, is counteracted by the neurofibromatosis type 2 (NF2, a 4.1 protein, ezrin, radixin, and moesin (FERM) domaincontaining molecule, also known as moesin/ezrin/radixin-like protein (Merlin) or schwannomin (Bretscher et al., 2002; Baser et al., 2003; McClatchey, 2003)) which exports YAP out of the nucleus via its nuclear localization signal (NLS) sequence and nuclear export signal (NES) sequences (Gladden et al., 2010; Furukawa et al., 2017). Such Merlin-assisted nuclear export of YAP acts independently of the Hippo pathway or other related molecules such as AMOT. Instead, it requires cells at high densities or with high intercellular tension (Furukawa et al., 2017). Another molecule for YAP nuclear export is DVL, which acts only when YAP S127 is phosphorylated (Barry et al., 2013; Lee Y. et al., 2018).

These lines of evidence indicate that the regulation of the Hippo pathway and YAP signaling occurs through PTMs (e.g., phosphorylation and ubiquitination) and compartmentalization. The question is how these processes are linked to the organ size and shape, or more explicitly, to the ROS-dependent cytokine/ ECM signaling and the cell mechanics in organ development, repair, and malignancy. Mechanistically, MST1 and MST2 share functional redundancy. They contain an N-terminal kinase domain and a C-terminal coiled-coil SAV/Ras-association domain family (RASSF)/HPO (SARAH) domain with a flexible linker in between (Jin et al., 2012; Ni et al., 2013). SARAH domains are self-associable. Through SARAH-domain self-association, MST1/2 form homodimers and undergo transautophosphorylation at T180 (in the kinase domain) and at T325, T336, and T378 (in the linker region) (Bae et al., 2017). The transphosphorylation of T180 leads to MST1/2 auto-activation. The trans-phosphorylation of the linker, however, inhibits MST1/2 by recruiting a multi-subunit PP2A complex, striatin- (STRN-) interacting phosphatase and kinase (STRIPAK), through an adaptor, sarcolemmal membrane-associated protein (SLMAP), to dephosphorylate T180 and counteract MST1/2 auto-activation (Bae et al., 2017). Initially defined as a non-canonical PP2A regulatory subunit (B subunit) (Moreno et al., 2000), STRN has a caveolin-binding domain, a coiled-coil domain, a Ca<sup>2+</sup>binding calmodulin-(CaM-) domain, and а tryptophan-aspartate- (WD-) repeat domain, by which it can recruit and bind to multiple partners (Hwang and Pallas, 2014). The resulting complex, STRIPAK, contains a PP2A catalytic subunit (PP2AC), scaffolding subunit (PP2AA), and the STRN regulatory subunit that recruits STRN-interacting protein (STRIP1/2), SLMAP, and members of the STE20 family of kinases (e.g., MST1/2) (Couzens et al., 2013).

The ability to auto-activate and recruit inhibitors to deactivate itself at the same time, as in the case of MST1/2 and STRIPAK, is not rare in biology. POPX2, for example, forms a trimeric complex with the Rac1/Cdc42 guanine nucleotide exchange factor ARHGEF7 (also known as the p21-activated protein kinase-exchange factor  $\beta$  ( $\beta$ PIX)) and PAK, wherein Rac1activated PAK is subject to immediate dephosphorylation by POPX2 (Kim P. R. et al., 2020). Another example is the complex formation of the scaffold molecule, muscle-selective A-kinase anchoring proteins (mAKAP), with cAMP-specific phosphodiesterase (PDE)-4D3 (PDE4D3) and PKA, wherein the PKA activity is subject to the downregulation of cAMP level by PDE4D3 (Sette and Conti, 1996; Lim et al., 1999; Rababa'h et al., 2013). From the thermodynamics point of view, having the auto-activation and auto-inhibition occur at the same time places the complex in a highly unstable state. However, from the evolutionary point of view, this scenario provides an ability to create instant Hippo "on/off" signals in response to tissue injury or remodeling. The inhibitory effect of STRIPAK on MST1/2 is antagonized by the association of SAV1, which contains an N-terminal flexible region, a tandem repeat of two WW domains, and a C-terminal SARAH domain (Bae et al., 2017). The N-terminal region of SAV1 has a FERM domainbinding motif to bind to FERM-domain proteins such as Merlin and Expanded (Ex) (Bretscher et al., 2002; Baser et al., 2003; McClatchey, 2003) and a protein interaction domain (PID) to bind to and suppress STRIPAK (Bae et al., 2017). Similar to the SARAH domains, the WW domains of SAV1 are self-associable (Ohnishi et al., 2007) but act through a domain-swapping mechanism between two SAV1s (Lin et al., 2020). Via the intermolecular association of SARAH and WW domains, two SAV1 and two MST1/2s can form a hetero-tetramer, thereby bringing the N-terminal of SAV1 to the proximity of STRIPAK to antagonize the phosphatase. However, the binding affinity between the SAV1 N-terminal and STRIPAK is low (with  $K_m$ ~100 µM (Bae et al., 2017)). Additional modulators are thus needed to facilitate the suppression.

The AJ- and TJ-associated factors, including WW domain and C2 domain-containing proteins (WWC), such as kidney and brain expressed protein (KIBRA /WWC1 (Hoffken et al., 2021)); PDZ-domain proteins, such as AMOT; and FERM domain proteins, such as Merlin, Ex, and PTPN14 appear to be the key modulators. Predominantly expressed in the kidney and the brain, the first key molecule, KIBRA, contains two WW domains (Kremerskothen et al., 2003), a potential coiled-coil domain, a C2 domain responsible for Ca<sup>2+</sup>-sensitive interaction with phospholipids, a class III PDZ-binding motif ADDV, and an atypical protein kinase C (aPKC) binding region (Baumgartner et al., 2010; Genevet et al., 2010; Yu et al., 2010; Boggiano and Fehon, 2012; Zhang et al., 2014; Su et al., 2017). More than 20 binding partners of KIBRA have been identified. These molecules include Merlin, Ex, FRM6 (FERM domain-containing protein 6), AMOT, PALS1- (protein associated with Caenorhabditis elegans

Lin-7 protein 1-) associated tight junction protein (PATJ), PTPN14, PP1, SAV1, LATS1/2, the mitotic serine/threonine kinase Aurora-A, PKCζ, and the apical polarity complexes PAR3/PAR6 $\beta$  (partition-defective 3/partition-defective 6 $\beta$ ) (Xiao et al., 2011a; Xiao et al., 2011b; Zhang et al., 2014; Zhou et al., 2017). At mature TJs, KIBRA forms a complex with Merlin, Ex, and AMOT to interact with MST1/2-SAV1 and LATS1/2-MOB1, thereby promoting LATS auto-activation and YAP phosphorylation (Zhang et al., 2014) (Figure 4D). By having such a complex formation, Merlin can likely be placed at the SAV1-STRIPAK binding interface, thereby stabilizing SAV1-STRIPAK interaction and suppressing STRIPAK activity (Bae et al., 2017). However, the association of Merlin with KIBRA is inhibited by Aurora-mediated phosphorylation at KIBRA S539, which is counteracted by PP1 and PTPN14 (Xiao et al., 2011b; Poernbacher et al., 2012; Wang W. et al., 2014), suggesting a link between cell mitosis and the Hippo pathway. In the presence of apicobasal polarity, KIBRA-Merlin-FRMD6 complex formation competes with Par3-aPKC- KIBRA complex formation (Suzuki and Ohno, 2006; Yoshihama et al., 2009; Zhou et al., 2017), and KIBRA directly suppresses aPKC and aPKC-mediated apical exocytosis (Yoshihama et al., 2011), by which cells can limit the expansion of apical surface, an important feature in stem cell homeostasis and absent in tumorigenesis.

The second key molecule, AMOT, is an AJ/TJ-associable PDZdomain protein that plays an important role in regulating the partitioning of Merlin and YAP, as shown in the differentiation of human pluripotent stem cells (Zaltsman et al., 2019). AMOT possesses an N-terminal domain, which contains a WW domainand actin-binding motif (157-191) that YAP and actin filaments compete binding to, followed by a coiled-coil domain that can bind to Merlin (Yi et al., 2011; Li et al., 2015), and a C-terminal PDZ domain that can bind to TJs (Hirate and Sasaki, 2014; Mana-Capelli et al., 2014). The competition of YAP and actin filaments with AMOT appears to depend on the "structural code" of the cells. In blastocysts, for example, the embryonic cells are segregated into an outer layer with cells forming apicobasal polarity and an inner layer without polarity formation. AMOT localizes to the AJs of non-polarized cells at the inner layer, with S176 phosphorylated by LATS, which inhibits actin binding, stabilizes the AMOT-LATS interaction (Dai et al., 2013; Hirate et al., 2013; Hirate and Sasaki, 2014), promotes AMOT-YAP association, and enables YAP phosphorylation (Mana-Capelli et al., 2014). By contrast, AMOT is unphosphorylated and sequestered to the apical actin at the outer layer, thereby releasing YAP for nuclear signaling (Hirate et al., 2013) (Figure 4D).

The third key molecule, Merlin, contains an N-terminal FERM domain (sequence 19–313), followed by one  $\alpha$ -helical domain (314–507) and one C-terminal domain (508–595) (Muranen et al., 2007; Li et al., 2015). The  $\alpha$  helical domain possesses a coiled-coil motif that can bind to AMOT (Yi et al., 2011; Li et al., 2015), whereas the N-terminal and the C-terminal can self-associate (McClatchey, 2003) with  $K_m \sim 3 \mu$ M, a much weaker affinity than that of ERM proteins ( $K_m \sim 0.016 \mu$ M) (Li et al., 2015). Merlin has many binding partners (Hennigan et al., 2019) through which it can associate with or dissociate from AJs. The

selection of binding partners is primarily modulated by Merlin PTMs such as phosphorylation and ubiquitination (Laulajainen et al., 2011). These PTMs displace the self-associated C-terminal and N-terminal of Merlin away from each other, thereby exposing the binding sites to, for example, MST1/2-SAV1, LATS1/2, YAP, AKT, paxillin, FAK, and integrin ß1 (Obremski et al., 1998; Fernandez-Valle et al., 2002; James et al., 2004; Tang et al., 2007; Yamauchi et al., 2008; Flaiz et al., 2009; Yi et al., 2011; Yin et al., 2013; Li et al., 2015; Bae et al., 2017). Alternatively, Merlin can bind to PIP<sub>2</sub> through its FERM domain, by which Merlin adopts an expanded conformation to expose the binding sites (Ali Khajeh et al., 2014). Thus, Merlin "with" and "without" PTMs (and/or PIP<sub>2</sub> binding) are often referred to as the "open" and "close" states, respectively. Historically, in the "close" state, Merlin has been known as the tumor suppressor (Li et al., 2015). For the "open" state, major phosphorylation sites include S10 and S518 by PKA (Laulajainen et al., 2008); S10, T230, and S315 by AKT (Tang et al., 2007; Laulajainen et al., 2011); and S518 by PAK (Shaw et al., 2001). Phosphorylating Merlin at S518 prevents Merlin from participating in the Hippo pathway and sequesters Merlin on the cell membrane through the association with the C-terminal of cell surface receptors such as CD44 (Morrison et al., 2001; Sherman and Gutmann, 2001) and/or bind to tubulin to enhance microtubule polymerization (Muranen et al., 2007). Merlin S518 phosphorylation is counteracted by myosin phosphatase target subunit 1- (MYPT1-) regulated PP1c, the phosphatase for MLC (Jin et al., 2006). MYPT1 is inactivated by ILK or ROCK-mediated phosphorylation at T696 (by ILK/ RCOK) and S854/T855 (by ROCK) (Serrano et al., 2013; Hartmann et al., 2015), which occurs during cell migration or spreading on stiff substrates. Alternatively, MYPT1 can be sequestered by phosphorylated MLC when cells are spreading on stiff substrates (Joo and Yamada, 2014). These lines of evidence provide an explanation for how stiff microenvironments might disable Merlin-mediated tumor suppression, enhance YAP nuclear translocation, and promote tumor invasion (Paszek et al., 2005; Guo et al., 2012).

In contrast to phosphorylation at S518, Merlin phosphorylated at S10, T230, and/or S315 is subject to ubiquitination and proteasome-mediated degradation (Laulajainen et al., 2011), which, however, requires S518 to be dephosphorylated (Li et al., 2015; Wei et al., 2020), suggesting that Merlin phosphorylated at S518 and Merlin phosphorylated at S10, T230, and/or S315 are two functionally exclusive states (Figure 4D). Merlin ubiquitination is mediated by the E3 ubiquitin ligase, neural precursor cell expressed developmentally downregulated protein 4 (NEDD4), which conjugates one or two ubiquitin molecules at Merlin K396 and K159 by the aid of AMOT (Wei et al., 2020). In this process, AMOT serves as a scaffold protein to bind to Merlin through their mutual coiled-coil domains (Yi et al., 2011; Li et al., 2015) and bind to NEDD4 through the association of its two PPXY motifs with the WW domains of NEDD4 (Skouloudaki and Walz, 2012). Although Merlin ubiquitination promotes the degradation of the Merlin-AMOT complex, it is required for MST-mediated LATS phosphorylation (Wei et al., 2020). The ubiquitinated

ROS in HIF-YAP-Notch Signaling

Merlin-AMOT complex can bind to the N-terminal FERMbinding domain (FBD) of LATS through the Merlin FERM domain (K<sub>m</sub> ~1.4 µM (Yin et al., 2013; Li et al., 2015)). Other associations include those between SAV1 and MOB-1 (Yin et al., 2013), between the Merlin FERM domain and the N-terminal FERM domain-binding motif of SAV1 (Bretscher et al., 2002; Baser et al., 2003; McClatchey, 2003; Bae et al., 2017), between the extreme N-terminal end of Merlin and a-catenin (Cole et al., 2008), and between AMOT and YAP (at the N-terminal actinbinding motif of AMOT (157-191)) (Mana-Capelli et al., 2014). Through these molecular associations, the ubiquitinated Merlin-AMOT complex likely promotes the clustering of YAP, LATS-MOB1, and MST-SAV1 at AJs (by Merlin-a-catenin-AJ association) or TJs (by AMOT PDZ domain-TJ association), wherein MST1/2 potentiate LATS1/2 auto-activation (Gladden et al., 2010; Hansen et al., 2015) (Figures 4B,D). In addition, independent of MST, AMOT can act along with MOB1 to promote LATS autophosphorylation and auto-activation (Mana-Capelli and Mccollum, 2018). Activated LATS phosphorylates not only YAP but also AMOT (at S175/S176), the phosphorylation of which suppresses actin binding to AMOT and stabilizes the binding between LATS-MOB1 and Merlin-AMOT (Dai et al., 2013; Hirate and Sasaki, 2014; Mana-Capelli et al., 2014; Moleirinho et al., 2017; Mana-Capelli and Mccollum, 2018) (Figure 4D). As a result, the Merlin-AMOT complex can likely promote LATS activation and YAP phosphorylation in a self-sustained manner.

The fourth key molecule, an AJ-associable FERM domain protein for YAP modulation, is PTPN14 (Wang et al., 2012; Huang et al., 2013; Liu et al., 2013; Wilson et al., 2014). PTPN14 contains an N-terminal FERM domain, followed by two PPXY motifs which are essential for the interactions with YAP and KIBRA through their WW domains (Poernbacher et al., 2012), and a C-terminal PTP catalytic domain which is essential to counteract Src kinase- or receptor tyrosine kinase- (RTK-) mediated phosphorylation at β-catenin Y654 and VE-cadherin, thereby stabilizing AJs (Van Veelen et al., 2011; Fu et al., 2020). Along with the PPXY motifs, the PTP domain of PTPN14 is required for the interactions with KIBRA (Wilson et al., 2014). Further, PTPN14 can bind to LATS1/2 and acts independently or cooperatively with KIBRA to enhance LATS1/2 auto-activation and YAP S127 phosphorylation, even in the absence of MST1/2 (Wilson et al., 2014). Thus, the KIBRA-AMOT-Merlin complex and KIBRA-PTPN14 complex can act in parallel to modulate YAP phosphorylation and sequestration at AJs (Figure 4D).

# Module BOX VI: The HIF/YAP/Notch Triad and PD-L1

YAP/TAZ forms complexes with HIF-1 $\alpha$  and functions as the transcription activator of HIF-1 $\alpha$  to enhance expressions of molecules involved in organ development, tissue homeostasis, and tumorigenesis (Xiang et al., 2015; Zhao et al., 2020). Under hypoxia, YAP binds to nuclear HIF-1 $\alpha$  and sustains its stability, thereby promoting the expression of pyruvate kinase isozymes M2 (PKM2), a key enzyme of glycolysis, in, for example, hepatocellular carcinoma cells (HCCs) (Zhang X. et al., 2018),

whereas in the cytoplasm, YAP enhances HIF-1a stability by inhibiting VHL-dependent degradation of hydroxylated HIF-1a (Ma et al., 2015; Zhao et al., 2020) (Figure 1A). Likewise, HIF-2a, another hypoxia responding subunit, has been found to increase YAP1 expression and activity, yet it does so without the involvement of Src kinase, PI3K, ERK, or MAPK signaling pathways (Ma et al., 2017). No direct association between YAP and HIF-2a was observed either (Ma et al., 2017). In addition to glycolysis, the YAP-HIF-1a complex promotes the transcription of genes involved in angiogenesis and cell growth (Zhao et al., 2020). Genes containing HREs that H1F-1a can bind to also include WWTR1 (i.e., TAZ) and SIAH1 (Zhao et al., 2020), and the TAZ-HIF-1a complex has been shown to promote the transcription of SIAH1 (Xiang et al., 2014; Xiang et al., 2015; Zhao et al., 2020). Similar to SIAH2 (Ma et al., 2015), SIAH1 induces LATS2 degradation and, in turn, TAZ nuclear localization (Xiang et al., 2014; Xiang et al., 2015; Zhao et al., 2020). Thus, positive feedback exists along the YAP/TAZ-HIF/SIAH axis (Figure 5A). In the development of growth plate, for example, HIF-1a was found to promote YAP activation and, in turn, upregulate the expression of sex-determining region-box 9tbox9 protein (SOX-9), a marker of stemness, for the maintenance of chondrogenic phenotype (Li H. et al., 2018).

Notch signaling is a highly conserved cell-cell communication mechanism by which cells regulate organ development, homeostasis, and repair through lateral inhibition (or "transinhibition") between neighboring cells (Kopan and Ilagan, 2009; Guruharsha et al., 2012; Kovall et al., 2017; Siebel and Lendahl, 2017). Notch is a cell surface receptor. Upon ligand binding, Notch is cleaved to release Notch intracellular domain (NICD), which translocates into the nucleus to bind to CSL (the transcriptional repressor CBF1/suppressor of hairless/Lag-1) or the human homolog RBPJ (recombination signal-binding protein for immunoglobulin KJ region, also known as CBF1) to facilitate the transcription of Notch target genes (Kopan and Ilagan, 2009). In tumorigenesis, Notch signaling promotes the CSC formation by reducing their proliferation yet increasing their resistance to therapies, thereby potentiating cancer cell dormancy and relapse (Janghorban et al., 2018). Moreover, Notch has been proposed as a mechanical sensor based on the observation that Notch can be activated by mechanical stretch and shear stress (Gordon et al., 2015; Chowdhury et al., 2016; Mack et al., 2017; Loerakker et al., 2018) and that Notch participates in mechanics-dependent periodic feather branch pattern formation (Cheng et al., 2018). For proper organ development, the specification of cell fate must be spatiotemporally coordinated with tissue morphogenesis. Therefore, it is plausible that the signaling of the "messengers" for tissue structure and mechanics (i.e., YAP/TAZ) is linked to Notch signaling pathways, by which cells can sense the mechanical changes in the niche through (e.g., cell-ECM adhesions and cell-cell contacts) and make a correspondent decision on the cell fate.

Several examples support the idea that YAP/TAZ and Notch signaling pathways are coupled (Totaro et al., 2018a). This coupling can be positive or negative, with YAP/TAZ acting upstream of, downstream of, or in parallel with Notch signaling. Such versatility is achieved by having YAP/TAZ and

Notch synergistically co-regulate shared target genes, having YAP/TAZ act upstream to regulate the expression of Notch ligands or receptors (thereby downregulating or upregulating Notch activity, respectively), or having Notch act upstream to upregulate or downregulate YAP activity (Totaro et al., 2018a). An example of the synergistic coupling is the control of smooth muscle differentiation from neural crest cells (Manderfield et al., 2015), where YAP/TAZ forms a complex with NICD to promote the transcription of Notch target genes for smooth muscle fate (Manderfield et al., 2012). Another example is the binary cell fate decision in the embryonic transition from morula to blastocyst. In this case, the binary decision occurs between cells becoming inner cell mass or outer-layer trophectoderm (TE) (Nishioka et al., 2009; Hirate et al., 2013; Leung and Zernicka-Goetz, 2013; Engel-Pizcueta and Pujades, 2021). In this case, Notch and YAP/ TAZ act in parallel and non-redundantly to drive the specification of the TE fate gene, Cdx2, by having Notch elicit the onset of Cdx2 expression and YAP maintain the expression of Cdx2, respectively (Watanabe et al., 2017). For YAP/TAZ acting upstream to upregulate Notch, one example is the binary cell fate decision made between cholangiocytes and hepatocytes in liver development (Kodama et al., 2004; Zong et al., 2009). In this case, YAP drives Notch2 expression and cholangiocyte specification and proliferation (Wu et al., 2017). Another is between the tip and stalk cells in angiogenesis, where YAP/TAZ suppresses the βcatenin-NICD-mediated expression of Notch ligand and endothelial Delta-like 4 (Dll4) protein in the tip cells (Yasuda et al., 2019). For YAP acting upstream to downregulate Notch, the example is the homeostasis of the epidermis, where Notch signaling is required for the transition of keratinocytes from the basal to the suprabasal layers (Siebel and Lendahl, 2017; Totaro et al., 2018a). In this case, the segregation of cell fate at different layers is achieved by spatially confining the Notch activity throughout the entire epidermis. Cells in the basal layer mainly express the Notch ligands Delta-like 1 (Dll1) and Jagged-2 (Jag2), whereas cells in the suprabasal layers mainly express the Notch receptors. Mechanical stretch and/or ECM stiffness in the basal layer activates YAP/TAZ signaling, which suppresses Notch activity by upregulating the expression of Notch ligands to counteract Notch activity through the "cisinhibition," that is, having the Notch ligand and receptor coexpressed on the same cell surface to suppress the Notch activity (Totaro et al., 2018a). Conversely, for Notch acting upstream of YAPTAZ, an example is the symmetric stem cell division in the embryonic brain development, where Notch upregulates YAP expression by the binding of NICD-RBPJ complex to the YAP promoter, thereby promoting neural stem cell symmetric proliferation (Li et al., 2012).

Recent studies on glioblastoma stem cells revealed the differential roles of HIF-1 $\alpha$  and HIF-2 $\alpha$  on Notch signaling. It was observed that these two HIF subunits bind to NICD in a competitive manner (Hu et al., 2014). When HIF-1 $\alpha$  binds to NICD and Notch-responsive promoters, Notch signaling is activated and cell differentiation is suppressed (Hu et al., 2014), thereby maintaining the undifferentiated cell state in various stem cells and precursor cells (Gustafsson et al., 2005). In contrast, when HIF-2 $\alpha$  binds to NICD, Notch signaling is repressed, leading to cell differentiation and stem

cell exhaustion (Hu et al., 2014). The coupling of NICD and HIF with the intracellular transducers of niche factor signaling is indeed a common behavior. In TGF- $\beta$  signaling, for example, both NICD and HIF-1 $\alpha$  can bind to the intracellular transducer of TGF- $\beta$  signals (Blokzijl et al., 2003; Huang Y. et al., 2021), smad3 (mothers against decapentaplegic homolog 3), and the association of HIF-1 $\alpha$  and smad3 has been shown to switch the functionality of TGF- $\beta$  signaling to glycolysis in non-small cell lung cancer (NSCLC) (Huang Y. et al., 2021).

Recently, applying blockade antibodies against PD-1 and its ligand PD-L1 has become a promising strategy for treating advanced cancers (Brahmer et al., 2012; Topalian et al., 2012). The capacity of immune suppression is also one essential feature in the mesenchymal stem cell- (MSC-) based cell therapy (Ankrum et al., 2014; Jiang and Xu, 2020). A growing interest has thus been focused on the interplay of PD-L1 and HIF/Notch/ YAP signaling pathways due to the exclusive involvement of HIF/ Notch/YAP signaling in the development and homeostasis of stem cells and in the progression of cancers. In particular, YAP can bind to the PD-L1 enhancer region to promote PD-L1 expression, independent of any existing signaling factors and pathways known to upregulate PD-L1, such as EGFR, AKT, MAPK, and interferon- (IFN-) y (Kim M. H. et al., 2018). In addition to being hypoxic, the TME contains multiple inflammatory factors such as interleukin-6 (IL-6) and remodeling factors such as TGF-\beta, which can activate signal transducer and activator of transcription 3 (STAT3) to increase the synthesis of HIF-1a and bind to NICD for a synergistic operation on Notch target genes, including the upregulation of PD-L1 expression (Blokzijl et al., 2003; Lee et al., 2009; Yu et al., 2009; Fan et al., 2013; Kitamura et al., 2017; Gupta et al., 2018; Kunnumakkara et al., 2018; Wen et al., 2020). Thus, the pharmaceutical targeting on YAP/Notch/HIF signaling pathways has been proposed as a potential adjunct therapy for cancer treatment, along with the conventional chemotherapy and immune therapy (Janghorban et al., 2018).

## **AUTHOR CONTRIBUTIONS**

C-LG prepared and wrote the entire manuscript, including the figures and Math Box.

## FUNDING

This work was supported by the Taiwan Ministry of Science and Technology *via* Grant MOST 107-2112-M-001-040-MY3, MOST 110-2112-M-001-039, and MOST 110-2314-B-001-004 and by Academia Sinica *via* Grant AS-TP-109-M04.

## ACKNOWLEDGMENTS

C-LG acknowledged the thoughtful discussion with Rita Yen-Hua Huang at the Taiwan Medical University and the support from the Institute of Physics, Academia Sinica.

### REFERENCES

- Abdollahi, H., Harris, L. J., Zhang, P., Mcilhenny, S., Srinivas, V., Tulenko, T., et al. (2011). The Role of Hypoxia in Stem Cell Differentiation and Therapeutics. J. Surg. Res. 165, 112–117. doi:10.1016/j.jss.2009.09.057
- Abe, J.-i., Kusuhara, M., Ulevitch, R. J., Berk, B. C., and Lee, J.-D. (1996). Big Mitogen-Activated Protein Kinase 1 (BMK1) Is a Redox-Sensitive Kinase. J. Biol. Chem. 271, 16586–16590. doi:10.1074/jbc.271.28.16586
- Abo, A., Webb, M. R., Grogan, A., and Segal, A. W. (1994). Activation of NADPH Oxidase Involves the Dissociation of P21rac from its Inhibitory GDP/GTP Exchange Protein (rhoGDI) Followed by its Translocation to the Plasma Membrane. *Biochem. J.* 298, 585–591. doi:10.1042/bj2980585
- Aceto, N., Bardia, A., Miyamoto, D. T., Donaldson, M. C., Wittner, B. S., Spencer, J. A., et al. (2014). Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis. *Cell* 158, 1110–1122. doi:10.1016/j.cell.2014.07.013
- Ago, T., Kuribayashi, F., Hiroaki, H., Takeya, R., Ito, T., Kohda, D., et al. (2003). Phosphorylation of P47 Phox Directs Phox Homology Domain from SH3 Domain toward Phosphoinositides, Leading to Phagocyte NADPH Oxidase Activation. *Proc. Natl. Acad. Sci. U.S.A.* 100, 4474–4479. doi:10.1073/pnas. 0735712100
- Aikawa, R., Komuro, I., Yamazaki, T., Zou, Y., Kudoh, S., Tanaka, M., et al. (1997). Oxidative Stress Activates Extracellular Signal-Regulated Kinases through Src and Ras in Cultured Cardiac Myocytes of Neonatal Rats. J. Clin. Invest. 100, 1813–1821. doi:10.1172/jci119709
- Al-Eisa, A., and Dhaunsi, G. S. (2017). NOX-mediated Impairment of PDGF-Induced DNA Synthesis in Peripheral Blood Lymphocytes of Children with Idiopathic Nephrotic Syndrome. *Pediatr. Res.* 82, 629–633. doi:10.1038/pr. 2017.122
- Ali Khajeh, J., Ju, J. H., Atchiba, M., Allaire, M., Stanley, C., Heller, W. T., et al. (2014). Molecular Conformation of the Full-Length Tumor Suppressor NF2/ Merlin-A Small-Angle Neutron Scattering Study. J. Mol. Biol. 426, 2755–2768. doi:10.1016/j.jmb.2014.05.011
- Ali, M. H., Mungai, P. T., and Schumacker, P. T. (2006). Stretch-induced Phosphorylation of Focal Adhesion Kinase in Endothelial Cells: Role of Mitochondrial Oxidants. Am. J. Physiology-Lung Cell. Mol. Physiology 291, L38–L45. doi:10.1152/ajplung.00287.2004
- Álvarez-Santos, M. D., Álvarez-González, M., Estrada-Soto, S., and Bazán-Perkins, B. (2020). Regulation of Myosin Light-Chain Phosphatase Activity to Generate Airway Smooth Muscle Hypercontractility. *Front. Physiol.* 11, 701. doi:10.3389/ fphys.2020.00701
- Ancel, J., Birembaut, P., Dewolf, M., Durlach, A., Nawrocki-Raby, B., Dalstein, V., et al. (2019). Programmed Death-Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC. *Cancers (Basel)* 11. doi:10.3390/ cancers11101411
- Andjongo, É., Benhamouche, S., Bouraoui, A., and Baciou, L. (2021). PolDIP2, une protéine clé de la régulation du fonctionnement mitochondrial et du métabolisme cellulaire. *Med. Sci. Paris.* 37, 97–100. doi:10.1051/medsci/2020263
- Andre, L., Fauconnier, J., Reboul, C., Feillet-Coudray, C., Meschin, P., Farah, C., et al. (2013). Subendocardial Increase in Reactive Oxygen Species Production Affects Regional Contractile Function in Ischemic Heart Failure. *Antioxidants Redox Signal.* 18, 1009–1020. doi:10.1089/ars.2012.4534
- Andreyev, A. Y., Kushnareva, Y. E., and Starkov, A. A. (2005). Mitochondrial Metabolism of Reactive Oxygen Species. *Biochem. Mosc.* 70, 200–214. doi:10. 1007/s10541-005-0102-7
- Anilkumar, N., Weber, R., Zhang, M., Brewer, A., and Shah, A. M. (2008). Nox4 and Nox2 NADPH Oxidases Mediate Distinct Cellular Redox Signaling Responses to Agonist Stimulation. *Atvb* 28, 1347–1354. doi:10.1161/atvbaha. 108.164277
- Ankrum, J. A., Ong, J. F., and Karp, J. M. (2014). Mesenchymal Stem Cells: Immune Evasive, Not Immune Privileged. *Nat. Biotechnol.* 32, 252–260. doi:10. 1038/nbt.2816
- Anraku, Y. (1988). Bacterial Electron Transport Chains. Annu. Rev. Biochem. 57, 101–132. doi:10.1146/annurev.bi.57.070188.000533
- Antón, I. M., and Wandosell, F. (2021). WIP, YAP/TAZ and Actin Connections Orchestrate Development and Transformation in the Central Nervous System. *Front. Cell Dev. Biol.* 9, 673986. doi:10.3389/fcell.2021.673986

- Aponte, P. M., and Caicedo, A. (2017). Stemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment. *Stem Cells Int.* 2017, 5619472. doi:10. 1155/2017/5619472
- Aragona, M., Panciera, T., Manfrin, A., Giulitti, S., Michielin, F., Elvassore, N., et al. (2013). A Mechanical Checkpoint Controls Multicellular Growth through YAP/TAZ Regulation by Actin-Processing Factors. *Cell* 154, 1047–1059. doi:10. 1016/j.cell.2013.07.042
- Artavanis-Tsakonas, S., Rand, M. D., and Lake, R. J. (1999). Notch Signaling: Cell Fate Control and Signal Integration in Development. *Science* 284, 770–776. doi:10.1126/science.284.5415.770
- Arthur, J. F., Shen, Y., Gardiner, E. E., Coleman, L., Kenny, D., Andrews, R. K., et al. (2011). TNF Receptor-Associated Factor 4 (TRAF4) Is a Novel Binding Partner of Glycoprotein Ib and Glycoprotein VI in Human Platelets. *J. Thromb. Haemost.* 9, 163–172. doi:10.1111/j.1538-7836.2010.04091.x
- Au, H.-K., Peng, S.-W., Guo, C.-L., Lin, C.-C., Wang, Y.-L., Kuo, Y.-C., et al. (2021). Niche Laminin and IGF-1 Additively Coordinate the Maintenance of Oct-4 through CD49f/IGF-1r-Hif-2a Feedforward Loop in Mouse Germline Stem Cells. Front. Cell Dev. Biol. 9, 646644. doi:10.3389/fcell.2021.646644
- Azimi, I., Petersen, R. M., Thompson, E. W., Roberts-Thomson, S. J., and Monteith, G. R. (2017). Hypoxia-induced Reactive Oxygen Species Mediate N-Cadherin and SERPINE1 Expression, EGFR Signalling and Motility in MDA-MB-468 Breast Cancer Cells. *Sci. Rep.* 7, 15140. doi:10.1038/s41598-017-15474-7
- Azzolin, L., Panciera, T., Soligo, S., Enzo, E., Bicciato, S., Dupont, S., et al. (2014). YAP/TAZ Incorporation in the β-Catenin Destruction Complex Orchestrates the Wnt Response. *Cell* 158, 157–170. doi:10.1016/j.cell.2014.06.013
- Bae, S. J., Ni, L., Osinski, A., Tomchick, D. R., Brautigam, C. A., and Luo, X. (2017). SAV1 Promotes Hippo Kinase Activation through Antagonizing the PP2A Phosphatase STRIPAK. *Elife* 6. doi:10.7554/elife.30278
- Bailly, C. (2020). Regulation of PD-L1 Expression on Cancer Cells with ROS-Modulating Drugs. Life Sci. 246, 117403. doi:10.1016/j.lfs.2020.117403
- Balistreri, C. R., Madonna, R., Melino, G., and Caruso, C. (2016). The Emerging Role of Notch Pathway in Ageing: Focus on the Related Mechanisms in Age-Related Diseases. Ageing Res. Rev. 29, 50–65. doi:10.1016/j.arr.2016.06.004
- Barry, E. R., Morikawa, T., Butler, B. L., Shrestha, K., De La Rosa, R., Yan, K. S., et al. (2013). Restriction of Intestinal Stem Cell Expansion and the Regenerative Response by YAP. *Nature* 493, 106–110. doi:10.1038/nature11693
- Barsoum, I. B., Smallwood, C. A., Siemens, D. R., and Graham, C. H. (2014). A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells. *Cancer Res.* 74, 665–674. doi:10.1158/0008-5472.can-13-0992
- Bartolini, F., Andres-Delgado, L., Qu, X., Nik, S., Ramalingam, N., Kremer, L., et al. (2016). An mDia1-INF2 Formin Activation Cascade Facilitated by IQGAP1 Regulates Stable Microtubules in Migrating Cells. *MBoC* 27, 1797–1808. doi:10. 1091/mbc.e15-07-0489
- Baser, M. E., R. Evans, D. G., and Gutmann, D. H. (2003). Neurofibromatosis 2. Curr. Opin. Neurology 16, 27–33. doi:10.1097/00019052-200302000-00004
- Basu, S., Totty, N. F., Irwin, M. S., Sudol, M., and Downward, J. (2003). Akt Phosphorylates the Yes-Associated Protein, YAP, to Induce Interaction with 14-3-3 and Attenuation of P73-Mediated Apoptosis. *Mol. Cell* 11, 11–23. doi:10. 1016/s1097-2765(02)00776-1
- Basu, U., Case, A. J., Liu, J., Tian, J., Li, Y.-L., and Zimmerman, M. C. (2019). Redox-sensitive Calcium/calmodulin-dependent Protein Kinase IIa in Angiotensin II Intra-neuronal Signaling and Hypertension. *Redox Biol.* 27, 101230. doi:10.1016/j.redox.2019.101230
- Battelli, M. G., Polito, L., Bortolotti, M., and Bolognesi, A. (2016a). Xanthine Oxidoreductase-Derived Reactive Species: Physiological and Pathological Effects. Oxid. Med. Cell Longev. 2016, 3527579. doi:10.1155/2016/3527579
- Battelli, M. G., Polito, L., Bortolotti, M., and Bolognesi, A. (2016b). Xanthine Oxidoreductase in Cancer: More Than a Differentiation Marker. *Cancer Med.* 5, 546–557. doi:10.1002/cam4.601
- Baumgartner, R., Poernbacher, I., Buser, N., Hafen, E., and Stocker, H. (2010). The WW Domain Protein Kibra Acts Upstream of Hippo in Drosophila. *Dev. Cell* 18, 309–316. doi:10.1016/j.devcel.2009.12.013
- Bays, J. L., Campbell, H. K., Heidema, C., Sebbagh, M., and Demali, K. A. (2017). Linking E-Cadherin Mechanotransduction to Cell Metabolism through Force-Mediated Activation of AMPK. *Nat. Cell Biol.* 19, 724–731. doi:10.1038/ ncb3537

- Bedard, K., and Krause, K.-H. (2007). The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology. *Physiol. Rev.* 87, 245–313. doi:10.1152/physrev.00044.2005
- Ben Mahdi, M. H., Andrieu, V., and Pasquier, C. (2000). Focal Adhesion Kinase Regulation by Oxidative Stress in Different Cell Types. *IUBMB Life* 50, 291–299. doi:10.1080/15216540051081038
- Bergert, M., Lembo, S., Sharma, S., Russo, L., Milovanović, D., Gretarsson, K. H., et al. (2021). Cell Surface Mechanics Gate Embryonic Stem Cell Differentiation. *Cell Stem Cell* 28, 209–216. doi:10.1016/j.stem.2020.10.017
- Besse-Patin, A., and Estall, J. L. (20142014). An Intimate Relationship between ROS and Insulin Signalling: Implications for Antioxidant Treatment of Fatty Liver Disease. *Int. J. Cell Biol.* 2014, 519153. doi:10.1155/2014/519153
- Best, A., Ahmed, S., Kozma, R., and Lim, L. (1996). The Ras-Related GTPase Rac1 Binds Tubulin. J. Biol. Chem. 271, 3756–3762. doi:10.1074/jbc.271.7.3756
- Bey, E. A., Xu, B., Bhattacharjee, A., Oldfield, C. M., Zhao, X., Li, Q., et al. (2004). Protein Kinase Cδ Is Required for p47phoxPhosphorylation and Translocation in Activated Human Monocytes. J. Immunol. 173, 5730–5738. doi:10.4049/ jimmunol.173.9.5730
- Bleier, L., and Dröse, S. (2013). Superoxide Generation by Complex III: From Mechanistic Rationales to Functional Consequences. *Biochimica Biophysica Acta (BBA) - Bioenergetics* 1827, 1320–1331. doi:10.1016/j.bbabio.2012.12.002
- Block, K., Eid, A., Griendling, K. K., Lee, D.-Y., Wittrant, Y., and Gorin, Y. (2008). Nox4 NAD(P)H Oxidase Mediates Src-dependent Tyrosine Phosphorylation of PDK-1 in Response to Angiotensin II. *J. Biol. Chem.* 283, 24061–24076. doi:10. 1074/jbc.m803964200
- Blokzijl, A., Dahlqvist, C., Reissmann, E., Falk, A., Moliner, A., Lendahl, U., et al. (2003). Cross-talk between the Notch and TGF-β Signaling Pathways Mediated by Interaction of the Notch Intracellular Domain with Smad3. *J. Cell Biol.* 163, 723–728. doi:10.1083/jcb.200305112
- Boggiano, J. C., and Fehon, R. G. (2012). Growth Control by Committee: Intercellular Junctions, Cell Polarity, and the Cytoskeleton Regulate Hippo Signaling. *Dev. Cell* 22, 695–702. doi:10.1016/j.devcel.2012.03.013
- Bolós, V., Gasent, J. M., Lopez-Tarruella, S., and Grande, E. (2010). The Dual Kinase Complex FAK-Src as a Promising Therapeutic Target in Cancer. Ott 3, 83–97. doi:10.2147/ott.s6909
- Bonner, M. Y., and Arbiser, J. L. (2012). Targeting NADPH Oxidases for the Treatment of Cancer and Inflammation. *Cell. Mol. Life Sci.* 69, 2435–2442. doi:10.1007/s00018-012-1017-2
- Boral, D., Vishnoi, M., Liu, H. N., Yin, W., Sprouse, M. L., Scamardo, A., et al. (2017). Molecular Characterization of Breast Cancer CTCs Associated with Brain Metastasis. *Nat. Commun.* 8, 196. doi:10.1038/s41467-017-00196-1
- Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., et al. (2012). Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N. Engl. J. Med. 366, 2455–2465. doi:10.1056/ nejmoa1200694
- Brandes, R. P., Weissmann, N., and Schröder, K. (2014a). Nox Family NADPH Oxidases in Mechano-Transduction: Mechanisms and Consequences. *Antioxidants Redox Signal.* 20, 887–898. doi:10.1089/ars.2013.5414
- Brandes, R. P., Weissmann, N., and Schröder, K. (2014b). Nox Family NADPH Oxidases: Molecular Mechanisms of Activation. *Free Radic. Biol. Med.* 76, 208–226. doi:10.1016/j.freeradbiomed.2014.07.046
- Brandt, D. T., Marion, S., Griffiths, G., Watanabe, T., Kaibuchi, K., and Grosse, R. (2007). Dia1 and IQGAP1 Interact in Cell Migration and Phagocytic Cup Formation. J. Cell Biol. 178, 193–200. doi:10.1083/jcb.200612071
- Bretscher, A., Edwards, K., and Fehon, R. G. (2002). ERM Proteins and Merlin: Integrators at the Cell Cortex. *Nat. Rev. Mol. Cell Biol.* 3, 586–599. doi:10.1038/ nrm882
- Brown, D. I., and Griendling, K. K. (2009). Nox Proteins in Signal Transduction. Free Radic. Biol. Med. 47, 1239–1253. doi:10.1016/j.freeradbiomed.2009.07.023
- Bruick, R. K., and Mcknight, S. L. (2001). A Conserved Family of Prolyl-4-Hydroxylases that Modify HIF. Science 294, 1337–1340. doi:10.1126/science. 1066373
- Buricchi, F., Giannoni, E., Grimaldi, G., Parri, M., Raugei, G., Ramponi, G., et al. (2007). Redox Regulation of Ephrin/integrin Cross-Talk. *Cell Adhesion Migr.* 1, 33–42. doi:10.4161/cam.3911
- Burtenshaw, D., Hakimjavadi, R., Redmond, E. M., and Cahill, P. A. (2017). Nox, Reactive Oxygen Species and Regulation of Vascular Cell Fate. *Antioxidants* (*Basel*) 6. doi:10.3390/antiox6040090

- Cai, D., Chen, S.-C., Prasad, M., He, L., Wang, X., Choesmel-Cadamuro, V., et al. (2014a). Mechanical Feedback through E-Cadherin Promotes Direction Sensing during Collective Cell Migration. *Cell* 157, 1146–1159. doi:10.1016/j. cell.2014.03.045
- Cai, W.-X., Liang, L., Wang, L., Han, J.-T., Zhu, X.-X., Han, H., et al. (2014b). Inhibition of Notch Signaling Leads to Increased Intracellular ROS by Up-Regulating Nox4 Expression in Primary HUVECs. *Cell. Immunol.* 287, 129–135. doi:10.1016/j.cellimm.2013.12.009
- Cai, X., Wang, K.-C., and Meng, Z. (2021). Mechanoregulation of YAP and TAZ in Cellular Homeostasis and Disease Progression. *Front. Cell Dev. Biol.* 9, 673599. doi:10.3389/fcell.2021.673599
- Caliceti, C., Nigro, P., Rizzo, P., and Ferrari, R. (2014). ROS, Notch, and Wnt Signaling Pathways: Crosstalk between Three Major Regulators of Cardiovascular Biology. *Biomed. Res. Int.* 2014, 318714. doi:10.1155/2014/ 318714
- Calvo, F., Ege, N., Grande-Garcia, A., Hooper, S., Jenkins, R. P., Chaudhry, S. I., et al. (2013). Mechanotransduction and YAP-dependent Matrix Remodelling Is Required for the Generation and Maintenance of Cancer-Associated Fibroblasts. *Nat. Cell Biol.* 15, 637–646. doi:10.1038/ncb2756
- Camargo, F. D., Gokhale, S., Johnnidis, J. B., Fu, D., Bell, G. W., Jaenisch, R., et al. (2007). YAP1 Increases Organ Size and Expands Undifferentiated Progenitor Cells. *Curr. Biol.* 17, 2054–2060. doi:10.1016/j.cub.2007.10.039
- Cao, X., Pfaff, S. L., and Gage, F. H. (2008). YAP Regulates Neural Progenitor Cell Number via the TEA Domain Transcription Factor. *Genes Dev.* 22, 3320–3334. doi:10.1101/gad.1726608
- Caporizzo, M. A., Chen, C. Y., and Prosser, B. L. (2019). Cardiac Microtubules in Health and Heart Disease. *Exp. Biol. Med. (Maywood)* 244, 1255–1272. doi:10. 1177/1535370219868960
- Caporizzo, M. A., Chen, C. Y., Salomon, A. K., Margulies, K. B., and Prosser, B. L. (2018). Microtubules Provide a Viscoelastic Resistance to Myocyte Motion. *Biophysical J.* 115, 1796–1807. doi:10.1016/j.bpj.2018.09.019
- Cathcart, M. K. (2004). Regulation of Superoxide Anion Production by NADPH Oxidase in Monocytes/Macrophages. *Atvb* 24, 23–28. doi:10.1161/01.atv. 0000097769.47306.12
- Cattaneo, I., Condorelli, L., Terrinoni, A. R., Antiga, L., Sangalli, F., and Remuzzi, A. (2011). Shear Stress Reverses Dome Formation in Confluent Renal Tubular Cells. *Cell Physiol. Biochem.* 28, 673–682. doi:10.1159/000335813
- Chakraborty, S., Njah, K., Pobbati, A. V., Lim, Y. B., Raju, A., Lakshmanan, M., et al. (2017). Agrin as a Mechanotransduction Signal Regulating YAP through the Hippo Pathway. *Cell Rep.* 18, 2464–2479. doi:10.1016/j.celrep.2017.02.041
- Chang, L., Azzolin, L., Di Biagio, D., Zanconato, F., Battilana, G., Lucon Xiccato, R., et al. (2018). The SWI/SNF Complex Is a Mechanoregulated Inhibitor of YAP and TAZ. *Nature* 563, 265–269. doi:10.1038/s41586-018-0658-1
- Chang, Y.-L., Yang, C.-Y., Lin, M.-W., Wu, C.-T., and Yang, P.-C. (2016). High Coexpression of PD-L1 and HIF-1α Correlates with Tumour Necrosis in Pulmonary Pleomorphic Carcinoma. *Eur. J. Cancer* 60, 125–135. doi:10. 1016/j.ejca.2016.03.012
- Chao, H.-C. A., Chung, C.-L., Pan, H.-A., Liao, P.-C., Kuo, P.-L., and Hsu, C.-C. (2011). Protein Tyrosine Phosphatase Non-receptor Type 14 Is a Novel Sperm-Motility Biomarker. J. Assist. Reprod. Genet. 28, 851–861. doi:10.1007/s10815-011-9602-0
- Chattopadhyay, R., Raghavan, S., and Rao, G. N. (2017). Resolvin D1 via Prevention of ROS-Mediated SHP2 Inactivation Protects Endothelial Adherens Junction Integrity and Barrier Function. *Redox Biol.* 12, 438–455. doi:10.1016/j.redox.2017.02.023
- Chen, C. S., Mrksich, M., Huang, S., Whitesides, G. M., and Ingber, D. E. (1997). Geometric Control of Cell Life and Death. *Science* 276, 1425–1428. doi:10.1126/ science.276.5317.1425
- Chen, C. Y., Caporizzo, M. A., Bedi, K., Vite, A., Bogush, A. I., Robison, P., et al. (2018). Suppression of Detyrosinated Microtubules Improves Cardiomyocyte Function in Human Heart Failure. *Nat. Med.* 24, 1225–1233. doi:10.1038/ s41591-018-0046-2
- Chen, H., Houshmand, G., Mishra, S., Fong, G.-H., Gittes, G. K., and Esni, F. (2010). Impaired Pancreatic Development in Hif2-Alpha Deficient Mice. *Biochem. Biophysical Res. Commun.* 399, 440–445. doi:10.1016/j.bbrc.2010. 07.111
- Chen, H. I., and Sudol, M. (1995). The WW Domain of Yes-Associated Protein Binds a Proline-Rich Ligand that Differs from the Consensus Established for Src

Homology 3-binding Modules. Proc. Natl. Acad. Sci. U.S.A. 92, 7819–7823. doi:10.1073/pnas.92.17.7819

- Chen, Q., Powell, D. W., Rane, M. J., Singh, S., Butt, W., Klein, J. B., et al. (2003). Akt Phosphorylates P47phoxand Mediates Respiratory Burst Activity in Human Neutrophils. J. Immunol. 170, 5302–5308. doi:10.4049/jimmunol. 170.10.5302
- Chen, S., and Sang, N. (2016). Hypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells. J. Cell. Biochem. 117, 267–278. doi:10.1002/ jcb.25283
- Chen, W.-J., Ho, C.-C., Chang, Y.-L., Chen, H.-Y., Lin, C.-A., Ling, T.-Y., et al. (2014). Cancer-associated Fibroblasts Regulate the Plasticity of Lung Cancer Stemness via Paracrine Signalling. *Nat. Commun.* 5, 3472. doi:10.1038/ ncomms4472
- Chen, X., Song, M., Zhang, B., and Zhang, Y. (2016). Reactive Oxygen Species Regulate T Cell Immune Response in the Tumor Microenvironment. Oxid. Med. Cell Longev. 2016, 1580967. doi:10.1155/2016/1580967
- Cheng, D., Yan, X., Qiu, G., Zhang, J., Wang, H., Feng, T., et al. (2018). Contraction of Basal Filopodia Controls Periodic Feather Branching via Notch and FGF Signaling. *Nat. Commun.* 9, 1345. doi:10.1038/s41467-018-03801-z
- Chiarugi, P., Pani, G., Giannoni, E., Taddei, L., Colavitti, R., Raugei, G., et al. (2003). Reactive Oxygen Species as Essential Mediators of Cell Adhesion. J. Cell Biol. 161, 933–944. doi:10.1083/jcb.200211118
- Chifflet, S., and Hernandez, J. A. (2016). The Epithelial Sodium Channel and the Processes of Wound Healing. *Biomed. Res. Int.* 2016, 5675047. doi:10.1155/ 2016/5675047
- Cho, Y., Park, M. J., Kim, K., Kim, S. W., Kim, W., Oh, S., et al. (2020). Reactive Oxygen Species-Induced Activation of Yes-Associated Protein-1 through the C-Myc Pathway Is a Therapeutic Target in Hepatocellular Carcinoma. *Wjg* 26, 6599–6613. doi:10.3748/wjg.v26.i42.6599
- Chong, H. C., Tan, M. J., Philippe, V., Tan, S. H., Tan, C. K., Ku, C. W., et al. (2009). Regulation of Epithelial-Mesenchymal IL-1 Signaling by PPAR $\beta/\delta$  Is Essential for Skin Homeostasis and Wound Healing. *J. Cell Biol.* 184, 817–831. doi:10.1083/jcb.200809028
- Chowdhury, F., Li, I. T. S., Ngo, T. T. M., Leslie, B. J., Kim, B. C., Sokoloski, J. E., et al. (2016). Defining Single Molecular Forces Required for Notch Activation Using Nano Yoyo. *Nano Lett.* 16, 3892–3897. doi:10.1021/acs.nanolett.6b01403
- Cole, B. K., Curto, M., Chan, A. W., and Mcclatchey, A. I. (2008). Localization to the Cortical Cytoskeleton Is Necessary for Nf2/merlin-dependent Epidermal Growth Factor Receptor Silencing. *Mol. Cell Biol.* 28, 1274–1284. doi:10.1128/ mcb.01139-07
- Cosset, É., Ilmjärv, S., Dutoit, V., Elliott, K., Von Schalscha, T., Camargo, M. F., et al. (2017). Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. *Cancer cell* 32, 856–868. doi:10.1016/j. ccell.2017.10.016
- Couzens, A. L., Knight, J. D., Kean, M. J., Teo, G., Weiss, A., Dunham, W. H., et al. (2013). Protein Interaction Network of the Mammalian Hippo Pathway Reveals Mechanisms of Kinase-Phosphatase Interactions. *Sci. Signal* 6, rs15. doi:10. 1126/scisignal.2004712
- Covello, K. L., Kehler, J., Yu, H., Gordan, J. D., Arsham, A. M., Hu, C.-J., et al. (2006). HIF-2a Regulates Oct-4: Effects of Hypoxia on Stem Cell Function, Embryonic Development, and Tumor Growth. *Genes Dev.* 20, 557–570. doi:10. 1101/gad.1399906
- Cummins, E. P., Keogh, C. E., Crean, D., and Taylor, C. T. (2016). The Role of HIF in Immunity and Inflammation. *Mol. Aspects Med.* 47-48, 24–34. doi:10.1016/j. mam.2015.12.004
- Cummins, E. P., Selfridge, A. C., Sporn, P. H., Sznajder, J. I., and Taylor, C. T. (2014). Carbon Dioxide-Sensing in Organisms and its Implications for Human Disease. *Cell. Mol. Life Sci.* 71, 831–845. doi:10.1007/s00018-013-1470-6
- Dai, X., She, P., Chi, F., Feng, Y., Liu, H., Jin, D., et al. (2013). Phosphorylation of Angiomotin by Lats1/2 Kinases Inhibits F-Actin Binding, Cell Migration, and Angiogenesis. J. Biol. Chem. 288, 34041–34051. doi:10.1074/jbc.m113.518019
- Danovi, S. A., Rossi, M., Gudmundsdottir, K., Yuan, M., Melino, G., and Basu, S. (2008). Yes-associated Protein (YAP) Is a Critical Mediator of C-jun-dependent Apoptosis. *Cell Death Differ*. 15, 217–219. doi:10.1038/sj.cdd.4402226
- Dao, J. H., Kurzeja, R. J. M., Morachis, J. M., Veith, H., Lewis, J., Yu, V., et al. (2009). Kinetic Characterization and Identification of a Novel Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 2 Using a Time-Resolved

Fluorescence Resonance Energy Transfer-Based Assay Technology. Anal. Biochem. 384, 213–223. doi:10.1016/j.ab.2008.09.052

- Davalli, P., Mitic, T., Caporali, A., Lauriola, A., and D'arca, D. (2016). ROS, Cell Senescence, and Novel Molecular Mechanisms in Aging and Age-Related Diseases. Oxid. Med. Cell Longev. 2016, 3565127. doi:10.1155/2016/3565127
- De Gaetano, A., Gibellini, L., Zanini, G., Nasi, M., Cossarizza, A., and Pinti, M. (2021). Mitophagy and Oxidative Stress: The Role of Aging. *Antioxidants* (*Basel*) 10. doi:10.3390/antiox10050794
- De Rezende, F. F., Martins Lima, A., Niland, S., Wittig, I., Heide, H., Schröder, K., et al. (2012). Integrin  $\alpha7\beta1$  Is a Redox-Regulated Target of Hydrogen Peroxide in Vascular Smooth Muscle Cell Adhesion. *Free Radic. Biol. Med.* 53, 521–531. doi:10.1016/j.freeradbiomed.2012.05.032
- Di Meo, S., Reed, T. T., Venditti, P., and Victor, V. M. (20162016). Role of ROS and RNS Sources in Physiological and Pathological Conditions. Oxid. Med. Cell Longev. 2016, 1245049. doi:10.1155/2016/1245049
- Diebold, I., Petry, A., Hess, J., and Görlach, A. (2010). The NADPH Oxidase Subunit NOX4 Is a New Target Gene of the Hypoxia-Inducible Factor-1. *MBoC* 21, 2087–2096. doi:10.1091/mbc.e09-12-1003
- Diekmann, D., Abo, A., Johnston, C., Segal, A. W., and Hall, A. (1994). Interaction of Rac with P67 Phox and Regulation Pf Phagocytic NADPH Oxidase Activity. *Science* 265, 531–533. doi:10.1126/science.8036496
- Discher, D. E., Mooney, D. J., and Zandstra, P. W. (2009). Growth Factors, Matrices, and Forces Combine and Control Stem Cells. *Science* 324, 1673–1677. doi:10.1126/science.1171643
- Dong, J., Feldmann, G., Huang, J., Wu, S., Zhang, N., Comerford, S. A., et al. (2007). Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals. *Cell* 130, 1120–1133. doi:10.1016/j.cell.2007.07.019
- Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., et al. (2011). Role of YAP/TAZ in Mechanotransduction. *Nature* 474, 179–183. doi:10.1038/nature10137
- Durán, R. V., Mackenzie, E. D., Boulahbel, H., Frezza, C., Heiserich, L., Tardito, S., et al. (2013). HIF-independent Role of Prolyl Hydroxylases in the Cellular Response to Amino Acids. Oncogene 32, 4549–4556. doi:10.1038/onc.2012.465
- Dustin, C. M., Heppner, D. E., Lin, M.-C. J., and Van Der Vliet, A. (2020). Redox Regulation of Tyrosine Kinase Signalling: More Than Meets the Eye. J. Biochem. 167, 151–163. doi:10.1093/jb/mvz085
- Eble, J. A., and De Rezende, F. F. (2014). Redox-Relevant Aspects of the Extracellular Matrix and its Cellular ContactsviaIntegrins. *Antioxidants Redox Signal.* 20, 1977–1993. doi:10.1089/ars.2013.5294
- Ehrismann, D., Flashman, E., Genn, D. N., Mathioudakis, N., Hewitson, K. S., Ratcliffe, P. J., et al. (2007). Studies on the Activity of the Hypoxia-Inducible-Factor Hydroxylases Using an Oxygen Consumption Assay. *Biochem. J.* 401, 227–234. doi:10.1042/bj20061151
- Elisi, G. M., Santucci, M., D'arca, D., Lauriola, A., Marverti, G., Losi, L., et al. (2018). Repurposing of Drugs Targeting YAP-TEAD Functions. *Cancers* (*Basel*) 10. doi:10.3390/cancers10090329
- Ellmark, S., Dusting, G., Ngtangfui, M., Guzzopernell, N., and Drummond, G. (2005). The Contribution of Nox4 to NADPH Oxidase Activity in Mouse Vascular Smooth Muscle. *Cardiovasc. Res.* 65, 495–504. doi:10.1016/j.cardiores. 2004.10.026
- Emerling, B. M., Platanias, L. C., Black, E., Nebreda, A. R., Davis, R. J., and Chandel, N. S. (2005). Mitochondrial Reactive Oxygen Species Activation of P38 Mitogen-Activated Protein Kinase Is Required for Hypoxia Signaling. *Mol. Cell Biol.* 25, 4853–4862. doi:10.1128/mcb.25.12.4853-4862.2005
- Engel-Pizcueta, C., and Pujades, C. (2021). Interplay between Notch and YAP/TAZ Pathways in the Regulation of Cell Fate during Embryo Development. *Front. Cell Dev. Biol.* 9, 711531. doi:10.3389/fcell.2021.711531
- Epstein, A. C. R., Gleadle, J. M., Mcneill, L. A., Hewitson, K. S., O'rourke, J., Mole, D. R., et al. (2001). *C. elegans* EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation. *Cell* 107, 43–54. doi:10.1016/s0092-8674(01)00507-4
- Ezashi, T., Das, P., and Roberts, R. M. (2005). Low O 2 Tensions and the Prevention of Differentiation of hES Cells. *Proc. Natl. Acad. Sci. U.S.A.* 102, 4783–4788. doi:10.1073/pnas.0501283102
- Fan, Y., Mao, R., and Yang, J. (2013). NF-κB and STAT3 Signaling Pathways Collaboratively Link Inflammation to Cancer. *Protein Cell* 4, 176–185. doi:10. 1007/s13238-013-2084-3

- Feno, S., Butera, G., Vecellio Reane, D., Rizzuto, R., and Raffaello, A. (2019). Crosstalk between Calcium and ROS in Pathophysiological Conditions. Oxid. Med. Cell Longev. 2019, 9324018. doi:10.1155/2019/9324018
- Fernandez-Valle, C., Tang, Y., Ricard, J., Rodenas-Ruano, A., Taylor, A., Hackler, E., et al. (2002). Paxillin Binds Schwannomin and Regulates its Densitydependent Localization and Effect on Cell Morphology. *Nat. Genet.* 31, 354–362. doi:10.1038/ng930
- Figtree, G. A., Liu, C.-C., Bibert, S., Hamilton, E. J., Garcia, A., White, C. N., et al. (2009). Reversible Oxidative Modification. *Circulation Res.* 105, 185–193. doi:10.1161/circresaha.109.199547
- Flaiz, C., Ammoun, S., Biebl, A., and Hanemann, C. O. (2009). Altered Adhesive Structures and Their Relation to RhoGTPase Activation in Merlin-Deficient Schwannoma. *Brain Pathol.* 19, 27–38. doi:10.1111/j.1750-3639.2008.00165.x
- Flügel, D., Görlach, A., Michiels, C., and Kietzmann, T. (2007). Glycogen Synthase Kinase 3 Phosphorylates Hypoxia-Inducible Factor 1alpha and Mediates its Destabilization in a VHL-independent Manner. *Mol. Cell Biol.* 27, 3253–3265. doi:10.1128/MCB.00015-07
- Folkman, J., and Moscona, A. (1978). Role of Cell Shape in Growth Control. *Nature* 273, 345–349. doi:10.1038/273345a0
- Fong, G.-H., and Takeda, K. (2008). Role and Regulation of Prolyl Hydroxylase Domain Proteins. Cell Death Differ. 15, 635–641. doi:10.1038/cdd.2008.10
- Fontayne, A., Dang, P. M.-C., Gougerot-Pocidalo, M.-A., and El Benna, J. (2002). Phosphorylation of P47phox Sites by PKC  $\alpha$ ,  $\beta$ II,  $\delta$ , and  $\zeta$ : Effect on Binding to P22phox and on NADPH Oxidase Activation. *Biochemistry* 41, 7743–7750. doi:10.1021/bi011953s
- Force, T., and Woodgett, J. R. (2009). Unique and Overlapping Functions of GSK-3 Isoforms in Cell Differentiation and Proliferation and Cardiovascular Development. J. Biol. Chem. 284, 9643–9647. doi:10.1074/jbc.r800077200
- Fu, P., Ramchandran, R., Shaaya, M., Huang, L., Ebenezer, D. L., Jiang, Y., et al. (2020). Phospholipase D2 Restores Endothelial Barrier Function by Promoting PTPN14-Mediated VE-Cadherin Dephosphorylation. J. Biol. Chem. 295, 7669–7685. doi:10.1074/jbc.ra119.011801
- Fujii, M., Toyoda, T., Nakanishi, H., Yatabe, Y., Sato, A., Matsudaira, Y., et al. (2012). TGF-β Synergizes with Defects in the Hippo Pathway to Stimulate Human Malignant Mesothelioma Growth. J. Exp. Med. 209, 479–494. doi:10. 1084/jem.20111653
- Fukai, T., and Ushio-Fukai, M. (2020). Cross-Talk between NADPH Oxidase and Mitochondria: Role in ROS Signaling and Angiogenesis. *Cells* 9. doi:10.3390/ cells9081849
- Funato, Y., and Miki, H. (2010). Redox Regulation of Wnt Signalling via Nucleoredoxin. Free Radic. Res. 44, 379–388. doi:10.3109/10715761003610745
- Funato, Y., Terabayashi, T., Sakamoto, R., Okuzaki, D., Ichise, H., Nojima, H., et al. (2010). Nucleoredoxin Sustains Wnt/β-Catenin Signaling by Retaining a Pool of Inactive Dishevelled Protein. *Curr. Biol.* 20, 1945–1952. doi:10.1016/j.cub. 2010.09.065
- Furukawa, K. T., Yamashita, K., Sakurai, N., and Ohno, S. (2017). The Epithelial Circumferential Actin Belt Regulates YAP/TAZ through Nucleocytoplasmic Shuttling of Merlin. *Cell Rep.* 20, 1435–1447. doi:10.1016/j.celrep.2017.07.032
- Gabrilovich, D. I., and Nagaraj, S. (2009). Myeloid-derived Suppressor Cells as Regulators of the Immune System. Nat. Rev. Immunol. 9, 162–174. doi:10.1038/ nri2506
- Gaete, D., Rodriguez, D., Watts, D., Sormendi, S., Chavakis, T., and Wielockx, B. (2021). HIF-prolyl Hydroxylase Domain Proteins (PHDs) in Cancer-Potential Targets for Anti-tumor Therapy? *Cancers* 13, 988. doi:10.3390/ cancers13050988
- Gao, Y., Nihira, N. T., Bu, X., Chu, C., Zhang, J., Kolodziejczyk, A., et al. (2020). Acetylation-dependent Regulation of PD-L1 Nuclear Translocation Dictates the Efficacy of Anti-PD-1 Immunotherapy. *Nat. Cell Biol.* 22, 1064–1075. doi:10.1038/s41556-020-0562-4
- Gargini, R., Escoll, M., García, E., García-Escudero, R., Wandosell, F., and Antón, I. M. (2016). WIP Drives Tumor Progression through YAP/TAZ-Dependent Autonomous Cell Growth. *Cell Rep.* 17, 1962–1977. doi:10.1016/j.celrep.2016. 10.064
- Gau, D., and Roy, P. (2018). SRF'ing and SAP'ing the Role of MRTF Proteins in Cell Migration. J. Cell Sci. 131. doi:10.1242/jcs.218222
- Ge, H., Tian, M., Pei, Q., Tan, F., and Pei, H. (2021). Extracellular Matrix Stiffness: New Areas Affecting Cell Metabolism. *Front. Oncol.* 11, 631991. doi:10.3389/ fonc.2021.631991

- Genevet, A., Wehr, M. C., Brain, R., Thompson, B. J., and Tapon, N. (2010). Kibra Is a Regulator of the Salvador/Warts/Hippo Signaling Network. *Dev. Cell* 18, 300–308. doi:10.1016/j.devcel.2009.12.011
- Gerald, D., Berra, E., Frapart, Y. M., Chan, D. A., Giaccia, A. J., Mansuy, D., et al. (2004). JunD Reduces Tumor Angiogenesis by Protecting Cells from Oxidative Stress. *Cell* 118, 781–794. doi:10.1016/j.cell.2004.08.025
- Gerhardt, H., and Betsholtz, C. (2003). Endothelial-pericyte Interactions in Angiogenesis. *Cell Tissue Res.* 314, 15–23. doi:10.1007/s00441-003-0745-x
- Ghio, A. J., Nozik-Grayck, E., Turi, J., Jaspers, I., Mercatante, D. R., Kole, R., et al. (2003). Superoxide-Dependent Iron Uptake. Am. J. Respir. Cell Mol. Biol. 29, 653–660. doi:10.1165/rcmb.2003-0070oc
- Gianni, D., Taulet, N., Dermardirossian, C., and Bokoch, G. M. (2010). c-Srcmediated Phosphorylation of NoxA1 and Tks4 Induces the Reactive Oxygen Species (ROS)-dependent Formation of Functional Invadopodia in Human Colon Cancer Cells. *MBoC* 21, 4287–4298. doi:10.1091/mbc.e10-08-0685
- Giannoni, E., Taddei, M. L., and Chiarugi, P. (2010). Src Redox Regulation: Again in the Front Line. *Free Radic. Biol. Med.* 49, 516–527. doi:10.1016/j. freeradbiomed.2010.04.025
- Gilkes, D. M., Bajpai, S., Chaturvedi, P., Wirtz, D., and Semenza, G. L. (2013). Hypoxia-inducible Factor 1 (HIF-1) Promotes Extracellular Matrix Remodeling under Hypoxic Conditions by Inducing P4HA1, P4HA2, and PLOD2 Expression in Fibroblasts. J. Biol. Chem. 288, 10819–10829. doi:10. 1074/jbc.m112.442939
- Gittes, F., Mickey, B., Nettleton, J., and Howard, J. (1993). Flexural Rigidity of Microtubules and Actin Filaments Measured from Thermal Fluctuations in Shape. J. Cell Biol. 120, 923–934. doi:10.1083/jcb.120.4.923
- Gladden, A. B., Hebert, A. M., Schneeberger, E. E., and Mcclatchey, A. I. (2010). The NF2 Tumor Suppressor, Merlin, Regulates Epidermal Development through the Establishment of a Junctional Polarity Complex. *Dev. Cell* 19, 727–739. doi:10.1016/j.devcel.2010.10.008
- Goettsch, C., Goettsch, W., Arsov, A., Hofbauer, L. C., Bornstein, S. R., and Morawietz, H. (2009). Long-term Cyclic Strain Downregulates Endothelial Nox4. Antioxidants Redox Signal. 11, 2385–2397. doi:10.1089/ars.2009.2561
- Gomez, E. W., Chen, Q. K., Gjorevski, N., and Nelson, C. M. (2010). Tissue Geometry Patterns Epithelial-Mesenchymal Transition via Intercellular Mechanotransduction. J. Cell Biochem. 110, 44–51. doi:10.1002/jcb.22545
- Gong, J., Yao, Y., Zhang, P., Udayasuryan, B., Komissarova, E. V., Chen, J., et al. (2015). The C2 Domain and Altered ATP-Binding Loop Phosphorylation at Ser 359 Mediate the Redox-dependent Increase in Protein Kinase C-δ Activity. *Mol. Cell Biol.* 35, 1727–1740. doi:10.1128/mcb.01436-14
- Goodson, P., Kumar, A., Jain, L., Kundu, K., Murthy, N., Koval, M., et al. (2012). Nadph Oxidase Regulates Alveolar Epithelial Sodium Channel Activity and Lung Fluid Balance In Vivo via O2– Signaling. Am. J. Physiology-Lung Cell. Mol. Physiology 302, L410–L419. doi:10.1152/ajplung.00260.2011
- Gordan, J. D., Bertout, J. A., Hu, C.-J., Diehl, J. A., and Simon, M. C. (2007). HIF-2α Promotes Hypoxic Cell Proliferation by Enhancing C-Myc Transcriptional Activity. *Cancer cell* 11, 335–347. doi:10.1016/j.ccr.2007.02.006
- Gordon, W. R., Zimmerman, B., He, L., Miles, L. J., Huang, J., Tiyanont, K., et al. (2015). Mechanical Allostery: Evidence for a Force Requirement in the Proteolytic Activation of Notch. *Dev. Cell* 33, 729–736. doi:10.1016/j.devcel. 2015.05.004
- Görlach, A., Bertram, K., Hudecova, S., and Krizanova, O. (2015). Calcium and ROS: A Mutual Interplay. *Redox Biol.* 6, 260–271. doi:10.1016/j.redox.2015. 08.010
- Greenwald, R. J., Freeman, G. J., and Sharpe, A. H. (2005). The B7 Family Revisited. Annu. Rev. Immunol. 23, 515–548. doi:10.1146/annurev.immunol.23.021704. 115611
- Gregg, D., De Carvalho, D. D., and Kovacic, H. (2004). Integrins and Coagulation: A Role for ROS/redox Signaling? *Antioxidants Redox Signal.* 6, 757–764. doi:10. 1089/1523086041361604
- Groemping, Y., Lapouge, K., Smerdon, S. J., and Rittinger, K. (2003). Molecular Basis of Phosphorylation-Induced Activation of the NADPH Oxidase. *Cell* 113, 343–355. doi:10.1016/s0092-8674(03)00314-3
- Grosberg, A., Kuo, P.-L., Guo, C.-L., Geisse, N. A., Bray, M.-A., Adams, W. J., et al. (2011). Self-organization of Muscle Cell Structure and Function. *PLoS Comput. Biol.* 7, e1001088. doi:10.1371/journal.pcbi.1001088
- Grote, K., Flach, I., Luchtefeld, M., Akin, E., Holland, S. M., Drexler, H., et al. (2003). Mechanical Stretch Enhances mRNA Expression and Proenzyme

Release of Matrix Metalloproteinase-2 (MMP-2) via NAD(P)H Oxidase-Derived Reactive Oxygen Species. *Circ. Res.* 92, e80–6. doi:10.1161/01.RES. 0000077044.60138.7C

- Guo, C.-L., Ouyang, M., Yu, J.-Y., Maslov, J., Price, A., and Shen, C.-Y. (2012). Long-range Mechanical Force Enables Self-Assembly of Epithelial Tubular Patterns. *Proc. Natl. Acad. Sci. U.S.A.* 109, 5576–5582. doi:10.1073/pnas. 1114781109
- Guo, R., Li, Y., Wang, Z., Bai, H., Duan, J., Wang, S., et al. (2019). Hypoxiainducible Factor-1α and Nuclear factor-κB Play Important Roles in Regulating Programmed Cell Death Ligand 1 Expression by Epidermal Growth Factor Receptor Mutants in Non-small-cell Lung Cancer Cells. *Cancer Sci.* 110, 1665–1675. doi:10.1111/cas.13989
- Gupta, S. C., Kunnumakkara, A. B., Aggarwal, S., and Aggarwal, B. B. (2018). Inflammation, a Double-Edge Sword for Cancer and Other Age-Related Diseases. Front. Immunol. 9, 2160. doi:10.3389/fimmu.2018.02160
- Guruharsha, K. G., Kankel, M. W., and Artavanis-Tsakonas, S. (2012). The Notch Signalling System: Recent Insights into the Complexity of a Conserved Pathway. *Nat. Rev. Genet.* 13, 654–666. doi:10.1038/nrg3272
- Gustafsson, M. V., Zheng, X., Pereira, T., Gradin, K., Jin, S., Lundkvist, J., et al. (2005). Hypoxia Requires Notch Signaling to Maintain the Undifferentiated Cell State. *Dev. Cell* 9, 617–628. doi:10.1016/j.devcel.2005.09.010
- Halligan, D. N., Murphy, S. J. E., and Taylor, C. T. (2016). The Hypoxia-Inducible Factor (HIF) Couples Immunity with Metabolism. *Seminars Immunol.* 28, 469–477. doi:10.1016/j.smim.2016.09.004
- Han, Y., Ishibashi, S., Iglesias-Gonzalez, J., Chen, Y., Love, N. R., and Amaya, E. (2018). Ca2+-Induced Mitochondrial ROS Regulate the Early Embryonic Cell Cycle. *Cell Rep.* 22, 218–231. doi:10.1016/j.celrep.2017.12.042
- Hansen, C. G., Moroishi, T., and Guan, K.-L. (2015). YAP and TAZ: a Nexus for Hippo Signaling and beyond. *Trends Cell Biol.* 25, 499–513. doi:10.1016/j.tcb. 2015.05.002
- Hao, Y., Chun, A., Cheung, K., Rashidi, B., and Yang, X. (2008). Tumor Suppressor LATS1 Is a Negative Regulator of Oncogene YAP. J. Biol. Chem. 283, 5496–5509. doi:10.1074/jbc.m709037200
- Harris, A. L. (2002). Hypoxia a Key Regulatory Factor in Tumour Growth. Nat. Rev. Cancer 2, 38–47. doi:10.1038/nrc704
- Hartmann, S., Ridley, A. J., and Lutz, S. (2015). The Function of Rho-Associated Kinases ROCK1 and ROCK2 in the Pathogenesis of Cardiovascular Disease. *Front. Pharmacol.* 6, 276. doi:10.3389/fphar.2015.00276
- Hashimoto, T., and Shibasaki, F. (2015). Hypoxia-inducible Factor as an Angiogenic Master Switch. Front. Pediatr. 3, 33. doi:10.3389/fped.2015.00033
- Hayward, M.-K., Muncie, J. M., and Weaver, V. M. (2021). Tissue Mechanics in Stem Cell Fate, Development, and Cancer. Dev. Cell 56, 1833–1847. doi:10. 1016/j.devcel.2021.05.011
- He, M., Zhou, Z., Shah, A. A., Hong, Y., Chen, Q., and Wan, Y. (2016). New Insights into Posttranslational Modifications of Hippo Pathway in Carcinogenesis and Therapeutics. *Cell Div.* 11, 4. doi:10.1186/s13008-016-0013-6
- Hecht, D., and Zick, Y. (1992). Selective Inhibition of Protein Tyrosine Phosphatase Activities by H2O2 and Vanadate In Vitro. *Biochem. Biophysical Res. Commun.* 188, 773–779. doi:10.1016/0006-291x(92)91123-8
- Hecker, L., Cheng, J., and Thannickal, V. J. (2012). Targeting NOX Enzymes in Pulmonary Fibrosis. *Cell. Mol. Life Sci.* 69, 2365–2371. doi:10.1007/s00018-012-1012-7
- Heddleston, J. M., Li, Z., Lathia, J. D., Bao, S., Hjelmeland, A. B., and Rich, J. N. (2010). Hypoxia Inducible Factors in Cancer Stem Cells. *Br. J. Cancer* 102, 789–795. doi:10.1038/sj.bjc.6605551
- Hedman, A. C., Li, Z., Gorisse, L., Parvathaneni, S., Morgan, C. J., and Sacks, D. B. (2021). IQGAP1 Binds AMPK and Is Required for Maximum AMPK Activation. J. Biol. Chem. 296, 100075. doi:10.1074/jbc.ra120.016193
- Helms, M. N., Jain, L., Self, J. L., and Eaton, D. C. (2008). Redox Regulation of Epithelial Sodium Channels Examined in Alveolar Type 1 and 2 Cells Patch-Clamped in Lung Slice Tissue. J. Biol. Chem. 283, 22875–22883. doi:10.1074/jbc. m801363200
- Hennigan, R. F., Fletcher, J. S., Guard, S., and Ratner, N. (2019). Proximity Biotinylation Identifies a Set of Conformation-specific Interactions between Merlin and Cell Junction Proteins. Sci. Signal 12. doi:10.1126/scisignal.aau8749
- Heo, J. S., and Lee, J.-C. (2011). β-Catenin Mediates Cyclic Strain-Stimulated Cardiomyogenesis in Mouse Embryonic Stem Cells through ROS-dependent

and Integrin-Mediated PI3K/Akt Pathways. J. Cell. Biochem. 112, 1880–1889. doi:10.1002/jcb.23108

- Heppner, D. E., Dustin, C. M., Liao, C., Hristova, M., Veith, C., Little, A. C., et al. (2018). Direct Cysteine Sulfenylation Drives Activation of the Src Kinase. *Nat. Commun.* 9, 4522. doi:10.1038/s41467-018-06790-1
- Heppner, D. E. (2021). Structural Insights into Redox-Active Cysteine Residues of the Src Family Kinases. *Redox Biol.* 41, 101934. doi:10.1016/j.redox.2021. 101934
- Hikage, F., Atkins, S., Kahana, A., Smith, T. J., and Chun, T.-H. (2019). HIF2A-LOX Pathway Promotes Fibrotic Tissue Remodeling in Thyroid-Associated Orbitopathy. *Endocrinology* 160, 20–35. doi:10.1210/en.2018-00272
- Hiraga, R., Kato, M., Miyagawa, S., and Kamata, T. (2013). Nox4-derived ROS Signaling Contributes to TGF-β-Induced Epithelial-Mesenchymal Transition in Pancreatic Cancer Cells. *Anticancer Res.* 33, 4431–4438.
- Hirate, Y., Hirahara, S., Inoue, K.-i., Suzuki, A., Alarcon, V. B., Akimoto, K., et al. (2013). Polarity-dependent Distribution of Angiomotin Localizes Hippo Signaling in Preimplantation Embryos. *Curr. Biol.* 23, 1181–1194. doi:10. 1016/j.cub.2013.05.014
- Hirate, Y., and Sasaki, H. (2014). The Role of Angiomotin Phosphorylation in the Hippo Pathway during Preimplantation Mouse Development. *Tissue Barriers* 2, e28127. doi:10.4161/tisb.28127
- Hirsilä, M., Koivunen, P., Günzler, V., Kivirikko, K. I., and Myllyharju, J. (2003). Characterization of the Human Prolyl 4-hydroxylases that Modify the Hypoxia-Inducible Factor. J. Biol. Chem. 278, 30772–30780. doi:10.1074/jbc. m304982200
- Hoare, M., and Narita, M. (2018). Notch and Senescence. Adv. Exp. Med. Biol. 1066, 299–318. doi:10.1007/978-3-319-89512-3\_15
- Höffken, V., Hermann, A., Pavenstädt, H., and Kremerskothen, J. (2021). WWC Proteins: Important Regulators of Hippo Signaling in Cancer. *Cancers (Basel)* 13. doi:10.3390/cancers13020306
- Holmström, K. M., and Finkel, T. (2014). Cellular Mechanisms and Physiological Consequences of Redox-dependent Signalling. *Nat. Rev. Mol. Cell Biol.* 15, 411–421. doi:10.1038/nrm3801
- Hong, A. W., Meng, Z., Yuan, H. X., Plouffe, S. W., Moon, S., Kim, W., et al. (2017). Osmotic Stress-induced Phosphorylation by NLK at Ser128 Activates YAP. *EMBO Rep.* 18, 72–86. doi:10.15252/embr.201642681
- Horowitz, A., Murakami, M., Gao, Y., and Simons, M. (1999). Phosphatidylinositol-4,5-bisphosphate Mediates the Interaction of Syndecan-4 with Protein Kinase C. *Biochemistry* 38, 15871–15877. doi:10.1021/bi991363i
- Houk, A. R., Jilkine, A., Mejean, C. O., Boltyanskiy, R., Dufresne, E. R., Angenent, S. B., et al. (2012). Membrane Tension Maintains Cell Polarity by Confining Signals to the Leading Edge during Neutrophil Migration. *Cell* 148, 175–188. doi:10.1016/j.cell.2011.10.050
- Hoyal, C. R., Gutierrez, A., Young, B. M., Catz, S. D., Lin, J.-H., Tsichlis, P. N., et al. (2003). Modulation of P47 PHOX Activity by Site-specific Phosphorylation: Akt-dependent Activation of the NADPH Oxidase. *Proc. Natl. Acad. Sci. U.S.A.* 100, 5130–5135. doi:10.1073/pnas.1031526100
- Hu, J. K.-H., Du, W., Shelton, S. J., Oldham, M. C., Dipersio, C. M., and Klein, O. D. (2017). An FAK-YAP-mTOR Signaling Axis Regulates Stem Cell-Based Tissue Renewal in Mice. *Cell Stem Cell* 21, 91–106. doi:10.1016/j.stem.2017.03.023
- Hu, Y.-Y., Fu, L.-A., Li, S.-Z., Chen, Y., Li, J.-C., Han, J., et al. (2014). Hif-1α and Hif-2α Differentially Regulate Notch Signaling through Competitive Interaction with the Intracellular Domain of Notch Receptors in Glioma Stem Cells. *Cancer Lett.* 349, 67–76. doi:10.1016/j.canlet.2014.03.035
- Huang, J.-M., Nagatomo, I., Suzuki, E., Mizuno, T., Kumagai, T., Berezov, A., et al. (2013). YAP Modifies Cancer Cell Sensitivity to EGFR and Survivin Inhibitors and Is Negatively Regulated by the Non-receptor Type Protein Tyrosine Phosphatase 14. Oncogene 32, 2220–2229. doi:10.1038/onc.2012.231
- Huang, J. H., Co, H. K., Lee, Y. C., Wu, C. C., and Chen, S. H. (2021a). Multistability Maintains Redox Homeostasis in Human Cells. *Mol. Syst. Biol.* 17, e10480. doi:10.15252/msb.202110480
- Huang, S., and Ingber, D. E. (1999). The Structural and Mechanical Complexity of Cell-Growth Control. Nat. Cell Biol. 1, E131–E138. doi:10.1038/13043
- Huang, Y., Chen, Z., Lu, T., Bi, G., Li, M., Liang, J., et al. (2021b). HIF-1α Switches the Functionality of TGF-β Signaling via Changing the Partners of Smads to Drive Glucose Metabolic Reprogramming in Non-small Cell Lung Cancer. J. Exp. Clin. Cancer Res. 40, 398. doi:10.1186/s13046-021-02188-y

- Huang, Y., Lin, D., and Taniguchi, C. M. (2017). Hypoxia Inducible Factor (HIF) in the Tumor Microenvironment: Friend or Foe? *Sci. China Life Sci.* 60, 1114–1124. doi:10.1007/s11427-017-9178-y
- Hubbi, M. E., and Semenza, G. L. (2015). Regulation of Cell Proliferation by Hypoxia-Inducible Factors. Am. J. Physiology-Cell Physiology 309, C775–C782. doi:10.1152/ajpcell.00279.2015
- Huff, L. P., Kikuchi, D. S., Faidley, E., Forrester, S. J., Tsai, M. Z., Lassègue, B., et al. (2019). Polymerase-δ-interacting Protein 2 Activates the RhoGEF Epithelial Cell Transforming Sequence 2 in Vascular Smooth Muscle Cells. Am. J. Physiology-Cell Physiology 316, C621–C631. doi:10.1152/ajpcell.00208.2018
- Hulikova, A., Harris, A. L., Vaughan-Jones, R. D., and Swietach, P. (2013). Regulation of Intracellular pH in Cancer Cell Lines under Normoxia and Hypoxia. J. Cell. Physiol. 228, 743–752. doi:10.1002/jcp.24221
- Hwang, J., and Pallas, D. C. (2014). STRIPAK Complexes: Structure, Biological Function, and Involvement in Human Diseases. *Int. J. Biochem. Cell Biol.* 47, 118–148. doi:10.1016/j.biocel.2013.11.021
- Ikeda, S., Yamaoka-Tojo, M., Hilenski, L., Patrushev, N. A., Anwar, G. M., Quinn, M. T., et al. (2005). IQGAP1 Regulates Reactive Oxygen Species-dependent Endothelial Cell Migration through Interacting with Nox2. *Atvb* 25, 2295–2300. doi:10.1161/01.atv.0000187472.55437.af
- Inamori, M., Mizumoto, H., and Kajiwara, T. (2009). An Approach for Formation of Vascularized Liver Tissue by Endothelial Cell-Covered Hepatocyte Spheroid Integration. *Tissue Eng. Part A* 15, 2029–2037. doi:10.1089/ten.tea.2008.0403
- Irrcher, I., Ljubicic, V., and Hood, D. A. (2009). Interactions between ROS and AMP Kinase Activity in the Regulation of PGC-1α Transcription in Skeletal Muscle Cells. Am. J. Physiology-Cell Physiology 296, C116–C123. doi:10.1152/ ajpcell.00267.2007
- Islam, S. M. A., Patel, R., and Acevedo-Duncan, M. (2018). Protein Kinase C-ζ Stimulates Colorectal Cancer Cell Carcinogenesis via PKC-ζ/Rac1/Pak1/β-Catenin Signaling Cascade. Biochimica Biophysica Acta (BBA) - Mol. Cell Res. 1865, 650–664. doi:10.1016/j.bbamcr.2018.02.002
- Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., et al. (2001). HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing. *Science* 292, 464–468. doi:10.1126/science. 1059817
- Iwasa, H., Maimaiti, S., Kuroyanagi, H., Kawano, S., Inami, K., Timalsina, S., et al. (2013). Yes-associated Protein Homolog, YAP-1, Is Involved in the Thermotolerance and Aging in the Nematode *Caenorhabditis elegans. Exp. Cell Res.* 319, 931–945. doi:10.1016/j.yexcr.2013.01.020
- Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., et al. (2001). Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O 2 -Regulated Prolyl Hydroxylation. *Science* 292, 468–472. doi:10.1126/ science.1059796
- Jaalouk, D. E., and Lammerding, J. (2009). Mechanotransduction Gone Awry. *Nat. Rev. Mol. Cell Biol.* 10, 63–73. doi:10.1038/nrm2597
- Jaccard, A., and Ho, P.-C. (2020). The Hidden Side of PD-L1. *Nat. Cell Biol.* 22, 1031–1032. doi:10.1038/s41556-020-0568-y
- James, M. F., Beauchamp, R. L., Manchanda, N., Kazlauskas, A., and Ramesh, V. (2004). A NHERF Binding Site Links the βPDGFR to the Cytoskeleton and Regulates Cell Spreading and Migration. J. Cell Sci. 117, 2951–2961. doi:10. 1242/jcs.01156
- Janghorban, M., Xin, L., Rosen, J. M., and Zhang, X. H.-F. (2018). Notch Signaling as a Regulator of the Tumor Immune Response: To Target or Not to Target? *Front. Immunol.* 9, 1649. doi:10.3389/fimmu.2018.01649
- Janse Van Rensburg, H. J., Azad, T., Ling, M., Hao, Y., Snetsinger, B., Khanal, P., et al. (2018). The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1. *Cancer Res.* 78, 1457–1470. doi:10.1158/ 0008-5472.can-17-3139
- Javadov, S. (2015). The Calcium-ROS-pH Triangle and Mitochondrial Permeability Transition: Challenges to Mimic Cardiac Ischemia-Reperfusion. *Front. Physiol.* 6, 83. doi:10.3389/fphys.2015.00083
- Ji, F., Wang, Y., Qiu, L., Li, S., Zhu, J., Liang, Z., et al. (2013). Hypoxia Inducible Factor 1α-Mediated LOX Expression Correlates with Migration and Invasion in Epithelial Ovarian Cancer. *Int. J. Oncol.* 42, 1578–1588. doi:10.3892/ijo.2013. 1878
- Jiang, F., Liu, G.-S., Dusting, G. J., and Chan, E. C. (2014). NADPH Oxidasedependent Redox Signaling in TGF-β-Mediated Fibrotic Responses. *Redox Biol.* 2, 267–272. doi:10.1016/j.redox.2014.01.012

- Jiang, W., and Xu, J. (2020). Immune Modulation by Mesenchymal Stem Cells. Cell Prolif. 53, e12712. doi:10.1111/cpr.12712
- Jin, H., Sperka, T., Herrlich, P., and Morrison, H. (2006). Tumorigenic Transformation by CPI-17 through Inhibition of a Merlin Phosphatase. *Nature* 442, 576–579. doi:10.1038/nature04856
- Jin, Y., Dong, L., Lu, Y., Wu, W., Hao, Q., Zhou, Z., et al. (2012). Dimerization and Cytoplasmic Localization Regulate Hippo Kinase Signaling Activity in Organ Size Control. J. Biol. Chem. 287, 5784–5796. doi:10.1074/jbc.m111.310334
- Johnson, R., and Halder, G. (2014). The Two Faces of Hippo: Targeting the Hippo Pathway for Regenerative Medicine and Cancer Treatment. *Nat. Rev. Drug Discov.* 13, 63–79. doi:10.1038/nrd4161
- Joo, E. E., and Yamada, K. M. (2014). MYPT1 Regulates Contractility and Microtubule Acetylation to Modulate Integrin Adhesions and Matrix Assembly. Nat. Commun. 5, 3510. doi:10.1038/ncomms4510
- Juan, C. A., Pérez de la Lastra, J. M., Plou, F. J., and Pérez-Lebeña, E. (2021). The Chemistry of Reactive Oxygen Species (ROS) Revisited: Outlining Their Role in Biological Macromolecules (DNA, Lipids and Proteins) and Induced Pathologies. Int. J. Mol. Sci. 22. doi:10.3390/ijms22094642
- Kanai, F., Liu, H., Field, S. J., Akbary, H., Matsuo, T., Brown, G. E., et al. (2001). The PX Domains of P47phox and P40phox Bind to Lipid Products of PI(3)K. *Nat. Cell Biol.* 3, 675–678. doi:10.1038/35083070
- Kang, X., Wei, X., Jiang, L., Niu, C., Zhang, J., Chen, S., et al. (2016). Nox2 and Nox4 Regulate Self-Renewal of Murine Induced-Pluripotent Stem Cells. *IUBMB Life* 68, 963–970. doi:10.1002/iub.1574
- Kaplan, N., Urao, N., Furuta, E., Kim, S.-J., Razvi, M., Nakamura, Y., et al. (2011). Localized Cysteine Sulfenic Acid Formation by Vascular Endothelial Growth Factor: Role in Endothelial Cell Migration and Angiogenesis. *Free Radic. Res.* 45, 1124–1135. doi:10.3109/10715762.2011.602073
- Kawahara, T., Quinn, M. T., and Lambeth, J. D. (2007). Molecular Evolution of the Reactive Oxygen-Generating NADPH Oxidase (Nox/Duox) Family of Enzymes. BMC Evol. Biol. 7, 109. doi:10.1186/1471-2148-7-109
- Kawano, Y., Fukata, Y., Oshiro, N., Amano, M., Nakamura, T., Ito, M., et al. (1999). Phosphorylation of Myosin-Binding Subunit (MBS) of Myosin Phosphatase by Rho-Kinase In Vivo. J. Cell Biol. 147, 1023–1038. doi:10.1083/jcb.147.5.1023
- Keith, B., and Simon, M. C. (2007). Hypoxia-inducible Factors, Stem Cells, and Cancer. Cell 129, 465–472. doi:10.1016/j.cell.2007.04.019
- Kerr, J. P., Robison, P., Shi, G., Bogush, A. I., Kempema, A. M., Hexum, J. K., et al. (2015). Detyrosinated Microtubules Modulate Mechanotransduction in Heart and Skeletal Muscle. *Nat. Commun.* 6, 8526. doi:10.1038/ncomms9526
- Kessler, M., Hoffmann, K., Brinkmann, V., Thieck, O., Jackisch, S., Toelle, B., et al. (2015). The Notch and Wnt Pathways Regulate Stemness and Differentiation in Human Fallopian Tube Organoids. *Nat. Commun.* 6, 8989. doi:10.1038/ ncomms9989
- Khairallah, R. J., Shi, G., Sbrana, F., Prosser, B. L., Borroto, C., Mazaitis, M. J., et al. (2012). Microtubules Underlie Dysfunction in Duchenne Muscular Dystrophy. *Sci. Signal* 5, ra56. doi:10.1126/scisignal.2002829
- Khurana, A., Nakayama, K., Williams, S., Davis, R. J., Mustelin, T., and Ronai, Z. e. (2006). Regulation of the Ring Finger E3 Ligase Siah2 by P38 MAPK. J. Biol. Chem. 281, 35316–35326. doi:10.1074/jbc.m606568200
- Kim, E., Kim, W., Lee, S., Chun, J., Kang, J., Park, G., et al. (2017). TRAF4 Promotes Lung Cancer Aggressiveness by Modulating Tumor Microenvironment in Normal Fibroblasts. Sci. Rep. 7, 8923. doi:10.1038/ s41598-017-09447-z
- Kim, E. Y., Anderson, M., and Dryer, S. E. (2012). Insulin Increases Surface Expression of TRPC6 Channels in Podocytes: Role of NADPH Oxidases and Reactive Oxygen Species. Am. J. Physiology-Renal Physiology 302, F298–F307. doi:10.1152/ajprenal.00423.2011
- Kim, G. S., Jung, J. E., Niizuma, K., and Chan, P. H. (2009). CK2 Is a Novel Negative Regulator of NADPH Oxidase and a Neuroprotectant in Mice after Cerebral Ischemia. J. Neurosci. 29, 14779–14789. doi:10.1523/jneurosci.4161-09.2009
- Kim, J.-S., Diebold, B. A., Babior, B. M., Knaus, U. G., and Bokoch, G. M. (2007). Regulation of Nox1 Activity via Protein Kinase A-Mediated Phosphorylation of NoxA1 and 14-3-3 Binding. J. Biol. Chem. 282, 34787–34800. doi:10.1074/jbc. m704754200
- Kim, M.-K., Jang, J.-W., and Bae, S.-C. (2018b). DNA Binding Partners of YAP/ TAZ. BMB Rep. 51, 126–133. doi:10.5483/bmbrep.2018.51.3.015
- Kim, M. H., Kim, C. G., Kim, S.-K., Shin, S. J., Choe, E. A., Park, S.-H., et al. (2018a). YAP-induced PD-L1 Expression Drives Immune Evasion in BRAFi-

Resistant Melanoma. *Cancer Immunol. Res.* 6, 255–266. doi:10.1158/2326-6066. cir-17-0320

- Kim, P. R., Zhang, S., Rahmat, M. B., and Koh, C.-G. (2020a). Partners in Crime: POPX2 Phosphatase and its Interacting Proteins in Cancer. *Cell Death Dis.* 11, 840. doi:10.1038/s41419-020-03061-0
- Kim, S., Lee, M., and Choi, Y. K. (2020b). The Role of a Neurovascular Signaling Pathway Involving Hypoxia-Inducible Factor and Notch in the Function of the Central Nervous System. *Biomol. Ther.* 28, 45–57. doi:10.4062/biomolther. 2019.119
- Kim, W., Youn, H., Kang, C., and Youn, B. (2015). Inflammation-induced Radioresistance Is Mediated by ROS-dependent Inactivation of Protein Phosphatase 1 in Non-small Cell Lung Cancer Cells. *Apoptosis* 20, 1242–1252. doi:10.1007/s10495-015-1141-1
- Kiss, A., Erdődi, F., and Lontay, B. (2019). Myosin Phosphatase: Unexpected Functions of a Long-Known Enzyme. *Biochimica Biophysica Acta (BBA) - Mol. Cell Res.* 1866, 2–15. doi:10.1016/j.bbamcr.2018.07.023
- Kitamura, H., Ohno, Y., Toyoshima, Y., Ohtake, J., Homma, S., Kawamura, H., et al. (2017). Interleukin-6/STAT3 Signaling as a Promising Target to Improve the Efficacy of Cancer Immunotherapy. *Cancer Sci.* 108, 1947–1952. doi:10. 1111/cas.13332
- Kobayashi, Y., Oguro, A., and Imaoka, S. (2021). Feedback of Hypoxia-Inducible Factor-1alpha (HIF-1alpha) Transcriptional Activity via Redox Factor-1 (Ref-1) Induction by Reactive Oxygen Species (ROS). *Free Radic. Res.* 55, 154–164. doi:10.1080/10715762.2020.1870685
- Kodama, R., Kato, M., Furuta, S., Ueno, S., Zhang, Y., Matsuno, K., et al. (2013). ROS-generating Oxidases Nox1 and Nox4 Contribute to Oncogenic Ras-Induced Premature Senescence. *Genes cells.* 18, 32–41. doi:10.1111/gtc.12015
- Kodama, Y., Hijikata, M., Kageyama, R., Shimotohno, K., and Chiba, T. (2004). The Role of Notch Signaling in the Development of Intrahepatic Bile Ducts. *Gastroenterology* 127, 1775–1786. doi:10.1053/j.gastro.2004.09.004
- Kohchi, C., Inagawa, H., Nishizawa, T., and Soma, G. (2009). ROS and Innate Immunity. Anticancer Res. 29, 817–821.
- Koivunen, P., Hirsilä, M., Günzler, V., Kivirikko, K. I., and Myllyharju, J. (2004). Catalytic Properties of the Asparaginyl Hydroxylase (FIH) in the Oxygen Sensing Pathway Are Distinct from Those of its Prolyl 4-hydroxylases. J. Biol. Chem. 279, 9899–9904. doi:10.1074/jbc.m312254200
- Kono, K., Saeki, Y., Yoshida, S., Tanaka, K., and Pellman, D. (2012). Proteasomal Degradation Resolves Competition between Cell Polarization and Cellular Wound Healing. *Cell* 150, 151–164. doi:10.1016/j.cell.2012.05.030
- Kopan, R., and Ilagan, M. X. G. (2009). The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism. *Cell* 137, 216–233. doi:10.1016/j.cell. 2009.03.045
- Koudelková, L., Brábek, J., and Rosel, D. (2021). Src Kinase: Key Effector in Mechanosignalling. *Int. J. Biochem. Cell Biol.* 131, 105908. doi:10.1016/j.biocel. 2020.105908
- Koundouros, N., and Poulogiannis, G. (2018). Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer. Front. Oncol. 8, 160. doi:10.3389/ fonc.2018.00160
- Kovall, R. A., Gebelein, B., Sprinzak, D., and Kopan, R. (2017). The Canonical Notch Signaling Pathway: Structural and Biochemical Insights into Shape, Sugar, and Force. *Dev. Cell* 41, 228–241. doi:10.1016/j.devcel.2017.04.001
- Kracke, F., Vassilev, I., and Krömer, J. O. (2015). Microbial Electron Transport and Energy Conservation €" the Foundation for Optimizing Bioelectrochemical Systems. *Front. Microbiol.* 6, 575. doi:10.3389/fmicb. 2015.00575
- Kremerskothen, J., Plaas, C., Büther, K., Finger, I., Veltel, S., Matanis, T., et al. (2003). Characterization of KIBRA, a Novel WW Domain-Containing Protein. *Biochem. Biophysical Res. Commun.* 300, 862–867. doi:10.1016/s0006-291x(02) 02945-5
- Krock, B. L., Skuli, N., and Simon, M. C. (2011). Hypoxia-induced Angiogenesis: Good and Evil. Genes & Cancer 2, 1117–1133. doi:10.1177/1947601911423654
- Kroviarski, Y., Debbabi, M., Bachoual, R., Pe'rianin, A., Gougerot-Pocidalo, M. A., El-Benna, J., et al. (2010). Phosphorylation of NADPH Oxidase Activator 1 (NOXA1) on Serine 282 by MAP Kinases and on Serine 172 by Protein Kinase C and Protein Kinase A Prevents NOX1 Hyperactivation. *FASEB J.* 24, 2077–2092. doi:10.1096/fj.09-147629
- Kulik, A. A., Maruszczak, K. K., Thomas, D. C., Nabi-Aldridge, N. L. A., Carr, M., Bingham, R. J., et al. (2021). Crystal Structure and Molecular Dynamics of

Human POLDIP2 , a Multifaceted Adaptor Protein in Metabolism and Genome Stability. *Protein Sci.* 30, 1196–1209. doi:10.1002/pro.4085

- Kulisz, A., Chen, N., Chandel, N. S., Shao, Z., and Schumacker, P. T. (2002). Mitochondrial ROS Initiate Phosphorylation of P38 MAP Kinase during Hypoxia in Cardiomyocytes. Am. J. Physiology-Lung Cell. Mol. Physiology 282, L1324–L1329. doi:10.1152/ajplung.00326.2001
- Kunnumakkara, A. B., Sailo, B. L., Banik, K., Harsha, C., Prasad, S., Gupta, S. C., et al. (2018). Chronic Diseases, Inflammation, and Spices: How Are They Linked? *J. Transl. Med.* 16, 14. doi:10.1186/s12967-018-1381-2
- Lai, D., Ho, K. C., Hao, Y., and Yang, X. (2011). Taxol Resistance in Breast Cancer Cells Is Mediated by the Hippo Pathway Component TAZ and its Downstream Transcriptional Targets Cyr61 and CTGF. *Cancer Res.* 71, 2728–2738. doi:10. 1158/0008-5472.can-10-2711
- Lamari, F., Braut-Boucher, F., Pongnimitprasert, N., Bernard, M., Foglietti, M.-J., Derappe, C., et al. (2007). Cell Adhesion and Integrin Expression Are Modulated by Oxidative Stress in EA.Hy 926 Cells. *Free Radic. Res.* 41, 812–822. doi:10.1080/10715760701390027
- Lando, D., Peet, D. J., Gorman, J. J., Whelan, D. A., Whitelaw, M. L., and Bruick, R. K. (2002). FIH-1 Is an Asparaginyl Hydroxylase Enzyme that Regulates the Transcriptional Activity of Hypoxia-Inducible Factor. *Genes Dev.* 16, 1466–1471. doi:10.1101/gad.991402
- Lasky, J. L., and Wu, H. (2005). Notch Signaling, Brain Development, and Human Disease. *Pediatr. Res.* 57, 104R–109R. doi:10.1203/01.pdr.0000159632.70510.3d
- Laulajainen, M., Muranen, T., Carpén, O., and Grönholm, M. (2008). Protein Kinase A-Mediated Phosphorylation of the NF2 Tumor Suppressor Protein Merlin at Serine 10 Affects the Actin Cytoskeleton. Oncogene 27, 3233–3243. doi:10.1038/sj.onc.1210988
- Laulajainen, M., Muranen, T., Nyman, T. A., Carpén, O., and Grönholm, M. (2011). Multistep Phosphorylation by Oncogenic Kinases Enhances the Degradation of the NF2 Tumor Suppressor Merlin. *Neoplasia* 13, 643–652. doi:10.1593/neo.11356
- Lavado, A., He, Y., Paré, J., Neale, G., Olson, E. N., Giovannini, M., et al. (2013). Tumor Suppressor Nf2 Limits Expansion of the Neural Progenitor Pool by Inhibiting Yap/Taz Transcriptional Coactivators. *Development* 140, 3323–3334. doi:10.1242/dev.096537
- Le Clainche, C., Schlaepfer, D., Ferrari, A., Klingauf, M., Grohmanova, K., Veligodskiy, A., et al. (2007). IQGAP1 Stimulates Actin Assembly through the N-WASP-Arp2/3 Pathway. J. Biol. Chem. 282, 426–435. doi:10.1074/jbc. m607711200
- Lecuit, T., and Lenne, P.-F. (2007). Cell Surface Mechanics and the Control of Cell Shape, Tissue Patterns and Morphogenesis. *Nat. Rev. Mol. Cell Biol.* 8, 633–644. doi:10.1038/nrm2222
- Lee, B. S., Park, D. I., Lee, D. H., Lee, J. E., Yeo, M.-k., Park, Y. H., et al. (2017). Hippo Effector YAP Directly Regulates the Expression of PD-L1 Transcripts in EGFR-TKI-Resistant Lung Adenocarcinoma. *Biochem. Biophysical Res. Commun.* 491, 493–499. doi:10.1016/j.bbrc.2017.07.007
- Lee, G., Won, H.-S., Lee, Y.-M., Choi, J.-W., Oh, T.-I., Jang, J.-H., et al. (2016). Oxidative Dimerization of PHD2 Is Responsible for its Inactivation and Contributes to Metabolic Reprogramming via HIF-1α Activation. *Sci. Rep.* 6, 18928. doi:10.1038/srep18928
- Lee, H. B., Yu, M. R., Song, J. S., and Ha, H. (2004a). Reactive Oxygen Species Amplify Protein Kinase C Signaling in High Glucose-Induced Fibronectin Expression by Human Peritoneal Mesothelial Cells. *Kidney Int.* 65, 1170–1179. doi:10.1111/j.1523-1755.2004.00491.x
- Lee, H., Herrmann, A., Deng, J.-H., Kujawski, M., Niu, G., Li, Z., et al. (2009). Persistently Activated Stat3 Maintains Constitutive NF-Kb Activity in Tumors. *Cancer cell* 15, 283–293. doi:10.1016/j.ccr.2009.02.015
- Lee, I.-T., Shih, R.-H., Lin, C.-C., Chen, J.-T., and Yang, C.-M. (2012). Role of TLR4/NADPH oxidase/ROS-Activated P38 MAPK in VCAM-1 Expression Induced by Lipopolysaccharide in Human Renal Mesangial Cells. Cell Commun. Signal 10, 33. doi:10.1186/1478-811x-10-33
- Lee, J.-W., Bae, S.-H., Jeong, J.-W., Kim, S.-H., and Kim, K.-W. (2004b). Hypoxiainducible Factor (HIF-1)α: its Protein Stability and Biological Functions. *Exp. Mol. Med.* 36, 1–12. doi:10.1038/emm.2004.1
- Lee, Y. A., Noon, L. A., Akat, K. M., Ybanez, M. D., Lee, T.-F., Berres, M.-L., et al. (2018b). Autophagy Is a Gatekeeper of Hepatic Differentiation and Carcinogenesis by Controlling the Degradation of Yap. *Nat. Commun.* 9, 4962. doi:10.1038/s41467-018-07338-z

- Lee, Y., Kim, N. H., Cho, E. S., Yang, J. H., Cha, Y. H., Kang, H. E., et al. (2018a). Dishevelled Has a YAP Nuclear Export Function in a Tumor Suppressor Context-dependent Manner. *Nat. Commun.* 9, 2301. doi:10.1038/s41467-018-04757-w
- Lennicke, C., and Cochemé, H. M. (2021a). Redox Metabolism: ROS as Specific Molecular Regulators of Cell Signaling and Function. *Mol. Cell* 81, 3691–3707. doi:10.1016/j.molcel.2021.08.018
- Lennicke, C., and Cochemé, H. M. (2021b). Redox Regulation of the Insulin Signalling Pathway. *Redox Biol.* 42, 101964. doi:10.1016/j.redox.2021.101964
- Leung, C. Y., and Zernicka-Goetz, M. (2013). Angiomotin Prevents Pluripotent Lineage Differentiation in Mouse Embryos via Hippo Pathway-dependent and -independent Mechanisms. *Nat. Commun.* 4, 2251. doi:10.1038/ncomms3251
- Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., et al. (2009). Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling. *Cell* 139, 891–906. doi:10.1016/j.cell.2009.10.027
- Lewis, B., and Aitken, R. J. (2001). A Redox-Regulated Tyrosine Phosphorylation Cascade in Rat Spermatozoa. J. Androl. 22, 611–622.
- Li, H., Li, X., Jing, X., Li, M., Ren, Y., Chen, J., et al. (2018a). Hypoxia Promotes Maintenance of the Chondrogenic Phenotype in Rat Growth Plate Chondrocytes through the HIF-1α/YAP Signaling Pathway. *Int. J. Mol. Med.* 42, 3181–3192. doi:10.3892/ijmm.2018.3921
- Li, J.-M., Fan, L. M., Christie, M. R., and Shah, A. M. (2005). Acute Tumor Necrosis Factor Alpha Signaling via NADPH Oxidase in Microvascular Endothelial Cells: Role of P47 Phox Phosphorylation and Binding to TRAF4. *Mol. Cell Biol.* 25, 2320–2330. doi:10.1128/mcb.25.6.2320-2330.2005
- Li, P., Silvis, M. R., Honaker, Y., Lien, W.-H., Arron, S. T., and Vasioukhin, V. (2016). Ae-catenin Inhibits a Src-YAP1 Oncogenic Module that Couples Tyrosine Kinases and the Effector of Hippo Signaling Pathway. *Genes Dev.* 30, 798–811. doi:10.1101/gad.274951.115
- Li, Y., Hibbs, M. A., Gard, A. L., Shylo, N. A., and Yun, K. (2012). Genome-wide Analysis of N1ICD/RBPJ Targets In Vivo Reveals Direct Transcriptional Regulation of Wnt, SHH, and Hippo Pathway Effectors by Notch1. *Stem Cells* 30, 741–752. doi:10.1002/stem.1030
- Li, Y., Wu, L., Yu, M., Yang, F., Wu, B., Lu, S., et al. (2018b). HIF-1α Is Critical for the Activation of Notch Signaling in Neurogenesis during Acute Epilepsy. *Neuroscience* 394, 206–219. doi:10.1016/j.neuroscience.2018.10.037
- Li, Y., Zhou, H., Li, F., Chan, S. W., Lin, Z., Wei, Z., et al. (2015). Angiomotin Binding-Induced Activation of Merlin/NF2 in the Hippo Pathway. *Cell Res.* 25, 801–817. doi:10.1038/cr.2015.69
- Li, Z., Zhao, B., Wang, P., Chen, F., Dong, Z., Yang, H., et al. (2010). Structural Insights into the YAP and TEAD Complex. *Genes Dev.* 24, 235–240. doi:10. 1101/gad.1865810
- Lian, I., Kim, J., Okazawa, H., Zhao, J., Zhao, B., Yu, J., et al. (2010). The Role of YAP Transcription Coactivator in Regulating Stem Cell Self-Renewal and Differentiation. *Genes Dev.* 24, 1106–1118. doi:10.1101/gad.1903310
- Lim, J., Pahlke, G., and Conti, M. (1999). Activation of the cAMP-specific Phosphodiesterase PDE4D3 by Phosphorylation. J. Biol. Chem. 274, 19677–19685. doi:10.1074/jbc.274.28.19677
- Lim, S.-O., Gu, J.-M., Kim, M. S., Kim, H.-S., Park, Y. N., Park, C. K., et al. (2008). Epigenetic Changes Induced by Reactive Oxygen Species in Hepatocellular Carcinoma: Methylation of the E-Cadherin Promoter. *Gastroenterology* 135, 2128–2140. doi:10.1053/j.gastro.2008.07.027
- Lim, S., Hermance, N., Mudianto, T., Mustaly, H. M., Mauricio, I. P. M., Vittoria, M. A., et al. (2019). Identification of the Kinase STK25 as an Upstream Activator of LATS Signaling. *Nat. Commun.* 10, 1547. doi:10. 1038/s41467-019-09597-w
- Limbu, S., Hoang-Trong, T. M., Prosser, B. L., Lederer, W. J., and Jafri, M. S. (2015). Modeling Local X-ROS and Calcium Signaling in the Heart. *Biophysical J.* 109, 2037–2050. doi:10.1016/j.bpj.2015.09.031
- Lin, Z., Xie, R., Guan, K., and Zhang, M. (2020). A WW Tandem-Mediated Dimerization Mode of SAV1 Essential for Hippo Signaling. *Cell Rep.* 32, 108118. doi:10.1016/j.celrep.2020.108118
- Liu, C.-Y., Zha, Z.-Y., Zhou, X., Zhang, H., Huang, W., Zhao, D., et al. (2010). The Hippo Tumor Pathway Promotes TAZ Degradation by Phosphorylating a Phosphodegron and Recruiting the SCFβ-TrCP E3 Ligase. J. Biol. Chem. 285, 37159–37169. doi:10.1074/jbc.m110.152942
- Liu, F., Lagares, D., Choi, K. M., Stopfer, L., Marinković, A., Vrbanac, V., et al. (2015). Mechanosignaling through YAP and TAZ Drives Fibroblast Activation

and Fibrosis. Am. J. Physiology-Lung Cell. Mol. Physiology 308, L344–L357. doi:10.1152/ajplung.00300.2014

- Liu, J., Guidry, J. J., and Worthylake, D. K. (2014). Conserved Sequence Repeats of IQGAP1 Mediate Binding to Ezrin. J. Proteome Res. 13, 1156–1166. doi:10. 1021/pr400787p
- Liu, J., Quan, J., Feng, J., Zhang, Q., Xu, Y., Liu, J., et al. (2016a). High Glucose Regulates LN Expression in Human Liver Sinusoidal Endothelial Cells through ROS/integrin αvβ3 Pathway. *Environ. Toxicol. Pharmacol.* 42, 231–236. doi:10. 1016/j.etap.2016.01.021
- Liu, L., Tao, T., Liu, S., Yang, X., Chen, X., Liang, J., et al. (2021a). An RFC4/Notch1 Signaling Feedback Loop Promotes NSCLC Metastasis and Stemness. *Nat. Commun.* 12, 2693. doi:10.1038/s41467-021-22971-x
- Liu, Q., Luo, Q., Ju, Y., and Song, G. (2020a). Role of the Mechanical Microenvironment in Cancer Development and Progression. *Cancer Biol. Med.* 17, 282–292. doi:10.20892/j.issn.2095-3941.2019.0437
- Liu, Q. P., Luo, Q., Deng, B., Ju, Y., and Song, G. B. (2020b). Stiffer Matrix Accelerates Migration of Hepatocellular Carcinoma Cells through Enhanced Aerobic Glycolysis via the MAPK-YAP Signaling. *Cancers (Basel)* 12. doi:10. 3390/cancers12020490
- Liu, W. J., Huang, Y. X., Wang, W., Zhang, Y., Liu, B. J., Qiu, J. G., et al. (2021b). NOX4 Signaling Mediates Cancer Development and Therapeutic Resistance through HER3 in Ovarian Cancer Cells. *Cells* 10. doi:10.3390/cells10071647
- Liu, X., Long, X., Gao, Y., Liu, W., Hayashi, T., Mizuno, K., et al. (2020c). Type I Collagen Inhibits Adipogenic Differentiation via YAP Activation In Vitro. J. Cell. Physiology 235, 1821–1837. doi:10.1002/jcp.29100
- Liu, X., Yang, N., Figel, S. A., Wilson, K. E., Morrison, C. D., Gelman, I. H., et al. (2013). PTPN14 Interacts with and Negatively Regulates the Oncogenic Function of YAP. Oncogene 32, 1266–1273. doi:10.1038/onc.2012.147
- Liu, Y., Jiang, B.-J., Zhao, R.-Z., and Ji, H.-L. (2016b). Epithelial Sodium Channels in Pulmonary Epithelial Progenitor and Stem Cells. Int. J. Biol. Sci. 12, 1150–1154. doi:10.7150/ijbs.15747
- Liu, Z.-J., Tan, Y., Beecham, G. W., Seo, D. M., Tian, R., Li, Y., et al. (2012). Notch Activation Induces Endothelial Cell Senescence and Pro-inflammatory Response: Implication of Notch Signaling in Atherosclerosis. *Atherosclerosis* 225, 296–303. doi:10.1016/j.atherosclerosis.2012.04.010
- Loehr, J. A., Wang, S., Cully, T. R., Pal, R., Larina, I. V., Larin, K. V., et al. (2018). NADPH Oxidase Mediates Microtubule Alterations and Diaphragm Dysfunction in Dystrophic Mice. *Elife* 7. doi:10.7554/eLife.31732
- Loerakker, S., Stassen, O. M. J. A., Ter Huurne, F. M., Boareto, M., Bouten, C. V. C., and Sahlgren, C. M. (2018). Mechanosensitivity of Jagged-Notch Signaling Can Induce a Switch-type Behavior in Vascular Homeostasis. *Proc. Natl. Acad. Sci.* U. S. A. 115, E3682–E3691. doi:10.1073/pnas.1715277115
- Lopes, L. R., Dagher, M.-C., Gutierrez, A., Young, B., Bouin, A.-P., Fuchs, A., et al. (2004). Phosphorylated p40PHOX as a Negative Regulator of NADPH Oxidase. *Biochemistry* 43, 3723–3730. doi:10.1021/bi035636s
- Low, I. C. C., Loh, T., Huang, Y., Virshup, D. M., and Pervaiz, S. (2014). Ser70 Phosphorylation of Bcl-2 by Selective Tyrosine Nitration of PP2A-B568 Stabilizes its Antiapoptotic Activity. *Blood* 124, 2223–2234. doi:10.1182/ blood-2014-03-563296
- Lu, P.-J., Zhou, X. Z., Shen, M., and Lu, K. P. (1999). Function of WW Domains as Phosphoserine- or Phosphothreonine-Binding Modules. *Science* 283, 1325–1328. doi:10.1126/science.283.5406.1325
- Lv, Y., Chen, C., Zhao, B., and Zhang, X. (2017). Regulation of Matrix Stiffness on the Epithelial-Mesenchymal Transition of Breast Cancer Cells under Hypoxia Environment. *Sci. Nat.* 104, 38. doi:10.1007/s00114-017-1461-9
- Lyle, A. N., Deshpande, N. N., Taniyama, Y., Seidel-Rogol, B., Pounkova, L., Du, P., et al. (2009). Poldip2, a Novel Regulator of Nox4 and Cytoskeletal Integrity in Vascular Smooth Muscle Cells. *Circulation Res.* 105, 249–259. doi:10.1161/ circresaha.109.193722
- Ma, B., Cheng, H., Gao, R., Mu, C., Chen, L., Wu, S., et al. (2016). Zyxin-Siah2-Lats2 axis Mediates Cooperation between Hippo and TGF-β Signalling Pathways. Nat. Commun. 7, 11123. doi:10.1038/ncomms11123
- Ma, B., Chen, Y., Chen, L., Cheng, H., Mu, C., Li, J., et al. (2015). Hypoxia Regulates Hippo Signalling through the SIAH2 Ubiquitin E3 Ligase. *Nat. Cell Biol.* 17, 95–103. doi:10.1038/ncb3073
- Ma, S., Meng, Z., Chen, R., and Guan, K.-L. (2019). The Hippo Pathway: Biology and Pathophysiology. *Annu. Rev. Biochem.* 88, 577–604. doi:10.1146/annurevbiochem-013118-111829

- Ma, T., and Liu, Z. (2013). Functions of Aquaporin 1 and α-epithelial Na+ Channel in Rat Acute Lung Injury Induced by Acute Ischemic Kidney Injury. *Int. Urol. Nephrol.* 45, 1187–1196. doi:10.1007/s11255-012-0355-1
- Ma, X., Zhang, H., Xue, X., and Shah, Y. M. (2017). Hypoxia-inducible Factor 2α (HIF-2α) Promotes Colon Cancer Growth by Potentiating Yes-Associated Protein 1 (YAP1) Activity. J. Biol. Chem. 292, 17046–17056. doi:10.1074/jbc. m117.805655
- Macias, M. J., Hyvönen, M., Baraldi, E., Schultz, J., Sudol, M., Saraste, M., et al. (1996). Structure of the WW Domain of a Kinase-Associated Protein Complexed with a Proline-Rich Peptide. *Nature* 382, 646–649. doi:10.1038/ 382646a0
- Mack, J. J., Mosqueiro, T. S., Archer, B. J., Jones, W. M., Sunshine, H., Faas, G. C., et al. (2017). NOTCH1 Is a Mechanosensor in Adult Arteries. *Nat. Commun.* 8, 1620. doi:10.1038/s41467-017-01741-8
- Mackay, C. E., Shaifta, Y., Snetkov, V. V., Francois, A. A., Ward, J. P. T., and Knock, G. A. (2017). ROS-dependent Activation of RhoA/Rho-Kinase in Pulmonary Artery: Role of Src-Family Kinases and ARHGEF1. *Free Radic. Biol. Med.* 110, 316–331. doi:10.1016/j.freeradbiomed.2017.06.022
- Maile, L. A., Badley-Clarke, J., and Clemmons, D. R. (2003). The Association between Integrin-Associated Protein and SHPS-1 Regulates Insulin-like Growth Factor-I Receptor Signaling in Vascular Smooth Muscle Cells. *MBoC* 14, 3519–3528. doi:10.1091/mbc.e03-04-0239
- Maile, L. A., Capps, B. E., Miller, E. C., Aday, A. W., and Clemmons, D. R. (2008). Integrin-associated Protein Association with SRC Homology 2 Domain Containing Tyrosine Phosphatase Substrate 1 Regulates Igf-I Signaling In Vivo. *Diabetes* 57, 2637–2643. doi:10.2337/db08-0326
- Majmundar, A. J., Wong, W. J., and Simon, M. C. (2010). Hypoxia-inducible Factors and the Response to Hypoxic Stress. *Mol. Cell* 40, 294–309. doi:10.1016/ j.molcel.2010.09.022
- Malarkannan, S., Awasthi, A., Rajasekaran, K., Kumar, P., Schuldt, K. M., Bartoszek, A., et al. (2012). IQGAP1: a Regulator of Intracellular Spacetime Relativity. J. I. 188, 2057–2063. doi:10.4049/jimmunol.1102439
- Mammoto, A., and Ingber, D. E. (2009). Cytoskeletal Control of Growth and Cell Fate Switching. Curr. Opin. Cell Biol. 21, 864–870. doi:10.1016/j.ceb.2009.08.001
- Mammoto, T., Mammoto, A., Torisawa, Y.-s., Tat, T., Gibbs, A., Derda, R., et al. (2011). Mechanochemical Control of Mesenchymal Condensation and Embryonic Tooth Organ Formation. *Dev. Cell* 21, 758–769. doi:10.1016/j. devcel.2011.07.006
- Mana-Capelli, S., and Mccollum, D. (2018). Angiomotins Stimulate LATS Kinase Autophosphorylation and Act as Scaffolds that Promote Hippo Signaling. J. Biol. Chem. 293, 18230–18241. doi:10.1074/jbc.ra118.004187
- Mana-Capelli, S., Paramasivam, M., Dutta, S., and Mccollum, D. (2014). Angiomotins Link F-Actin Architecture to Hippo Pathway Signaling. *MBoC* 25, 1676–1685. doi:10.1091/mbc.e13-11-0701
- Manderfield, L. J., Aghajanian, H., Engleka, K. A., Lim, L. Y., Liu, F., Jain, R., et al. (2015). Hippo Signaling Is Required for Notch-dependent Smooth Muscle Differentiation of Neural Crest. *Development* 142, 2962–2971. doi:10.1242/dev. 125807
- Manderfield, L. J., High, F. A., Engleka, K. A., Liu, F., Li, L., Rentschler, S., et al. (2012). Notch Activation of Jagged1 Contributes to the Assembly of the Arterial Wall. *Circulation* 125, 314–323. doi:10.1161/circulationaha.111.047159
- Mansour, F. A., Al-Mazrou, A., Al-Mohanna, F., Al-Alwan, M., and Ghebeh, H. (2020). PD-L1 Is Overexpressed on Breast Cancer Stem Cells through notch3/ mTOR axis. Oncoimmunology 9, 1729299. doi:10.1080/2162402x.2020.1729299
- Marazita, M. C., Dugour, A., Marquioni-Ramella, M. D., Figueroa, J. M., and Suburo, A. M. (2016). Oxidative Stress-Induced Premature Senescence Dysregulates VEGF and CFH Expression in Retinal Pigment Epithelial Cells: Implications for Age-Related Macular Degeneration. *Redox Biol.* 7, 78–87. doi:10.1016/j.redox.2015.11.011
- Marklund, S. (1976). Spectrophotometric Study of Spontaneous Disproportionation of Superoxide Anion Radical and Sensitive Direct Assay for Superoxide Dismutase. J. Biol. Chem. 251, 7504–7507. doi:10.1016/s0021-9258(17)32878-8
- Martyn, K. D., Kim, M.-J., Quinn, M. T., Dinauer, M. C., and Knaus, U. G. (2005). p21-activated Kinase (Pak) Regulates NADPH Oxidase Activation in Human Neutrophils. *Blood* 106, 3962–3969. doi:10.1182/blood-2005-03-0859
- Marxsen, J. H., Stengel, P., Doege, K., Heikkinen, P., Jokilehto, T., Wagner, T., et al. (2004). Hypoxia-inducible Factor-1 (HIF-1) Promotes its Degradation by

Induction of HIF-α-Prolyl-4-Hydroxylases. *Biochem. J.* 381, 761–767. doi:10. 1042/bj20040620

- Masoud, G. N., and Li, W. (2015). HIF-1a Pathway: Role, Regulation and Intervention for Cancer Therapy. Acta Pharm. Sin. B 5, 378–389. doi:10. 1016/j.apsb.2015.05.007
- Masson, N., and Ratcliffe, P. J. (2014). Hypoxia Signaling Pathways in Cancer Metabolism: the Importance of Co-selecting Interconnected Physiological Pathways. *Cancer Metab.* 2, 3. doi:10.1186/2049-3002-2-3
- Matsuno, Y., Coelho, A. L., Jarai, G., Westwick, J., and Hogaboam, C. M. (2012). Notch Signaling Mediates TGF-B1-Induced Epithelial-Mesenchymal Transition through the Induction of Snai1. *Int. J. Biochem. Cell Biol.* 44, 776–789. doi:10.1016/j.biocel.2012.01.021
- Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., et al. (1999). The Tumour Suppressor Protein VHL Targets Hypoxia-Inducible Factors for Oxygen-dependent Proteolysis. *Nature* 399, 271–275. doi:10.1038/20459
- Maydan, M., Mcdonald, P. C., Sanghera, J., Yan, J., Rallis, C., Pinchin, S., et al. (2010). Integrin-Linked Kinase Is a Functional Mn2+-dependent Protein Kinase that Regulates Glycogen Synthase Kinase-3β (GSK-3β) Phosphorylation. *PloS one* 5, e12356. doi:10.1371/journal.pone.0012356
- Mazumdar, J., Dondeti, V., and Simon, M. C. (2009). Hypoxia-inducible Factors in Stem Cells and Cancer. J. Cell Mol. Med. 13, 4319–4328. doi:10.1111/j.1582-4934.2009.00963.x
- Mcclatchey, A. I. (2003). Merlin and ERM Proteins: Unappreciated Roles in Cancer Development? Nat. Rev. Cancer 3, 877–883. doi:10.1038/nrc1213
- Meng, D., Lv, D.-D., and Fang, J. (2008). Insulin-like Growth Factor-I Induces Reactive Oxygen Species Production and Cell Migration through Nox4 and Rac1 in Vascular Smooth Muscle Cells. *Cardiovasc. Res.* 80, 299–308. doi:10. 1093/cvr/cvn173
- Meng, Z., Moroishi, T., and Guan, K.-L. (2016). Mechanisms of Hippo Pathway Regulation. *Genes Dev.* 30, 1–17. doi:10.1101/gad.274027.115
- Meng, Z., Moroishi, T., Mottier-Pavie, V., Plouffe, S. W., Hansen, C. G., Hong, A. W., et al. (2015). MAP4K Family Kinases Act in Parallel to MST1/2 to Activate LATS1/2 in the Hippo Pathway. *Nat. Commun.* 6, 8357. doi:10.1038/ncomms9357
- Miao, J., Hsu, P.-C., Yang, Y.-L., Xu, Z., Dai, Y., Wang, Y., et al. (2017). YAP Regulates PD-L1 Expression in Human NSCLC Cells. Oncotarget 8, 114576–114587. doi:10.18632/oncotarget.23051
- Mo, J.-S., Meng, Z., Kim, Y. C., Park, H. W., Hansen, C. G., Kim, S., et al. (2015). Cellular Energy Stress Induces AMPK-Mediated Regulation of YAP and the Hippo Pathway. *Nat. Cell Biol.* 17, 500–510. doi:10.1038/ncb3111
- Mo, J. S., Park, H. W., and Guan, K. L. (2014). The Hippo Signaling Pathway in Stem Cell Biology and Cancer. EMBO Rep. 15, 642–656. doi:10.15252/embr. 201438638
- Moeller, B. J., Cao, Y., Li, C. Y., and Dewhirst, M. W. (2004). Radiation Activates HIF-1 to Regulate Vascular Radiosensitivity in Tumors. *Cancer cell* 5, 429–441. doi:10.1016/s1535-6108(04)00115-1
- Moi, P., Chan, K., Asunis, I., Cao, A., and Kan, Y. W. (1994). Isolation of NF-E2-Related Factor 2 (Nrf2), a NF-E2-like Basic Leucine Zipper Transcriptional Activator that Binds to the Tandem NF-E2/ap1 Repeat of the Beta-Globin Locus Control Region. Proc. Natl. Acad. Sci. U.S.A. 91, 9926–9930. doi:10.1073/ pnas.91.21.9926
- Moleirinho, S., Hoxha, S., Mandati, V., Curtale, G., Troutman, S., Ehmer, U., et al. (2017). Regulation of Localization and Function of the Transcriptional Coactivator YAP by Angiomotin. *Elife* 6. doi:10.7554/eLife.23966
- Moon, S., Kim, W., Kim, S., Kim, Y., Song, Y., Bilousov, O., et al. (2017). Phosphorylation by NLK Inhibits YAP -14-3-3-interactions and Induces its Nuclear Localization. *EMBO Rep.* 18, 61–71. doi:10.15252/embr. 201642683
- Morel, F., Rousset, F., Vu Chuong Nguyen, M., Trocme, C., Grange, L., and Lardy, B. (2015). La NADPH Oxydase Nox4, Une Cible Thérapeutique Potentielle Dans L'arthrose. Bull. l'Académie Natl. Médecine 199, 673–687. doi:10.1016/ s0001-4079(19)30941-0
- Moreno, C. S., Park, S., Nelson, K., Ashby, D., Hubalek, F., Lane, W. S., et al. (2000). WD40 Repeat Proteins Striatin and S/G2 Nuclear Autoantigen Are Members of a Novel Family of Calmodulin-Binding Proteins that Associate with Protein Phosphatase 2A. J. Biol. Chem. 275, 5257–5263. doi:10.1074/jbc. 275.8.5257

- Morrison, H., Sherman, L. S., Legg, J., Banine, F., Isacke, C., Haipek, C. A., et al. (2001). The NF2 Tumor Suppressor Gene Product, Merlin, Mediates Contact Inhibition of Growth through Interactions with CD44. *Genes Dev.* 15, 968–980. doi:10.1101/gad.189601
- Muranen, T., Grönholm, M., Lampin, A., Lallemand, D., Zhao, F., Giovannini, M., et al. (2007). The Tumor Suppressor Merlin Interacts with Microtubules and Modulates Schwann Cell Microtubule Cytoskeleton. *Hum. Mol. Genet.* 16, 1742–1751. doi:10.1093/hmg/ddm122
- Murphy, M. P. (2009). How Mitochondria Produce Reactive Oxygen Species. Biochem. J. 417, 1-13. doi:10.1042/bj20081386
- Nagarkoti, S., Dubey, M., Awasthi, D., Kumar, V., Chandra, T., Kumar, S., et al. (2018). S-glutathionylation of P47phox Sustains Superoxide Generation in Activated Neutrophils. *Biochimica Biophysica Acta (BBA) - Mol. Cell Res.* 1865, 444–454. doi:10.1016/j.bbamcr.2017.11.014
- Nakano, Y., Banfi, B., Jesaitis, A. J., Dinauer, M. C., Allen, L.-A. H., and Nauseef, W. M. (2007). Critical Roles for P22phox in the Structural Maturation and Subcellular Targeting of Nox3. *Biochem. J.* 403, 97–108. doi:10.1042/ bj20060819
- Nakayama, K., and Ronai, Z. e. (2004). Siah: New Players in the Cellular Response to Hypoxia. *Cell Cycle* 3, 1345–1347. doi:10.4161/cc.3.11.1207
- Nelson, C. M., Vanduijn, M. M., Inman, J. L., Fletcher, D. A., and Bissell, M. J. (2006). Tissue Geometry Determines Sites of Mammary Branching Morphogenesis in Organotypic Cultures. *Science* 314, 298–300. doi:10.1126/ science.1131000
- Nguyen Dinh Cat, A., Montezano, A. C., Burger, D., and Touyz, R. M. (2013). Angiotensin II, NADPH Oxidase, and Redox Signaling in the Vasculature. *Antioxidants Redox Signal.* 19, 1110–1120. doi:10.1089/ars.2012.4641
- Ni, L., Li, S., Yu, J., Min, J., Brautigam, C. A., Tomchick, D. R., et al. (2013). Structural Basis for Autoactivation of Human Mst2 Kinase and its Regulation by RASSF5. *Structure* 21, 1757–1768. doi:10.1016/j.str.2013.07.008
- Ni, L., Zheng, Y., Hara, M., Pan, D., and Luo, X. (2015). Structural Basis for Mob1dependent Activation of the Core Mst-Lats Kinase Cascade in Hippo Signaling. *Genes Dev.* 29, 1416–1431. doi:10.1101/gad.264929.115
- Ning, W., Song, R., Li, C., Park, E., Mohsenin, A., Choi, A. M. K., et al. (2002). TGF-β1stimulates HO-1 via the P38 Mitogen-Activated Protein Kinase in A549 Pulmonary Epithelial Cells. Am. J. Physiology-Lung Cell. Mol. Physiology 283, L1094–L1102. doi:10.1152/ajplung.00151.2002
- Nishioka, N., Inoue, K.-i., Adachi, K., Kiyonari, H., Ota, M., Ralston, A., et al. (2009). The Hippo Signaling Pathway Components Lats and Yap Pattern Tead4 Activity to Distinguish Mouse Trophectoderm from Inner Cell Mass. *Dev. Cell* 16, 398–410. doi:10.1016/j.devcel.2009.02.003
- Noguchi, S., Saito, A., and Nagase, T. (2018). YAP/TAZ Signaling as a Molecular Link between Fibrosis and Cancer. Int. J. Mol. Sci. 19. doi:10.3390/ ijms19113674
- Noguchi, S., Saito, A., Mikami, Y., Urushiyama, H., Horie, M., Matsuzaki, H., et al. (2017). TAZ Contributes to Pulmonary Fibrosis by Activating Profibrotic Functions of Lung Fibroblasts. *Sci. Rep.* 7, 42595. doi:10.1038/srep42595
- Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., et al. (2014). PD-L1 Is a Novel Direct Target of HIF-1α, and its Blockade under Hypoxia Enhanced MDSC-Mediated T Cell Activation. J. Exp. Med. 211, 781–790. doi:10.1084/jem.20131916
- Novianti, T., Juniantito, V., Jusuf, A. A., Arida, E. A., Sadikin, M., and Jusman, S. W. A. (2020). High Expressions of the Cytoglobin and PGC-1α Genes during the Tissue Regeneration of House Gecko (Hemidactylus Platyurus) Tails. BMC Dev. Biol. 20, 11. doi:10.1186/s12861-020-00214-4
- Obremski, V. J., Hall, A. M., and Fernandez-Valle, C. (1998). Merlin, the Neurofibromatosis Type 2 Gene Product, and ?1 Integrin Associate in Isolated and Differentiating Schwann Cells. J. Neurobiol. 37, 487–501. doi:10.1002/(sici)1097-4695(199812)37:4<487::aid-neu1>3.0.co;2-b
- Ohnishi, S., Güntert, P., Koshiba, S., Tomizawa, T., Akasaka, R., Tochio, N., et al. (2007). Solution Structure of an Atypical WW Domain in a Novel βclam-like Dimeric Form. *FEBS Lett.* 581, 462–468. doi:10.1016/j.febslet. 2007.01.008
- Oshima, K., Ruhul Amin, A. R. M., Suzuki, A., Hamaguchi, M., and Matsuda, S. (2002). SHPS-1, a Multifunctional Transmembrane Glycoprotein. *FEBS Lett.* 519, 1–7. doi:10.1016/s0014-5793(02)02703-5
- Pan, D. (2010). The Hippo Signaling Pathway in Development and Cancer. Dev. Cell 19, 491–505. doi:10.1016/j.devcel.2010.09.011

- Panciera, T., Azzolin, L., Cordenonsi, M., and Piccolo, S. (2017). Mechanobiology of YAP and TAZ in Physiology and Disease. *Nat. Rev. Mol. Cell Biol.* 18, 758–770. doi:10.1038/nrm.2017.87
- Park, J., Kim, D.-H., Shah, S. R., Kim, H.-N., KshitizKim, P., Kim, P., et al. (2019). Switch-like Enhancement of Epithelial-Mesenchymal Transition by YAP through Feedback Regulation of WT1 and Rho-Family GTPases. *Nat. Commun.* 10, 2797. doi:10.1038/s41467-019-10729-5
- Paszek, M. J., Zahir, N., Johnson, K. R., Lakins, J. N., Rozenberg, G. I., Gefen, A., et al. (2005). Tensional Homeostasis and the Malignant Phenotype. *Cancer cell* 8, 241–254. doi:10.1016/j.ccr.2005.08.010
- Paul, M. K., Bisht, B., Darmawan, D. O., Chiou, R., Ha, V. L., Wallace, W. D., et al. (2014). Dynamic Changes in Intracellular ROS Levels Regulate Airway Basal Stem Cell Homeostasis through Nrf2-dependent Notch Signaling. *Cell Stem Cell* 15, 199–214. doi:10.1016/j.stem.2014.05.009
- Peng, G., and Liu, Y. (2015). Hypoxia-inducible Factors in Cancer Stem Cells and Inflammation. *Trends Pharmacol. Sci.* 36, 374–383. doi:10.1016/j.tips.2015. 03.003
- Peng, J.-J., Xiong, S.-Q., Ding, L.-X., Peng, J., and Xia, X.-B. (2019). Diabetic Retinopathy: Focus on NADPH Oxidase and its Potential as Therapeutic Target. *Eur. J. Pharmacol.* 853, 381–387. doi:10.1016/j.ejphar.2019.04.038
- Perillo, B., Di Donato, M., Pezone, A., Di Zazzo, E., Giovannelli, P., Galasso, G., et al. (2020). ROS in Cancer Therapy: the Bright Side of the Moon. *Exp. Mol. Med.* 52, 192–203. doi:10.1038/s12276-020-0384-2
- Pervaiz, S., Taneja, R., and Ghaffari, S. (2009). Oxidative Stress Regulation of Stem and Progenitor Cells. Antioxidants Redox Signal. 11, 2777–2789. doi:10.1089/ ars.2009.2804
- Petruzzelli, R., Christensen, D. R., Parry, K. L., Sanchez-Elsner, T., and Houghton, F. D. (2014). HIF-2α Regulates NANOG Expression in Human Embryonic Stem Cells Following Hypoxia and Reoxygenation through the Interaction with an Oct-Sox Cis Regulatory Element. *PloS one* 9, e108309. doi:10.1371/journal. pone.0108309
- Piccolo, S., Dupont, S., and Cordenonsi, M. (2014). The Biology of YAP/TAZ: Hippo Signaling and beyond. *Physiol. Rev.* 94, 1287–1312. doi:10.1152/physrev. 00005.2014
- Pietruczuk, P., Jain, A., Simo-Cheyou, E. R., Anand-Srivastava, M. B., and Srivastava, A. K. (2019). Protein Kinase B/AKT Mediates Insulin-like Growth Factor 1-induced Phosphorylation and Nuclear Export of Histone Deacetylase 5 via NADPH Oxidase 4 Activation in Vascular Smooth Muscle Cells. J. Cell. Physiology 234, 17337–17350. doi:10.1002/jcp.28353
- Pires, P. W., and Earley, S. (2017). Redox Regulation of Transient Receptor Potential Channels in the Endothelium. *Microcirculation* 24. doi:10.1111/ micc.12329
- Poernbacher, I., Baumgartner, R., Marada, S. K., Edwards, K., and Stocker, H. (2012). Drosophila Pez Acts in Hippo Signaling to Restrict Intestinal Stem Cell Proliferation. *Curr. Biol.* 22, 389–396. doi:10.1016/j.cub.2012.01.019
- Poon, E., Harris, A. L., and Ashcroft, M. (2009). Targeting the Hypoxia-Inducible Factor (HIF) Pathway in Cancer. *Expert Rev. Mol. Med.* 11, e26. doi:10.1017/ s1462399409001173
- Prabhakar, N. R., and Semenza, G. L. (2012). Adaptive and Maladaptive Cardiorespiratory Responses to Continuous and Intermittent Hypoxia Mediated by Hypoxia-Inducible Factors 1 and 2. *Physiol. Rev.* 92, 967–1003. doi:10.1152/physrev.00030.2011
- Pratt, S. J. P., Lee, R. M., Chang, K. T., Hernández-Ochoa, E. O., Annis, D. A., Ory, E. C., et al. (2020). Mechanoactivation of NOX2-Generated ROS Elicits Persistent TRPM8 Ca 2+ Signals that Are Inhibited by Oncogenic KRas. Proc. Natl. Acad. Sci. U.S.A. 117, 26008–26019. doi:10.1073/pnas. 2009495117
- Prior, K.-K., Wittig, I., Leisegang, M. S., Groenendyk, J., Weissmann, N., Michalak, M., et al. (2016). The Endoplasmic Reticulum Chaperone Calnexin Is a NADPH Oxidase NOX4 Interacting Protein. J. Biol. Chem. 291, 7045–7059. doi:10.1074/jbc.m115.710772
- Prosser, B. L., Khairallah, R. J., Ziman, A. P., Ward, C. W., and Lederer, W. J. (2013). X-ROS Signaling in the Heart and Skeletal Muscle: Stretch-dependent Local ROS Regulates [Ca2+]i. J. Mol. Cell. Cardiol. 58, 172–181. doi:10.1016/j. yjmcc.2012.11.011
- Prosser, B. L., Ward, C. W., and Lederer, W. J. (2011). X-ROS Signaling: Rapid Mechano-Chemo Transduction in Heart. *Science* 333, 1440–1445. doi:10.1126/ science.1202768

- Qi, J., Kim, H., Scortegagna, M., and Ronai, Z. e. A. (2013). Regulators and Effectors of Siah Ubiquitin Ligases. *Cell Biochem. Biophys.* 67, 15–24. doi:10.1007/ s12013-013-9636-2
- Qiang, L., Wu, T., Zhang, H.-W., Lu, N., Hu, R., Wang, Y.-J., et al. (2012). HIF-1α Is Critical for Hypoxia-Mediated Maintenance of Glioblastoma Stem Cells by Activating Notch Signaling Pathway. *Cell Death Differ*. 19, 284–294. doi:10. 1038/cdd.2011.95
- Quinn, N. P., Garcia-Gutierrez, L., Doherty, C., Von Kriegsheim, A., Fallahi, E., Sacks, D. B., et al. (2021). IQGAP1 Is a Scaffold of the Core Proteins of the Hippo Pathway and Negatively Regulates the Pro-apoptotic Signal Mediated by This Pathway. *Cells* 10. doi:10.3390/cells10020478
- Raad, H., Paciet, M.-H., Boussetta, T., Kroviarski, Y., Morel, F., Quinn, M. T., et al. (2009).
  Regulation of the Phagocyte NADPH Oxidase Activity: Phosphorylation of gp91phox/NOX2 by Protein Kinase C Enhances its Diaphorase Activity and Binding to Rac2, P67phox, and P47phox. FASEB J. 23, 1011–1022. doi:10.1096/fj.08-114553
- Rababa'h, A., Craft, J. W., Jr., Wijaya, C. S., Atrooz, F., Fan, Q., Singh, S., et al. (2013). Protein Kinase A and phosphodiesterase-4D3 Binding to Coding Polymorphisms of Cardiac Muscle Anchoring Protein (mAKAP). J. Mol. Biol. 425, 3277–3288. doi:10.1016/j.jmb.2013.06.014
- Ragsdale, G. K., Phelps, J., and Luby-Phelps, K. (1997). Viscoelastic Response of Fibroblasts to Tension Transmitted through Adherens Junctions. *Biophysical J.* 73, 2798–2808. doi:10.1016/s0006-3495(97)78309-7
- Raman, D., and Pervaiz, S. (2019). Redox Inhibition of Protein Phosphatase PP2A: Potential Implications in Oncogenesis and its Progression. *Redox Biol.* 27, 101105. doi:10.1016/j.redox.2019.101105
- Rao, R. K., and Clayton, L. W. (2002). Regulation of Protein Phosphatase 2A by Hydrogen Peroxide and Glutathionylation. *Biochem. Biophysical Res. Commun.* 293, 610–616. doi:10.1016/s0006-291x(02)00268-1
- Rastogi, R., Geng, X., Li, F., and Ding, Y. (2016). NOX Activation by Subunit Interaction and Underlying Mechanisms in Disease. *Front. Cell Neurosci.* 10, 301. doi:10.3389/fncel.2016.00301
- Ray, P. D., Huang, B.-W., and Tsuji, Y. (2012). Reactive Oxygen Species (ROS) Homeostasis and Redox Regulation in Cellular Signaling. *Cell. Signal.* 24, 981–990. doi:10.1016/j.cellsig.2012.01.008
- Regier, D. S., Waite, K. A., Wallin, R., and Mcphail, L. C. (1999). A Phosphatidic Acid-Activated Protein Kinase and Conventional Protein Kinase C Isoforms Phosphorylate P22, an NADPH Oxidase Component. J. Biol. Chem. 274, 36601–36608. doi:10.1074/jbc.274.51.36601
- Reinhart-King, C. A., Dembo, M., and Hammer, D. A. (2008). Cell-cell Mechanical Communication through Compliant Substrates. *Biophysical J.* 95, 6044–6051. doi:10.1529/biophysj.107.127662
- Reynafarje, B., Costa, L. E., and Lehninger, A. L. (1985). O2 Solubility in Aqueous Media Determined by a Kinetic Method. *Anal. Biochem.* 145, 406–418. doi:10. 1016/0003-2697(85)90381-1
- Richard, D. E., Berra, E., Gothié, E., Roux, D., and Pouysségur, J. (1999). p42/ p44 Mitogen-Activated Protein Kinases Phosphorylate Hypoxia-Inducible Factor 1α (HIF-1α) and Enhance the Transcriptional Activity of HIF-1. J. Biol. Chem. 274, 32631–32637. doi:10.1074/jbc.274.46.32631
- Rivas, S., Antón, I. M., and Wandosell, F. (2018). WIP-YAP/TAZ as A New Prooncogenic Pathway in Glioma. *Cancers (Basel)* 10. doi:10.3390/cancers10060191
- Robison, P., Caporizzo, M. A., Ahmadzadeh, H., Bogush, A. I., Chen, C. Y., Margulies, K. B., et al. (2016). Detyrosinated Microtubules Buckle and Bear Load in Contracting Cardiomyocytes. *Science* 352, aaf0659. doi:10.1126/science.aaf0659
- Rohwer, N., and Cramer, T. (2011). Hypoxia-mediated Drug Resistance: Novel Insights on the Functional Interaction of HIFs and Cell Death Pathways. Drug Resist. Updat. 14, 191–201. doi:10.1016/j.drup.2011.03.001
- Rosenbluh, J., Nijhawan, D., Cox, A. G., Li, X., Neal, J. T., Schafer, E. J., et al. (2012). β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis. *Cell* 151, 1457–1473. doi:10.1016/j.cell.2012.11.026
- Rudolph, J. (2005). Redox Regulation of the Cdc25 Phosphatases. Antioxidants Redox Signal. 7, 761–767. doi:10.1089/ars.2005.7.761
- Saito, S., Lin, Y.-C., Tsai, M.-H., Lin, C.-S., Murayama, Y., Sato, R., et al. (2015). Emerging Roles of Hypoxia-Inducible Factors and Reactive Oxygen Species in Cancer and Pluripotent Stem Cells. *Kaohsiung J. Med. Sci.* 31, 279–286. doi:10. 1016/j.kjms.2015.03.002

- Sánchez-de-Diego, C., Valer, J. A., Pimenta-Lopes, C., Rosa, J. L., and Ventura, F. (2019). Interplay between BMPs and Reactive Oxygen Species in Cell Signaling and Pathology. *Biomolecules* 9. doi:10.3390/biom9100534
- Santabárbara-Ruiz, P., López-Santillán, M., Martínez-Rodríguez, I., Binagui-Casas, A., Pérez, L., Milán, M., et al. (2015). ROS-induced JNK and P38 Signaling Is Required for Unpaired Cytokine Activation during Drosophila Regeneration. *PLoS Genet.* 11, e1005595. doi:10.1371/journal.pgen.1005595
- Santinon, G., Pocaterra, A., and Dupont, S. (2016). Control of YAP/TAZ Activity by Metabolic and Nutrient-Sensing Pathways. *Trends Cell Biol.* 26, 289–299. doi:10.1016/j.tcb.2015.11.004
- Santos, C. X., Hafstad, A. D., Beretta, M., Zhang, M., Molenaar, C., Kopec, J., et al. (2016). Targeted Redox Inhibition of Protein Phosphatase 1 by Nox4 Regulates eIF 2α-mediated Stress Signaling. *EMBO J.* 35, 319–334. doi:10.15252/embj. 201592394
- Sarkar, T. R., Sharan, S., Wang, J., Pawar, S. A., Cantwell, C. A., Johnson, P. F., et al. (2012). Identification of a Src Tyrosine Kinase/SIAH2 E3 Ubiquitin Ligase Pathway that Regulates C/EBPδ Expression and Contributes to Transformation of Breast Tumor Cells. *Mol. Cell Biol.* 32, 320–332. doi:10.1128/mcb.05790-11
- Sarmasti Emami, S., Zhang, D., and Yang, X. (2020). Interaction of the Hippo Pathway and Phosphatases in Tumorigenesis. *Cancers (Basel)* 12. doi:10.3390/ cancers12092438
- Sarti, P., Antonini, G., Malatesta, R., Vallone, B., and Brunori, M. (1988). Is the Internal Electron Transfer the Rate-Limiting Step in the Catalytic Cycle of Cytochrome C Oxidase? Ann. N. Y. Acad. Sci. 550, 161–166. doi:10.1111/j.1749-6632.1988.tb35332.x
- Sasai, Y. (2013). Cytosystems Dynamics in Self-Organization of Tissue Architecture. Nature 493, 318–326. doi:10.1038/nature11859
- Saucedo, L. J., and Edgar, B. A. (2007). Filling Out the Hippo Pathway. *Nat. Rev. Mol. Cell Biol.* 8, 613–621. doi:10.1038/nrm2221
- Sauer, H., Ruhe, C., Müller, J. P., Schmelter, M., D'Souza, R., and Wartenberg, M. (2008). Reactive Oxygen Species and Upregulation of NADPH Oxidases in Mechanotransduction of Embryonic Stem Cells. *Methods Mol. Biol.* 477, 397–418. doi:10.1007/978-1-60327-517-0\_30
- Sayedyahossein, S., Li, Z., Hedman, A. C., Morgan, C. J., and Sacks, D. B. (2016). IQGAP1 Binds to Yes-Associated Protein (YAP) and Modulates its Transcriptional Activity. *J. Biol. Chem.* 291, 19261–19273. doi:10.1074/jbc. m116.732529
- Scarborough, E. A., Uchida, K., Vogel, M., Erlitzki, N., Iyer, M., Phyo, S. A., et al. (2021). Microtubules Orchestrate Local Translation to Enable Cardiac Growth. *Nat. Commun.* 12, 1547. doi:10.1038/s41467-021-21685-4
- Schieber, M., and Chandel, N. S. (2014). ROS Function in Redox Signaling and Oxidative Stress. Curr. Biol. 24, R453–R462. doi:10.1016/j.cub.2014.03.034
- Schlegelmilch, K., Mohseni, M., Kirak, O., Pruszak, J., Rodriguez, J. R., Zhou, D., et al. (2011). Yap1 Acts Downstream of α-Catenin to Control Epidermal Proliferation. *Cell* 144, 782–795. doi:10.1016/j.cell.2011.02.031
- Schmelter, M., et al.Schmelter, M., Ateghang, B., Helmig, S., Wartenberg, M., Sauer, H. (2006). Embryonic Stem Cells Utilize Reactive Oxygen Species as Transducers of Mechanical Strain-induced Cardiovascular Differentiation. *FASEB J.* 20, 1182–1184. doi:10.1096/fj.05-4723fje
- Schofield, C. J., and Ratcliffe, P. J. (2004). Oxygen Sensing by HIF Hydroxylases. Nat. Rev. Mol. Cell Biol. 5, 343–354. doi:10.1038/nrm1366
- Schöning, J. P., Monteiro, M., and Gu, W. (2017). Drug Resistance and Cancer Stem Cells: the Shared but Distinct Roles of Hypoxia-inducible Factors HIF 1a and HIF 2a. *Clin. Exp. Pharmacol. Physiol.* 44, 153–161. doi:10.1111/1440-1681. 12693
- Schröder, K., Wandzioch, K., Helmcke, I., and Brandes, R. P. (2009). Nox4 Acts as a Switch between Differentiation and Proliferation in Preadipocytes. *Arterioscler. Thromb. Vasc. Biol.* 29, 239–245. doi:10.1161/ATVBAHA.108.174219
- Schröder, K. (2014). NADPH Oxidases in Redox Regulation of Cell Adhesion and Migration. Antioxidants Redox Signal. 20, 2043–2058. doi:10.1089/ars.2013. 5633
- Selfridge, A. C., Cavadas, M. A. S., Scholz, C. C., Campbell, E. L., Welch, L. C., Lecuona, E., et al. (2016). Hypercapnia Suppresses the HIF-dependent Adaptive Response to Hypoxia. *J. Biol. Chem.* 291, 11800–11808. doi:10. 1074/jbc.m116.713941

- Seltana, A., Basora, N., and Beaulieu, J.-F. o. (2010). Intestinal Epithelial Wound Healing Assay in an Epithelialâ€"mesenchymal Co-culture System. *Wound Repair Regen.* 18, 114–122. doi:10.1111/j.1524-475x.2009.00554.x
- Semenza, G. L. (2010). HIF-1: Upstream and Downstream of Cancer Metabolism. Curr. Opin. Genet. Dev. 20, 51–56. doi:10.1016/j.gde.2009.10.009
- Semenza, G. L. (2003). Targeting HIF-1 for Cancer Therapy. Nat. Rev. Cancer 3, 721–732. doi:10.1038/nrc1187
- Serrano, I., Mcdonald, P. C., Lock, F., Muller, W. J., and Dedhar, S. (2013). Inactivation of the Hippo Tumour Suppressor Pathway by Integrin-Linked Kinase. Nat. Commun. 4, 2976. doi:10.1038/ncomms3976
- Seth, D., and Rudolph, J. (2006). Redox Control of Cell Cycle Progression via Cdc25 Phosphatase (Mih1p) in S. cerevisiae. Cell Cycle 5, 2172–2173. doi:10. 4161/cc.5.18.3252
- Sette, C., and Conti, M. (1996). Phosphorylation and Activation of a cAMP-specific Phosphodiesterase by the cAMP-dependent Protein Kinase. J. Biol. Chem. 271, 16526–16534. doi:10.1074/jbc.271.28.16526
- Settleman, J., and Baum, B. (2008). Cell Shape and Tissue Morphogenesis. Seminars Cell & Dev. Biol. 19, 213-214. doi:10.1016/j.semcdb.2008.02.002
- Sharma, S., Sirin, Y., and Susztak, K. (2011). The Story of Notch and Chronic Kidney Disease. *Curr. Opin. Nephrol. Hypertens.* 20, 56–61. doi:10.1097/mnh. 0b013e3283414c88
- Shaw, R. J., Paez, J. G., Curto, M., Yaktine, A., Pruitt, W. M., Saotome, I., et al. (2001). The Nf2 Tumor Suppressor, Merlin, Functions in Rac-dependent Signaling. *Dev. Cell* 1, 63–72. doi:10.1016/s1534-5807(01)00009-0
- Shen, X., Xi, G., Radhakrishnan, Y., and Clemmons, D. R. (2009). Identification of Novel SHPS-1-Associated Proteins and Their Roles in Regulation of Insulinlike Growth Factor-dependent Responses in Vascular Smooth Muscle Cells. *Mol. Cell. Proteomics* 8, 1539–1551. doi:10.1074/mcp.m800543-mcp200
- Sherman, L. S., and Gutmann, D. H. (2001). Merlin: Hanging Tumor Suppression on the Rac. Trends Cell Biol. 11, 442–444. doi:10.1016/s0962-8924(01)81334-9
- Shin, S. Y., Kim, C. G., Jho, E.-H., Rho, M.-S., Kim, Y. S., Kim, Y.-H., et al. (2004). Hydrogen Peroxide Negatively Modulates Wnt Signaling through Downregulation of β-catenin. *Cancer Lett.* 212, 225–231. doi:10.1016/j. canlet.2004.03.003
- Shirai, Y., and Saito, N. (2002). Activation Mechanisms of Protein Kinase C: Maturation, Catalytic Activation, and Targeting. J. Biochem. 132, 663–668. doi:10.1093/oxfordjournals.jbchem.a003271
- Sick, S., Reinker, S., Timmer, J., and Schlake, T. (2006). WNT and DKK Determine Hair Follicle Spacing through a Reaction-Diffusion Mechanism. *Science* 314, 1447–1450. doi:10.1126/science.1130088
- Sidhaye, V. K., Schweitzer, K. S., Caterina, M. J., Shimoda, L., and King, L. S. (2008). Shear Stress Regulates Aquaporin-5 and Airway Epithelial Barrier Function. *Proc. Natl. Acad. Sci. U.S.A.* 105, 3345–3350. doi:10.1073/pnas. 0712287105
- Siebel, C., and Lendahl, U. (2017). Notch Signaling in Development, Tissue Homeostasis, and Disease. *Physiol. Rev.* 97, 1235–1294. doi:10.1152/physrev. 00005.2017
- Silver, B. B., Wolf, A. E., Lee, J., Pang, M.-F., and Nelson, C. M. (2020). Epithelial Tissue Geometry Directs Emergence of Bioelectric Field and Pattern of Proliferation. *MBoC* 31, 1691–1702. doi:10.1091/mbc.e19-12-0719
- Silvis, M. R., Kreger, B. T., Lien, W. H., Klezovitch, O., Rudakova, G. M., Camargo, F. D., et al. (2011). α-Catenin Is a Tumor Suppressor that Controls Cell Accumulation by Regulating the Localization and Activity of the Transcriptional Coactivator Yap1. Sci. Signal 4, ra33. doi:10.1126/scisignal. 2001823
- Sim, J., Cowburn, A. S., Palazon, A., Madhu, B., Tyrakis, P. A., Macías, D., et al. (2018). The Factor Inhibiting HIF Asparaginyl Hydroxylase Regulates Oxidative Metabolism and Accelerates Metabolic Adaptation to Hypoxia. *Cell Metab.* 27, 898–913. doi:10.1016/j.cmet.2018.02.020
- Singh, R., Adhya, P., and Sharma, S. S. (2021). Redox-sensitive TRP Channels: a Promising Pharmacological Target in Chemotherapy-Induced Peripheral Neuropathy. *Expert Opin. Ther. Targets* 25, 529–545. doi:10.1080/14728222. 2021.1956464
- Sirin, Y., and Susztak, K. (2012). Notch in the Kidney: Development and Disease. J. Pathol. 226, 394–403. doi:10.1002/path.2967
- Skonieczna, M., Hejmo, T., Poterala-Hejmo, A., Cieslar-Pobuda, A., and Buldak, R. J. (2017). NADPH Oxidases: Insights into Selected Functions and Mechanisms

of Action in Cancer and Stem Cells. Oxid. Med. Cell Longev. 2017, 9420539. doi:10.1155/2017/9420539

- Skouloudaki, K., and Walz, G. (2012). YAP1 Recruits C-Abl to Protect Angiomotin-like 1 from Nedd4-Mediated Degradation. *PloS one* 7, e35735. doi:10.1371/journal.pone.0035735
- Smith, J. M., Hedman, A. C., and Sacks, D. B. (2015). IQGAPs Choreograph Cellular Signaling from the Membrane to the Nucleus. *Trends Cell Biol.* 25, 171–184. doi:10.1016/j.tcb.2014.12.005
- Smoot, R. L., Werneburg, N. W., Sugihara, T., Hernandez, M. C., Yang, L., Mehner, C., et al. (2018). Platelet-derived Growth Factor Regulates YAP Transcriptional Activity via Src Family Kinase Dependent Tyrosine Phosphorylation. J. Cell. Biochem. 119, 824–836. doi:10.1002/jcb.26246
- Sodhi, A., Montaner, S., Patel, V., Zohar, M., Bais, C., Mesri, E. A., et al. (2000). The Kaposi's Sarcoma-Associated Herpes Virus G Protein-Coupled Receptor Up-Regulates Vascular Endothelial Growth Factor Expression and Secretion through Mitogen-Activated Protein Kinase and P38 Pathways Acting on Hypoxia-Inducible Factor 1alpha. *Cancer Res.* 60, 4873–4880.
- Song, M. Y., Makino, A., and Yuan, J. X.-J. (2011). Role of Reactive Oxygen Species and Redox in Regulating the Function of Transient Receptor Potential Channels. *Antioxidants Redox Signal.* 15, 1549–1565. doi:10.1089/ars.2010. 3648
- Spiegelman, B. M., and Ginty, C. A. (1983). Fibronectin Modulation of Cell Shape and Lipogenic Gene Expression in 3T3-Adipocytes. *Cell* 35, 657–666. doi:10. 1016/0092-8674(83)90098-3
- Sporn, M. B., and Liby, K. T. (2012). NRF2 and Cancer: the Good, the Bad and the Importance of Context. Nat. Rev. Cancer 12, 564–571. doi:10.1038/nrc3278
- Sprouse, M. L., Welte, T., Boral, D., Liu, H. N., Yin, W., Vishnoi, M., et al. (2019). PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling. *Int. J. Mol. Sci.* 20. doi:10. 3390/ijms20081916
- Stegen, S., Laperre, K., Eelen, G., Rinaldi, G., Fraisl, P., Torrekens, S., et al. (2019). HIF-1α Metabolically Controls Collagen Synthesis and Modification in Chondrocytes. *Nature* 565, 511–515. doi:10.1038/s41586-019-0874-3
- Steinberg, S. F. (2015). Mechanisms for Redox-Regulation of Protein Kinase C. Front. Pharmacol. 6, 128. doi:10.3389/fphar.2015.00128
- Strowitzki, M. J., Cummins, E. P., and Taylor, C. T. (2019). Protein Hydroxylation by Hypoxia-Inducible Factor (HIF) Hydroxylases: Unique or Ubiquitous? *Cells* 8. doi:10.3390/cells8050384
- Su, T., Ludwig, M. Z., Xu, J., and Fehon, R. G. (2017). Kibra and Merlin Activate the Hippo Pathway Spatially Distinct from and Independent of Expanded. *Dev. Cell* 40, 478–490. doi:10.1016/j.devcel.2017.02.004
- Sudol, M. (1994). Yes-associated Protein (YAP65) Is a Proline-Rich Phosphoprotein that Binds to the SH3 Domain of the Yes Proto-Oncogene Product. Oncogene 9, 2145–2152.
- Sudol, M., Chen, H. I., Bougeret, C., Einbond, A., and Bork, P. (1995). Characterization of a Novel Protein-Binding Module - the WW Domain. *FEBS Lett.* 369, 67–71. doi:10.1016/0014-5793(95)00550-s
- Sugihara, T., Werneburg, N. W., Hernandez, M. C., Yang, L., Kabashima, A., Hirsova, P., et al. (2018). YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. *Mol. Cancer Res.* 16, 1556–1567. doi:10. 1158/1541-7786.mcr-18-0158
- Suzuki, A., and Ohno, S. (2006). The PAR-aPKC System: Lessons in Polarity. J. Cell Sci. 119, 979–987. doi:10.1242/jcs.02898
- Taddei, M. L., Parri, M., Mello, T., Catalano, A., Levine, A. D., Raugei, G., et al. (2007). Integrin-mediated Cell Adhesion and Spreading Engage Different Sources of Reactive Oxygen Species. *Antioxidants Redox Signal.* 9, 469–481. doi:10.1089/ars.2006.1392
- Takemura, Y., Goodson, P., Bao, H. F., Jain, L., and Helms, M. N. (2010). Rac1mediated NADPH Oxidase Release of O2– Regulates Epithelial Sodium Channel Activity in the Alveolar Epithelium. Am. J. Physiology-Lung Cell. Mol. Physiology 298, L509–L520. doi:10.1152/ajplung.00230.2009
- Tamura, M., Itoh, K., Akita, H., Takano, K., and Oku, S. (2006). Identification of an Actin-Binding Site in P47phoxan Organizer Protein of NADPH Oxidase. FEBS Lett. 580, 261–267. doi:10.1016/j.febslet.2005.11.080
- Tang, X., Jang, S.-W., Wang, X., Liu, Z., Bahr, S. M., Sun, S.-Y., et al. (2007). Akt Phosphorylation Regulates the Tumour-Suppressor Merlin through

Ubiquitination and Degradation. Nat. Cell Biol. 9, 1199-1207. doi:10.1038/ncb1641

- $Tannahill, G. M., Curtis, A. M., Adamik, J., Palsson-Mcdermott, E. M., Mcgettrick, A. F., Goel, G., et al. (2013). Succinate Is an Inflammatory Signal that Induces IL-1<math>\beta$  through HIF-1 $\alpha$ . *Nature* 496, 238–242. doi:10.1038/nature11986
- Tarhonskaya, H., Hardy, A. P., Howe, E. A., Loik, N. D., Kramer, H. B., Mccullagh, J. S. O., et al. (2015). Kinetic Investigations of the Role of Factor Inhibiting Hypoxia-Inducible Factor (FIH) as an Oxygen Sensor. J. Biol. Chem. 290, 19726–19742. doi:10.1074/jbc.m115.653014
- Tawadros, A. I. F., and Khalafalla, M. M. M. (2018). Expression of Programmed Death-Ligand 1 and Hypoxia-Inducible Factor-1α Proteins in Endometrial Carcinoma. J. Cancer Res. Ther. 14, S1063–S1069. doi:10.4103/0973-1482. 202891
- Taylor-Clark, T. E. (2016). Role of Reactive Oxygen Species and TRP Channels in the Cough Reflex. Cell Calcium 60, 155–162. doi:10.1016/j.ceca.2016.03.007
- Teo, Y. V., Rattanavirotkul, N., Olova, N., Salzano, A., Quintanilla, A., Tarrats, N., et al. (2019). Notch Signaling Mediates Secondary Senescence. *Cell Rep.* 27, 997–1007. doi:10.1016/j.celrep.2019.03.104
- Terraciano, V., Hwang, N., Moroni, L., Park, H. B., Zhang, Z., Mizrahi, J., et al. (2007). Differential Response of Adult and Embryonic Mesenchymal Progenitor Cells to Mechanical Compression in Hydrogels. *Stem Cells* 25, 2730–2738. doi:10.1634/stemcells.2007-0228
- Terry, S., Buart, S., and Chouaib, S. (2017). Hypoxic Stress-Induced Tumor and Immune Plasticity, Suppression, and Impact on Tumor Heterogeneity. *Front. Immunol.* 8, 1625. doi:10.3389/fimmu.2017.01625
- Tian, H., Mcknight, S. L., and Russell, D. W. (1997). Endothelial PAS Domain Protein 1 (EPAS1), a Transcription Factor Selectively Expressed in Endothelial Cells. *Genes Dev.* 11, 72–82. doi:10.1101/gad.11.1.72
- Tominaga, T., Sahai, E., Chardin, P., Mccormick, F., Courtneidge, S. A., and Alberts, A. S. (2000). Diaphanous-related Formins Bridge Rho GTPase and Src Tyrosine Kinase Signaling. *Mol. Cell* 5, 13–25. doi:10.1016/s1097-2765(00) 80399-8
- Tong, W. W., Tong, G. H., and Liu, Y. (2018). Cancer Stem Cells and Hypoxia-Inducible Factors (Review). Int. J. Oncol. 53, 469–476. doi:10.3892/ijo.2018.4417
- Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., Mcdermott, D. F., et al. (2012). Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N. Engl. J. Med. 366, 2443–2454. doi:10.1056/ nejmoa1200690
- Toriyama, M., Sakumura, Y., Shimada, T., Ishii, S., and Inagaki, N. (2010). A Diffusion-based Neurite Length-sensing Mechanism Involved in Neuronal Symmetry Breaking. *Mol. Syst. Biol.* 6, 394. doi:10.1038/msb.2010.51
- Totaro, A., Castellan, M., Di Biagio, D., and Piccolo, S. (2018a). Crosstalk between YAP/TAZ and Notch Signaling. *Trends Cell Biol.* 28, 560–573. doi:10.1016/j.tcb. 2018.03.001
- Totaro, A., Panciera, T., and Piccolo, S. (2018b). YAP/TAZ Upstream Signals and Downstream Responses. *Nat. Cell Biol.* 20, 888–899. doi:10.1038/s41556-018-0142-z
- Touyz, R. M., and Briones, A. M. (2011). Reactive Oxygen Species and Vascular Biology: Implications in Human Hypertension. *Hypertens. Res.* 34, 5–14. doi:10. 1038/hr.2010.201
- Tu, X., Yasuda, R., and Colgan, L. A. (2020). Rac1 Is a Downstream Effector of PKCα in Structural Synaptic Plasticity. Sci. Rep. 10, 1777. doi:10.1038/s41598-020-58610-6
- Tung, J.-N., Lin, P.-L., Wang, Y.-C., Wu, D.-W., Chen, C.-Y., and Lee, H. (2018). PD-L1 Confers Resistance to EGFR Mutation-independent Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer via Upregulation of YAP1 Expression. Oncotarget 9, 4637–4646. doi:10.18632/oncotarget.23161
- Turing, A. (1952). The Chemical Basis of Morphogenesis. Phil. Trans. Roy. Soc. Lond. B Biol. Sci. 237, 37.
- Turrens, J. F. (2003). Mitochondrial Formation of Reactive Oxygen Species. J. Physiology 552, 335–344. doi:10.1113/jphysiol.2003.049478
- Tykocki, N. R., Jackson, W. F., and Watts, S. W. (2012). Reverse-mode Na+/Ca2+ Exchange Is an Important Mediator of Venous Contraction. *Pharmacol. Res.* 66, 544–554. doi:10.1016/j.phrs.2012.08.004
- Uchida, K., Scarborough, E. A., and Prosser, B. L. (2021). Cardiomyocyte Microtubules: Control of Mechanics, Transport, and Remodeling. Annu. Rev. Physiol. 10, 257–283. doi:10.1146/annurev-physiol-062421-040656

- Ushio-Fukai, M. (2009). Compartmentalization of Redox Signaling through NADPH Oxidase-Derived ROS. *Antioxidants Redox Signal.* 11, 1289–1299. doi:10.1089/ars.2008.2333
- Vaezi, A., Bauer, C., Vasioukhin, V., and Fuchs, E. (2002). Actin Cable Dynamics and Rho/Rock Orchestrate a Polarized Cytoskeletal Architecture in the Early Steps of Assembling a Stratified Epithelium. *Dev. Cell* 3, 367–381. doi:10.1016/ s1534-5807(02)00259-9
- Valle-Prieto, A., and Conget, P. A. (2010). Human Mesenchymal Stem Cells Efficiently Manage Oxidative Stress. Stem cells Dev. 19, 1885–1893. doi:10.1089/ scd.2010.0093
- Van Mameren, J., Vermeulen, K. C., Gittes, F., and Schmidt, C. F. (2009). Leveraging Single Protein Polymers to Measure Flexural Rigidity. J. Phys. Chem. B 113, 3837–3844. doi:10.1021/jp808328a
- Van Veelen, W., Le, N. H., Helvensteijn, W., Blonden, L., Theeuwes, M., Bakker, E. R. M., et al. (2011). -catenin Tyrosine 654 Phosphorylation Increases Wnt Signalling and Intestinal Tumorigenesis. *Gut* 60, 1204–1212. doi:10.1136/gut. 2010.233460
- Veith, A., and Moorthy, B. (2018). Role of Cytochrome P450s in the Generation and Metabolism of Reactive Oxygen Species. *Curr. Opin. Toxicol.* 7, 44–51. doi:10.1016/j.cotox.2017.10.003
- Violi, F., and Pignatelli, P. (2014). Platelet NOX, a Novel Target for Antithrombotic Treatment. *Thromb. Haemost.* 111, 817–823. doi:10.1160/TH13-10-0818
- Voet, D., and Voet, J. G. (2011). Biochemistry. Hoboken, NJ: John Wiley & Sons.
- Wang, C.-Y., Yang, T.-T., Chen, C.-L., Lin, W.-C., and Lin, C.-F. (2014a). Reactive Oxygen Species-Regulated Glycogen Synthase Kinase-3β Activation Contributes to All-Trans Retinoic Acid-Induced Apoptosis in Granulocyte-Differentiated HL60 Cells. *Biochem. Pharmacol.* 88, 86–94. doi:10.1016/j.bcp. 2013.12.021
- Wang, G. L., Jiang, B. H., Rue, E. A., and Semenza, G. L. (1995). Hypoxia-inducible Factor 1 Is a Basic-Helix-Loop-Helix-PAS Heterodimer Regulated by Cellular O2 Tension. *Proc. Natl. Acad. Sci. U.S.A.* 92, 5510–5514. doi:10.1073/pnas.92. 12.5510
- Wang, K., Degerny, C., Xu, M., and Yang, X.-J. (2009). YAP, TAZ, and Yorkie: a Conserved Family of Signal-Responsive Transcriptional Coregulators in Animal Development and Human diseaseThis Paper Is One of a Selection of Papers Published in This Special Issue, Entitled CSBMCB's 51st Annual Meeting - Epigenetics and Chromatin Dynamics, and Has Undergone the Journal's Usual Peer Review Process. *Biochem. Cell Biol.* 87, 77–91. doi:10.1139/ 008-114
- Wang, M., Dai, M., Wang, D., Xiong, W., Zeng, Z., and Guo, C. (2021). The Regulatory Networks of the Hippo Signaling Pathway in Cancer Development. J. Cancer 12, 6216–6230. doi:10.7150/jca.62402
- Wang, R., Peterson, J., Aster, R. H., and Newman, P. J. (1997). Disruption of a Long-Range Disulfide Bond between Residues Cys406 and Cys655 in Glycoprotein IIIa Does Not Affect the Function of Platelet Glycoprotein IIb-IIIa. Blood 90, 1718–1719. doi:10.1182/blood.v90.4.1718.1718\_1718\_1719
- Wang, W., Huang, J., Wang, X., Yuan, J., Li, X., Feng, L., et al. (2012). PTPN14 Is Required for the Density-dependent Control of YAP1. *Genes Dev.* 26, 1959–1971. doi:10.1101/gad.192955.112
- Wang, W., Li, X., Huang, J., Feng, L., Dolinta, K. G., and Chen, J. (2014b). Defining the Protein-Protein Interaction Network of the Human Hippo Pathway. *Mol. Cell. Proteomics* 13, 119–131. doi:10.1074/mcp.m113.030049
- Wang, Z., Da Silva, T. G., Jin, K., Han, X., Ranganathan, P., Zhu, X., et al. (2014c). Notch Signaling Drives Stemness and Tumorigenicity of Esophageal Adenocarcinoma. *Cancer Res.* 74, 6364–6374. doi:10.1158/0008-5472.can-14-2051
- Watanabe, T., Noritake, J., Kakeno, M., Matsui, T., Harada, T., Wang, S., et al. (2009). Phosphorylation of CLASP2 by GSK-3β Regulates its Interaction with IQGAP1, EB1 and Microtubules. J. Cell Sci. 122, 2969–2979. doi:10.1242/jcs. 046649
- Watanabe, Y., Miyasaka, K. Y., Kubo, A., Kida, Y. S., Nakagawa, O., Hirate, Y., et al. (2017). Notch and Hippo Signaling Converge on Strawberry Notch 1 (Sbno1) to Synergistically Activate Cdx2 during Specification of the Trophectoderm. *Sci. Rep.* 7, 46135. doi:10.1038/srep46135
- Watson, W. H., Ritzenthaler, J. D., and Roman, J. (2016). Lung Extracellular Matrix and Redox Regulation. *Redox Biol.* 8, 305–315. doi:10.1016/j.redox.2016.02.005

- Wei, Y., Yee, P. P., Liu, Z., Zhang, L., Guo, H., Zheng, H., et al. (2020). NEDD4Lmediated Merlin Ubiquitination Facilitates Hippo Pathway Activation. *EMBO Rep.* 21, e50642. doi:10.15252/embr.202050642
- Wen, Q., Han, T., Wang, Z., and Jiang, S. (2020). Role and Mechanism of Programmed Death-Ligand 1 in Hypoxia-Induced Liver Cancer Immune Escape. Oncol. Lett. 19, 2595–2601. doi:10.3892/ol.2020.11369
- Weng, M.-S., Chang, J.-H., Hung, W.-Y., Yang, Y.-C., and Chien, M.-H. (2018). The Interplay of Reactive Oxygen Species and the Epidermal Growth Factor Receptor in Tumor Progression and Drug Resistance. J. Exp. Clin. Cancer Res. 37, 61. doi:10.1186/s13046-018-0728-0
- Werner, E., and Werb, Z. (2002). Integrins Engage Mitochondrial Function for Signal Transduction by a Mechanism Dependent on Rho GTPases. J. Cell Biol. 158, 357–368. doi:10.1083/jcb.200111028
- White, C. D., Erdemir, H. H., and Sacks, D. B. (2012). IQGAP1 and its Binding Proteins Control Diverse Biological Functions. *Cell. Signal.* 24, 826–834. doi:10. 1016/j.cellsig.2011.12.005
- Widmaier, M., Rognoni, E., Radovanac, K., Azimifar, S. B., and Fässler, R. (2012). Integrin-linked Kinase at a Glance. J. Cell Sci. 125, 1839–1843. doi:10.1242/jcs. 093864
- Wikström, M., and Springett, R. (2020). Thermodynamic Efficiency, Reversibility, and Degree of Coupling in Energy Conservation by the Mitochondrial Respiratory Chain. Commun. Biol. 3, 451. doi:10.1038/s42003-020-01192-w
- Wilkinson, H. N., and Hardman, M. J. (2020). Wound Healing: Cellular Mechanisms and Pathological Outcomes. Open Biol. 10, 200223. doi:10. 1098/rsob.200223
- Wilkinson-Berka, J. L., Rana, I., Armani, R., and Agrotis, A. (2013). Reactive Oxygen Species, Nox and Angiotensin II in Angiogenesis: Implications for Retinopathy. *Clin. Sci. (Lond)* 124, 597–615. doi:10.1042/cs20120212
- Wilson, C., and González-Billault, C. (2015). Regulation of Cytoskeletal Dynamics by Redox Signaling and Oxidative Stress: Implications for Neuronal Development and Trafficking. *Front. Cell. Neurosci.* 9, 381. doi:10.3389/ fncel.2015.00381
- Wilson, K. E., Li, Y.-W., Yang, N., Shen, H., Orillion, A. R., and Zhang, J. (2014). PTPN14 Forms a Complex with Kibra and LATS1 Proteins and Negatively Regulates the YAP Oncogenic Function. J. Biol. Chem. 289, 23693–23700. doi:10.1074/jbc.m113.534701
- Wozniak, M. A., and Chen, C. S. (2009). Mechanotransduction in Development: a Growing Role for Contractility. *Nat. Rev. Mol. Cell Biol.* 10, 34–43. doi:10.1038/ nrm2592
- Wu, L., Li, Y., Yu, M., Yang, F., Tu, M., and Xu, H. (2018). Notch Signaling Regulates Microglial Activation and Inflammatory Reactions in a Rat Model of Temporal Lobe Epilepsy. *Neurochem. Res.* 43, 1269–1282. doi:10.1007/s11064-018-2544-5
- Wu, N., Nguyen, Q., Wan, Y., Zhou, T., Venter, J., Frampton, G. A., et al. (2017). The Hippo Signaling Functions through the Notch Signaling to Regulate Intrahepatic Bile Duct Development in Mammals. *Lab. Invest* 97, 843–853. doi:10.1038/labinvest.2017.29
- Wu, R. F., Gu, Y., Xu, Y. C., Nwariaku, F. E., and Terada, L. S. (2003). Vascular Endothelial Growth Factor Causes Translocation of P47 to Membrane Ruffles through WAVE1. J. Biol. Chem. 278, 36830–36840. doi:10.1074/jbc. m302251200
- Xi, G., Shen, X.-C., Wai, C., and Clemmons, D. R. (2013). Recruitment of Nox4 to a Plasma Membrane Scaffold Is Required for Localized Reactive Oxygen Species Generation and Sustained Src Activation in Response to Insulin-like Growth Factor-I. J. Biol. Chem. 288, 15641–15653. doi:10.1074/jbc.m113.456046
- Xiang, L., Gilkes, D. M., Hu, H., Luo, W., Bullen, J. W., Liang, H., et al. (2015). HIF-1α and TAZ Serve as Reciprocal Co-activators in Human Breast Cancer Cells. *Oncotarget* 6, 11768–11778. doi:10.18632/oncotarget.4190
- Xiang, L., Gilkes, D. M., Hu, H., Takano, N., Luo, W., Lu, H., et al. (2014). Hypoxiainducible Factor 1 Mediates TAZ Expression and Nuclear Localization to Induce the Breast Cancer Stem Cell Phenotype. *Oncotarget* 5, 12509–12527. doi:10.18632/oncotarget.2997
- Xiao, L., Chen, Y., Ji, M., and Dong, J. (2011a). KIBRA Regulates Hippo Signaling Activity via Interactions with Large Tumor Suppressor Kinases. J. Biol. Chem. 286, 7788–7796. doi:10.1074/jbc.m110.173468
- Xiao, L., Chen, Y., Ji, M., Volle, D. J., Lewis, R. E., Tsai, M.-Y., et al. (2011b). KIBRA Protein Phosphorylation Is Regulated by Mitotic Kinase Aurora and Protein Phosphatase 1. J. Biol. Chem. 286, 36304–36315. doi:10.1074/jbc.m111.246850

- Xie, Q., Chen, J., Feng, H., Peng, S., Adams, U., Bai, Y., et al. (2013). YAP/TEADmediated Transcription Controls Cellular Senescence. *Cancer Res.* 73, 3615–3624. doi:10.1158/0008-5472.can-12-3793
- Xiu, M., Wang, Y., Li, B., Wang, X., Xiao, F., Chen, S., et al. (2021). The Role of Notch3 Signaling in Cancer Stemness and Chemoresistance: Molecular Mechanisms and Targeting Strategies. *Front. Mol. Biosci.* 8, 694141. doi:10. 3389/fmolb.2021.694141
- Xu, D., and Li, C. (2021). Regulation of the SIAH2-HIF-1 Axis by Protein Kinases and its Implication in Cancer Therapy. *Front. Cell Dev. Biol.* 9, 646687. doi:10. 3389/fcell.2021.646687
- Xu, M. Z., Yao, T.-J., Lee, N. P. Y., Ng, I. O. L., Chan, Y.-T., Zender, L., et al. (2009). Yes-associated Protein Is an Independent Prognostic Marker in Hepatocellular Carcinoma. *Cancer* 115, 4576–4585. doi:10.1002/cncr.24495
- Xu, Q., Huff, L. P., Fujii, M., and Griendling, K. K. (2017). Redox Regulation of the Actin Cytoskeleton and its Role in the Vascular System. *Free Radic. Biol. Med.* 109, 84–107. doi:10.1016/j.freeradbiomed.2017.03.004
- Xu, X., Shen, X., Wang, J., Feng, W., Wang, M., Miao, X., et al. (2021a). YAP Prevents Premature Senescence of Astrocytes and Cognitive Decline of Alzheimer's Disease through Regulating CDK6 Signaling. Aging Cell 20, e13465. doi:10.1111/acel.13465
- Xu, Z., Liang, Y., Delaney, M. K., Zhang, Y., Kim, K., Li, J., et al. (2021b). Shear and Integrin Outside-In Signaling Activate NADPH-Oxidase 2 to Promote Platelet Activation. *Atvb* 41, 1638–1653. doi:10.1161/atvbaha.120.315773
- Yamauchi, J., Miyamoto, Y., Kusakawa, S., Torii, T., Mizutani, R., Sanbe, A., et al. (2008). Neurofibromatosis 2 Tumor Suppressor, the Gene Induced by Valproic Acid, Mediates Neurite Outgrowth through Interaction with Paxillin. *Exp. Cell Res.* 314, 2279–2288. doi:10.1016/j.yexcr.2008.03.019
- Yan, F., Wang, Y., Wu, X., Peshavariya, H. M., Dusting, G. J., Zhang, M., et al. (2014). Nox4 and Redox Signaling Mediate TGF-β-Induced Endothelial Cell Apoptosis and Phenotypic Switch. *Cell Death Dis.* 5, e1010. doi:10.1038/cddis. 2013.551
- Yan, Z.-Y., Ban, T., Fan, Y., Chen, W.-R., Sun, H.-L., Chen, H., et al. (2015). Na+induced Ca2+ Influx through Reverse Mode of Na+-Ca2+ Exchanger in Mouse Ventricular Cardiomyocyte. *Oncotarget* 6, 23272–23280. doi:10.18632/ oncotarget.4878
- Yang, M., Soga, T., Pollard, P. J., and Adam, J. (2012). The Emerging Role of Fumarate as an Oncometabolite. *Front. Oncol.* 2, 85. doi:10.3389/fonc.2012. 00085
- Yasuda, D., Kobayashi, D., Akahoshi, N., Ohto-Nakanishi, T., Yoshioka, K., Takuwa, Y., et al. (2019). Lysophosphatidic Acid-Induced YAP/TAZ Activation Promotes Developmental Angiogenesis by Repressing Notch Ligand Dll4. J. Clin. Invest 129, 4332–4349. doi:10.1172/jci121955
- Yazaki, K., Matsuno, Y., Yoshida, K., Sherpa, M., Nakajima, M., Matsuyama, M., et al. (2021). ROS-Nrf2 Pathway Mediates the Development of TGF-B1-Induced Epithelial-Mesenchymal Transition through the Activation of Notch Signaling. *Eur. J. Cell Biol.* 100, 151181. doi:10.1016/j.ejcb.2021.151181
- Yeo, C. D., Kang, N., Choi, S. Y., Kim, B. N., Park, C. K., Kim, J. W., et al. (2017). The Role of Hypoxia on the Acquisition of Epithelial-Mesenchymal Transition and Cancer Stemness: a Possible Link to Epigenetic Regulation. *Korean J. Intern Med.* 32, 589–599. doi:10.3904/kjim.2016.302
- Yi, C., Shen, Z., Stemmer-Rachamimov, A., Dawany, N., Troutman, S., Showe, L. C., et al. (2013). The P130 Isoform of Angiomotin Is Required for Yap-Mediated Hepatic Epithelial Cell Proliferation and Tumorigenesis. *Sci. Signal* 6, ra77. doi:10.1126/scisignal.2004060
- Yi, C., Troutman, S., Fera, D., Stemmer-Rachamimov, A., Avila, J. L., Christian, N., et al. (2011). A Tight Junction-Associated Merlinangiomotin Complex Mediates Merlin's Regulation of Mitogenic Signaling and Tumor Suppressive Functions. *Cancer cell* 19, 527–540. doi:10.1016/j.ccr.2011.02.017
- Yin, F., Yu, J., Zheng, Y., Chen, Q., Zhang, N., and Pan, D. (2013). Spatial Organization of Hippo Signaling at the Plasma Membrane Mediated by the Tumor Suppressor Merlin/NF2. *Cell* 154, 1342–1355. doi:10.1016/j.cell.2013. 08.025
- Yoshihama, Y., Hirai, T., Ohtsuka, T., and Chida, K. (2009). KIBRA Co-localizes with Protein Kinase Mζ (PKMζ) in the Mouse Hippocampus. *Biosci. Biotechnol. Biochem.* 73, 147–151. doi:10.1271/bbb.80564
- Yoshihama, Y., Sasaki, K., Horikoshi, Y., Suzuki, A., Ohtsuka, T., Hakuno, F., et al. (2011). KIBRA Suppresses Apical Exocytosis through Inhibition of aPKC

Kinase Activity in Epithelial Cells. Curr. Biol. 21, 705–711. doi:10.1016/j.cub. 2011.03.029

- Yu, F.-X., and Guan, K.-L. (2013). The Hippo Pathway: Regulators and Regulations. *Genes Dev.* 27, 355–371. doi:10.1101/gad.210773.112
- Yu, F.-X., Zhao, B., and Guan, K.-L. (2015). Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. *Cell* 163, 811–828. doi:10.1016/j. cell.2015.10.044
- Yu, H., Pardoll, D., and Jove, R. (2009). STATs in Cancer Inflammation and Immunity: a Leading Role for STAT3. *Nat. Rev. Cancer* 9, 798–809. doi:10. 1038/nrc2734
- Yu, J., Zheng, Y., Dong, J., Klusza, S., Deng, W.-M., and Pan, D. (2010). Kibra Functions as a Tumor Suppressor Protein that Regulates Hippo Signaling in Conjunction with Merlin and Expanded. *Dev. Cell* 18, 288–299. doi:10.1016/j. devcel.2009.12.012
- Zaltsman, Y., Masuko, S., Bensen, J. J., and Kiessling, L. L. (2019). Angiomotin Regulates YAP Localization during Neural Differentiation of Human Pluripotent Stem Cells. *Stem Cell Rep.* 12, 869–877. doi:10.1016/j.stemcr.2019.03.009
- Zanconato, F., Battilana, G., Cordenonsi, M., and Piccolo, S. (2016a). YAP/TAZ as Therapeutic Targets in Cancer. *Curr. Opin. Pharmacol.* 29, 26–33. doi:10.1016/ j.coph.2016.05.002
- Zanconato, F., Cordenonsi, M., and Piccolo, S. (2016b). YAP/TAZ at the Roots of Cancer. Cancer cell 29, 783–803. doi:10.1016/j.ccell.2016.05.005
- Zeller, K. S., Riaz, A., Sarve, H., Li, J., Tengholm, A., and Johansson, S. (2013). The Role of Mechanical Force and ROS in Integrin-dependent Signals. *PloS one* 8, e64897. doi:10.1371/journal.pone.0064897
- Zergane, M., Kuebler, W. M., and Michalick, L. (2021). Heteromeric TRP Channels in Lung Inflammation. *Cells* 10. doi:10.3390/cells10071654
- Zhang, H.-M., Chen, W., Liu, R.-N., and Zhao, Y. (2018a). Notch Inhibitor Can Attenuate Apparent Diffusion Coefficient and Improve Neurological Function through Downregulating NOX2-ROS in Severe Traumatic Brain Injury. *Dddt* 12, 3847–3854. doi:10.2147/dddt.s174037
- Zhang, J., Yang, P. L., and Gray, N. S. (2009). Targeting Cancer with Small Molecule Kinase Inhibitors. Nat. Rev. Cancer 9, 28–39. doi:10.1038/nrc2559
- Zhang, L., Wu, J., Duan, X., Tian, X., Shen, H., Sun, Q., et al. (2016). NADPH Oxidase: A Potential Target for Treatment of Stroke. Oxid. Med. Cell Longev. 2016, 5026984. doi:10.1155/2016/5026984
- Zhang, L., Yang, S., Wennmann, D. O., Chen, Y., Kremerskothen, J., and Dong, J. (2014). KIBRA: In the Brain and beyond. *Cell. Signal.* 26, 1392–1399. doi:10. 1016/j.cellsig.2014.02.023
- Zhang, R., Pan, Y., Fanelli, V., Wu, S., Luo, A. A., Islam, D., et al. (2015). Mechanical Stress and the Induction of Lung Fibrosis via the Midkine Signaling Pathway. Am. J. Respir. Crit. Care Med. 192, 315–323. doi:10. 1164/rccm.201412-2326oc
- Zhang, X., Li, Y., Ma, Y., Yang, L., Wang, T., Meng, X., et al. (2018b). Yesassociated Protein (YAP) Binds to HIF-1α and Sustains HIF-1α Protein Stability to Promote Hepatocellular Carcinoma Cell Glycolysis under Hypoxic Stress. J. Exp. Clin. Cancer Res. 37, 216. doi:10.1186/s13046-018-0892-2
- Zhao, B., Li, L., Lei, Q., and Guan, K.-L. (2010a). The Hippo-YAP Pathway in Organ Size Control and Tumorigenesis: an Updated Version. *Genes Dev.* 24, 862–874. doi:10.1101/gad.1909210
- Zhao, B., Li, L., Lu, Q., Wang, L. H., Liu, C.-Y., Lei, Q., et al. (2011a). Angiomotin Is a Novel Hippo Pathway Component that Inhibits YAP Oncoprotein. *Genes Dev.* 25, 51–63. doi:10.1101/gad.2000111

- Zhao, B., Li, L., Tumaneng, K., Wang, C.-Y., and Guan, K.-L. (2010b). A Coordinated Phosphorylation by Lats and CK1 Regulates YAP Stability through SCFβ-TRCP. *Genes Dev.* 24, 72–85. doi:10.1101/gad.1843810
- Zhao, B., Tumaneng, K., and Guan, K.-L. (2011b). The Hippo Pathway in Organ Size Control, Tissue Regeneration and Stem Cell Self-Renewal. *Nat. Cell Biol.* 13, 877–883. doi:10.1038/ncb2303
- Zhao, C., Zeng, C., Ye, S., Dai, X., He, Q., Yang, B., et al. (2020). Yes-associated Protein (YAP) and Transcriptional Coactivator with a PDZ-Binding Motif (TAZ): a Nexus between Hypoxia and Cancer. Acta Pharm. Sin. B 10, 947–960. doi:10.1016/j.apsb.2019.12.010
- Zhao, X., and Guan, J.-L. (2011). Focal Adhesion Kinase and its Signaling Pathways in Cell Migration and Angiogenesis. Adv. Drug Deliv. Rev. 63, 610–615. doi:10. 1016/j.addr.2010.11.001
- Zhao, Y., and Yang, X. (2015). The Hippo Pathway in Chemotherapeutic Drug Resistance. Int. J. Cancer 137, 2767–2773. doi:10.1002/ijc.29293
- Zheng, Y., and Pan, D. (2019). The Hippo Signaling Pathway in Development and Disease. Dev. Cell 50, 264–282. doi:10.1016/j.devcel.2019.06.003
- Zhong, H., De Marzo, A. M., Laughner, E., Lim, M., Hilton, D. A., Zagzag, D., et al. (1999). Overexpression of Hypoxia-Inducible Factor 1alpha in Common Human Cancers and Their Metastases. *Cancer Res.* 59, 5830–5835.
- Zhou, L., Cha, G., Chen, L., Yang, C., Xu, D., and Ge, M. (2019). HIF1α/PD-L1 axis Mediates Hypoxia-Induced Cell Apoptosis and Tumor Progression in Follicular Thyroid Carcinoma. Ott 12, 6461–6470. doi:10.2147/ott.s203724
- Zhou, P.-J., Xue, W., Peng, J., Wang, Y., Wei, L., Yang, Z., et al. (2017). Elevated Expression of Par3 Promotes Prostate Cancer Metastasis by Forming a Par3/ aPKC/KIBRA Complex and Inactivating the Hippo Pathway. J. Exp. Clin. Cancer Res. 36, 139. doi:10.1186/s13046-017-0609-y
- Zhou, R., Wu, Q., Wang, M., Irani, S., Li, X., Zhang, Q., et al. (2021). The Protein Phosphatase PPM1A Dephosphorylates and Activates YAP to Govern Mammalian Intestinal and Liver Regeneration. *PLoS Biol.* 19, e3001122. doi:10.1371/journal.pbio.3001122
- Zong, Y., Panikkar, A., Xu, J., Antoniou, A., Raynaud, P., Lemaigre, F., et al. (2009). Notch Signaling Controls Liver Development by Regulating Biliary Differentiation. *Development* 136, 1727–1739. doi:10.1242/dev.029140
- Zorov, D. B., Juhaszova, M., and Sollott, S. J. (2014). Mitochondrial Reactive Oxygen Species (ROS) and ROS-Induced ROS Release. *Physiol. Rev.* 94, 909–950. doi:10.1152/physrev.00026.2013

**Conflict of Interest:** The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

AEC2, anion cachange protein 2ErKl/2, cartacelolar regulated kinases 1/2AJ, aborens jurationErC, elatron transfer chainAJ, aborens jurationEX, ExpandaAKAP, A kinase andoring proteinEAD, lavia adeaine dinactoxideALKS, activity a creciptor type II-like kinase, 53kDa, transforming proteinEAD, lavia adeaine dinactoxideAMOT, angioansinEAK, for adoation of FADAMOT, angioansinERKM, 41 protein, critin, nalkin, and moresinAMF, S, AMP-activated protein kinaseECR, freioballs growth factorAPC, adoannous polyonic origiERKM, 41 protein, critin, nalkin, and moresinAPC, adoannous polyonic origiERKM, 41 protein, critin, nalkin, and moresinAPC, adoannous polyonic origiERKM, 41 protein, critin, makin, and moresinAPC, adoannous polyonic origiERKM, 41 protein, critin, makin, and moresinAPC, adoannous polyonic origiERKM, 41 protein, critin, makin, and moresinAPC, adoannous polyonic origiERKM, 41 protein, critin, makin, and moresinAPC, adoannous polyonic origiERKM, 41 protein, critin, makin, and moresinAPC, adoannous polyonic protein kinase CAGRK, genovalu factor and adoationARHGEF, Kink Sug MAP kinaseERKM, 41 protein, adoatiant critin, adoatiant, adoatiant, adoatiant, adoatiant, adoatiant, adoatiant, adoatiant, ad	GLOSSARY	ENO1, enolase 1
Al, adherens junctionEx, ExpandedAKAP, A kinase and/oring proteinFAD, havin aderine dimonstrolledAKAP, Arinase and/oring proteinFAD, havin aderine dimonstrolledAKSP, settin A receptor type II-like kinase, 33kDa, transforming growthFAD, havin aderine dimonstrolledAMOT, angiomotinFAD, favin aderine dimonstrolledAMOT, angiomotinFERM, 41 protein, eritin, rabitin, and moesinAMOT, angiomotinFERM, 41 protein, eritin, rabitin, and moesinAMPC, aderomators polyrosis colitFERM, 41 protein, eritin, rabitin, and moesinAPC, aderomators polyrosis colitFERM, 41 protein, eritin, rabitin, and moesinaPKC, atypical protein kinase CGEF, guanten succotide exchange factorARHOEF, Ro-guanten molecidie exchange factorGLUT, glacose transporterARHOEF, Ro-guanten molecidie exchange factorGKS3§, glycogen synthase kinase 3§BMR, brenz morphogenic proteinHK, koadinaseBMR, pol-activated protein kinase exchange factor §HK, horodinaseBMP, beer morphogenic proteinHK, koadinaseBMP, CaAKS, cakorskin RE 10 kDa protein-interacting proteinHK, koadinaseAGMES, cak's Jahonghutar response element-binding proteinIGF-11 receptorCaMKS, CaKK phoophataseIGF-11 receptorCaMSS, cak's adonsine monophophate response element-binding protein factorIGF-11 receptorCKL, caeen kinase 1IGF-11 receptorCKL, caeen kinase 1KEBa, moder factor of larga light polypeptide gene enhancer in 8-cellsCLASPE, contexter encol-likeIGPAL, IqPAL -1 receptorCKL, caeen kinase 1IGF-11 r		ErK1/2, extracellular regulated kinases 1/2
AKAP, A-Janase andvoring protein       FAD, favin admine dinucleotide         ALKS, scivin A receptor J       FAD, favin admine dinucleotide         AMOT, angiomotin       FAD, favin admine dinucleotide         AMOT, angiomotin       FAD, favin admine dinucleotide         ANDY, angiomotin       FAD, favin admine dinucleotide         AMPK, 5' AMP activated protein kinase       FBD, FRMA hinding domain         APC, admonstore polyposis coll       FRMA, fFEM domain containing protein 6         aPKC, attpical protein kinase       GEF, guantice-nucleotide exchange factor         ARHGFF, Rbo guantine muchtoride exchange factor       GLUT, glucose transporter         ARHORF, sby MAP kinase       GKS3β, glycogen synthase kinase 3β         BMK1/FrEAS, the MAP kinase       HCC, haptactellate carcinoma cell         BNR1, p. CL2/adenovirus LB19 PUX protein-interacting protein       GKS3β, glycogen synthase kinase 3β         CAMKS2, cd <sup>2</sup> /sclinochulin-dependent kinase 2       HPH, HIT prolyl hydroxylass         CAMKRD, CaMK phosphatase       HPH, HIT prolyl hydroxylass         CBP, cyclu adnosime monophosphate response element-binding protein 1       HP, interferon         CLASP1, volta-danosime monophosphate response element-binding protein 1       Li, interferon         CLASP1, volta-danosime monophosphate response element-binding protein 1       Li, interferon         CLASP1, volta-danobine monophosphate r	AEC2, anion exchange protein 2	ETC, electron transfer chain
ALKS, strivin A receptor type II-like kinase. 53kDa, transforming growth       FADIH, sp. her reduced form OF EAD         MAOT, angiomoin       FADIH, sp. her reduced form OF EAD         Ang II,       FAR, focal adhesion kinase         angiotensin II       FAR, social adhesion kinase         AMPC, argonomic solvposis coli       FBR, focal adhesion kinase         APC, adeomonitons polyposis coli       FRR, 4.1 protein, ezrin, radixin, and moesin         APC, adeomonitons polyposis coli       FRR, focal adhesion kinase         APC, adeomonitons polyposis coli       FRR, focal adhesion kinase         APC, adeomonitons polyposis coli       FRR, focal agrowth factor         ARHGER, Rich egnanine nucleotide exchange factor       GLT, glucose transporter         ARIDIA, AT-rich interactive domain-containing protein 1A       GKS(3), glycogen synthase kinase 33         BMR, bole morphogenic protein       HICC, heputcollablar carcinoma cell         BMR, bole divervine EIP 19 Do protein-interacting protein       HIC, heputcollablar carcinoma cell         BMR, bole divervine Kinase 2       GAKS(2, GV) polyhatic response chemet-binding protein 1         CRA, Cari-faalmodulin-dependent kinase 2       IAP, integrin-associated protein         CAK, caseni kinase 1       IGF-11, mistell-ite growth factor 1         CKA, caseni kinase 2       IKB, nucler factor of karpa light polypoptide gene enhancer in it-cells inbibliot, alpha <td>AJ, adherens junction</td> <td>Ex, Expanded</td>	AJ, adherens junction	Ex, Expanded
factor frequent 1Find the frequent is the factor influenceAMOT, angiomotinFAK, focal albesion kinaseAMOT, angiomotinFAK, focal albesion kinaseang II,FRM, 4.1 protein, extin, and mousinangiotensin IIFRM, 4.1 protein, extin, and mousinAMPK, sf AMP-activated protein kinaseFRM, 4.1 protein, extin, and mousinAPC, stemamous polyposis coliFRM, 6.1 protein curving IIPAPC, stemamous polyposis coliFRM, 6.1 protein curving IIPAPR, apaporinGUT, glocose transporterARHDEA, Tr-ch interactive domain-containing protein 1AGSK3, glocogen synthase kinase 3§BMK1/ErK5, big MAP kinaseGSK3, glocogen synthase kinase 3§BMR, bone morphogenic proteinHIT, hypotai-inductible factorBNIP, BCL2/adenovirus EII 19 kDap orden-interacting proteinHIT, hypotai-inductible factorGMX2, Ca <sup>2+</sup> Calmodulin dependent kinase 2IAP, integrin associated proteinCaMK2, Ca <sup>2+</sup> Calmodulin dependent kinase 2IAP, integrin associated proteinCAR, cancer associated fibrobiatIGF-1, main-like growth factor-1CK2, casein kinase 1IGF-1, main-like growth factor-1CK3, casein kinase 2IGF-1, inself-1 exceptorCK4, casein kinase 2IGF-1, inself-1 exceptorCK4, casein kinase 3IGF-1, inself-1 exceptorCK4, casein kinase 2IGF-1, inself-1 exceptorCK4, casein kinase 2IGF-1, inself-1 exceptorCK4, casein kinase 2IGF-1, inself-1 exceptorCK4, casein kinase 1IL, interfa-1 exceptorCK4, casein kinase 2IGA-1 exceptorCK4	AKAP, A-kinase anchoring protein	FAD, flavin adenine dinucleotide
AMOT, angiomotinFAK, focia dificion kinaseAng II,FBD, FERM-binding domainangiotensin IIFERM, 41 protein, criti, radiain, and moesinAMPK, s' AMP-activated protein kinaseFGF, fibroblast growth factorAPC, adenomatous polyposis coliFRMG, FERM domain-containing protein 6aPKC, stypical protein kinase CGEE, guanine-nucleotide exchange factorAQP, aquaporinGHZ, growth factor receptor-bound protein 2ARHGEF, Rho-guanine nucleotide exchange factorGLUT, glucose transporterARHOLA, AT-rich interactive domain-containing protein 1AGKS(3b, glycogen synthase kinase 3)BMK, Direk AP kinaseHCC, hepatocellular carcinona cellBMP, bose morphogenic proteinHTF, hypoxia-responsive elementBMR, y 21-activated protein kinase change factor \$HPH, HIF prob/sh/droxplaseCAFC, cancer-associated fibroblastIRE, hypoxia-responsive elementIndiang protein, also named CREB-binding protein 1IGF-11, insulin-like growth factor-1CKA, casein kinase 1IGF-11, insulin-like growth factor-1CKA, casein kinase 2IAP, integrin associated proteinCLASP1, cyclic adenosite monophophate response element-binding protein, also named CREB-binding protein 1II, interleukinCLIP1, CAF-GLY Aomain-containing Inker protein 1II, interleukinCKC, casein kinase 3IKK, integrin-linked kinase 1CKC, casein kinase 4IKK, integrin-linked kinase 1CKC, casein kinase 5IKG, interleukinCKC, casein kinase 7IKGACKG, tasein kinase 7IKGACKG, tasein kinase 7IKGA </td <td>1 /1 00</td> <td>FADH<sub>2</sub>, the reduced form of FAD</td>	1 /1 00	FADH <sub>2</sub> , the reduced form of FAD
Ang II,FBD, FERM-binding domainangiotensin IIFERM, 4.1 protein, exrin, radixin, and moesinAMPK, s' AMP activated protein kinaseFGE, fibroblast growth factorAPC, adeomotises polyposis coliFH, the factor inhibiting HIPaPKC, atypical protein kinase CFRM6, FERM domain-containing protein 6AQP, aquaporinGEF, guanine-nucleotide exchange factorARHGFF, Rho-guanine-nucleotide exchange factorGUT, glucose transporterARHD1A, AT-tch interactive domain-containing protein 1AGSK38, glycogen synthase kinase 3PBMK1/Erk5, big MAP kinaseHFC, hepstoin-inductible factorBMP, bone morphogenic proteinHFL, hypoxia-inductible factorPJY, p21-adivited protein kinase exchange factor PHFL, hypoxia-inductible factorGAMPC, Casen kinase 1HFL, hypoxia-inductible factorPGR, cyclic adenosine monophosphate response element-binding proteinHFL, hypoxia-inductible factorInding protein, also named CREPs-binding protein 1GFP-11, insulin-lake growth factor-1CLASP1, cyclic adenosine monophosphate response element-binding proteinIGP-11, insulin-lake growth factor-1CLASP1, cyclic adenosine monophosphate response element-bindingIGP-11, insulin-lake growth factor-1CLASP1, cyclic adenosine monophosphate response element-bindingIGP-11, insulin-lake growth factor-1CLASP1, cyclic adenosine monophosphate response element-bindingInj, interfaronCLASP1, cyclic adenosine monophosphate response element-bindingInj, interfaronCLASP1, cyclic adenosine monophosphate response element-bindingInj, interfaronCLASP1, cyclic adenosine		FAK, focal adhesion kinase
angiotensin IIFBRM. 4.1 protein, extin, radikin, and moesinAMPK, sy AMP-activated protein kinaseFGF, fibroblast growth factorAPC, adenomatous polyposis coliFRM6, FERM domain-containing protein 6APC, adenomatous polyposis coliFRM6, FERM domain-containing protein 6AQP, aquaporinGEF, guanine-muclotide exchange factorARHDIA, AT-rich interactive domain-containing protein 1AGKS3β, glycogen synthase kinase 3βBMK1/FEAS, big MAP kinaseGKS3β, glycogen synthase kinase 3βBMK1/FEAS, big MAP kinaseHIF, hypoxia-inducible factorBNP, bone morphogenic proteinHIF, hypoxia-inducible factorGCA, cacar-associated fibroblastHPH, HIF prolyl hydroxylasesCARK2, Ca <sup>21</sup> /calmooduin-dependent kinase 2HRF, hypoxia-responsive elementCaMK2, Ca <sup>21</sup> /calmoduin-dependent kinase 2HRF, hypoxia-responsive elementCaMK4, Ca <sup>21</sup> /calmoduin-dependent kinase 2HRF, hypoxia-responsive elementCLASP1, cyclic adenosine monophosphate response element-binding proteinIGF-11, insulin-like growth factor -1CLASP1, cyclic adenosine monophosphate response element-binding proteinILK, interferonCLASP1, cyclic adenosine monophosphate response element-binding proteinILK, interferonCLASP1, cyclic adenosine monophosphate response element-bindingILK, interferonCLASP1, cyclic adenosine monophosphate re	-	FBD, FERM-binding domain
AMPK, s' AMP-activated protein kinaseFGF, fabroblast growth factorAPC, adenomatous polypois coliFHH, the factor inhibiting HIFaPKC, atypical protein kinase CFEMA domain-containing protein 6APC, aquaporinGEF, guanine-nucleotide exchange factorARHGEF, Rho guanine nucleotide exchange factorGLUT, glucose transporterARHOLA, AT-rich interactive domain-containing protein 1AGKS/β, glycogen synthase kinase 3βBMK, bore morphogenic proteinHCC, hepatocellular carcinoma cellBMR, BCL2/adenovirus Ell B / DD protein-interacting proteinHIF, hypoxia-inducible factorβPTX, p21-activated protein kinase-exchange factor βHK, hecokinaseCARF, cancer-associated fibroblastHRF, hypoxia-inducible factorCARK, Cari'/calmodulin-dependent kinase 2IAP, integrin-associated proteinCARMKP, Carik phosphaseIGF-1, insulin-like growth factor -1CKL; casein kinase 1IGF-1, insulin-like growth factor -1CKL; casein kinase 2IKBGa, nuclear factor of kappa light polypeptide gene enhancer in B-cellsCLASP1, cytoplasmic linker associated protein 1IL, interduxinCLASP1, cytoplasmic linker associated protein 1ILK, interduxinCSC, cancer stem cell-likeIGF-1, insulin-linke growth factor -1CSC, cancer stem cell-likeIGF-1, insulin-linke growth factor of lappa light polypeptide gene enhancer in B-cellsCSC, circulating trumor cellILK, interduxinCSC, cancer stem cell-likeIJGF-2, inverted formin-2CSC, cancer stem cell-likeIJGK2/2, laust kinase 2/2CTG, circulating trumor cellIJK2/2, laust kina	-	FERM, 4.1 protein, ezrin, radixin, and moesin
APC, adenomatous polyposis coli       FIH, the factor inhibiting HIP         aPKC, atypical protein kinase C       FRM6, FERM domain-containing protein 6         AQP, aquaporin       GEF, guanine-nucleotide exchange factor         ARHGEF, kho-guanine nucleotide exchange factor       GLUT, glucose transporter         ARNA, AT-rich interactive domain-containing protein 1A       GSK38, glycogen synthase kinase 3β         BMK1/Erk5, big MAP kinase       HCC, hepatocellular carcinoma cell         BNP, bone morphogenic protein       HIF, hypoxia-inducible factor         GAVE, care- associated fibroblast       HIP, hypoxia-inducible factor         CaMK2, Ca <sup>2</sup> /calmodulin-dependent kinase 2       HRR, hypoxia-responsive element         CaMKP, CaMF, phosphatase       INP, integrin-associated protein         CBP, cyclic adenosine monophosphate response element-binding protein       IGF-11 receptor         ICK1, cascin kinase 1       IGF-11 receptor         CLASP1, cyclic adenosine monophosphate response element-binding protein i       IL, interfaren         CREBBP, cyclic adenosine monophosphate response element-binding protein i       IL, interfaren         CREAG, cancer stem cell       IQG AP1, IQ motif-containing GTPase activating protein 1         CLIP, CAPC GLY domain-containing linker protein 1       IL, interfarent         CREBBP, cyclic adenosine monophosphate response element-binding protein 1       ILK, integrin-linked ki	-	FGF, fibroblast growth factor
aPKC, atypical protein kinase CFRM6, FERM domain-containing protein 6AQP, aquaporinGEF, guanine-nucleotide exchange factorARHDIA, AT-rich interactive domain-containing protein 1AGbZ, growth factor receptor-bound protein 2ARIDIA, AT-rich interactive domain-containing protein 1AGSK3β, glycogen synthase kinase 3βBMK1/ErKS, big MAP kinaseHCC, hepatocellular carcinoma cellBMRD, BC12/adenovirus EIB 19 kDa protein interacting proteinHIF, hypoxia-inducible factorGARCS, Ca <sup>2+</sup> /calmodulin-dependent kinase 2HRE, hypoxia-inducible factorCAF, cancer associated fibroblastHRE, hypoxia-responsive clementCAMK2, Ca <sup>2+</sup> /calmodulin-dependent kinase 2IAP, interferonCK1, casein kinase 1IGF-1R, IGF-1 receptorCK2, casein kinase 2IkK6, nuclear factor of karps light polypeptide gene enhancer in B-cells inhibitor. alphaCLMP1, CAP-GLY domain-containing linker protein 1IL, interferonCLBP1, cyclic adenosine monophosphate response element-binding protein 1ILK, integrin-linked kinaseCLASP1, etcplasmic linker associated protein 1ILK, integrin-linked kinaseCLSP1, cancer kinne cell-likeIg2, Jaggd-2CSC, cancer stem cellIg2, Jaggd-1CSC-Like, cancer stem cell-likeIg2, Jaggd-1CSC, crancer stem cell-likeIg2, Jaggd-1CSC, chechange monophosphater seponse element-binding protein-binding protein also named CBBIgX, Janus kinase 2CSC, cancer stem cell-likeIg2, Jaggd-1CSC-Like, cancer stem cell-likeIg2, Jaggd-1CSC, diculating trumor cellIKC, Janus kinase 1/2 </td <td></td> <td>FIH, the factor inhibiting HIF</td>		FIH, the factor inhibiting HIF
AQP, aquporinGEF, guanine-nucleotide exchange factorARHGEF, Rho-guanine nucleotide exchange factorGLUT, glucose transporterARHOIA, AT-rich interactive domain-containing protein 1AGrb2, growth factor receptor-bound protein 2BMK1/Erk5, big MAP kinaseGK35β, glycogen synthase kinase 3βBMP, BC12/adenovirus EIB 19 kDa protein-interacting proteinHIF, bypoxia-inducible factorβPIX, p21-activated protein kinase exchange factor βHIF, hypoxia-inducible factorCAK2, ca*-rassociated fibroblastHRE, hypoxia-inducible factorCaMK2, Ca*/ralmodulin-dependent kinase 2IAP, integrin-associated proteinCaMK42, Ca*/ralmodulin-dependent kinase 2IAP, integrin-associated proteinCaMK42, Ca*/ralmodulin-dependent kinase 2IAP, integrin-associated proteinCK1, casein kinase 1IGF-1R, IGF-1 receptorCK2, casein kinase 1IGF-1R, IGF-1 receptorCLASP1, cyclpasmic linker associated protein 1II, interlevalinCLISP1, cyclpasmic linker associated protein 1II, interlevalinCLSP2, cyclic adenosine monophosphate response element-binding protein-binding protein, also named CBPIBQ2, jagged-2CSC, ike, cancer stem cell-likeJag2, jagged-2CSC, the transcriptional represor CEFI/suppressor of hairless/Lag-1JKC2, Janux kinase 2CTGF, connective tissue growth factorKBPA, kidney and brain eseptesed protein 1DII, pela-like 1LATS1/2, larget umor suppressor kinase 1/2DV1, DishevelledLDHA, lactate dehydrogenase AECG4, epithelial cell transforming sequence 2LOXI, hyv) oxidaseECG5, epithelial cell trans		FRM6, FERM domain-containing protein 6
ARHGEF, Rho-guanine nucleotide exchange factorGLUT, glucose transporterARID1A, AT-rich interactive domain-containing protein 1AGrb2, growth factor receptor-bound protein 2BMK, IL/ErkS, hig MAP kinaseGSK3β, glycogen synthase kinase 3βBMP, bone morphogenic proteinHCC, hepatocellular carcinoma cellBNP, P.(2)-activated protein kinase-exchange factor βHIF, hypoxia-inducible factorCAK2, cac'r (annodulin-dependent kinase 2HRE, hypoxia-responsive elementCAMK2, Ca <sup>+</sup> (calmodulin-dependent kinase 2IAP, integrin-associated proteinCBP, cyclic adenosine monophosphate response element-binding protein, also named CREB-binding protein (CREBBP)IGF-1R, 10F-11 receptorCK1, casein kinase 1IGF-1R, 10F-11 receptorCLAPJ, c, CAP-GLY domain- containing linker protein 1IL, interleukinCLAPJ, c, CAP-GLY domain- containing linker protein 1IL, interleukinCSC, casein sem cellIQGAPI, 1Q motif-containing GTPase activating protein 1CSC, careet sem cell-likeJag2, Jagged-2CSL, the transcriptional repressor CRFI/suppressor of hairless/Lag-1JAK3, Janus kinase 2CTGF, connective tissue growth factorKIBRA, kidney and brain expressed protein 1DIL, Dela-like 4LATS1/2, large tumor suppressor kinase 1/2DVL, DishevelledLDHA, lactate dehydrogenase AECM, extracellular relation matrixLMW-PTP, low molecular weight protein 1/2DIL, Dela-like 4LDXL, LOXLike enzymesENT, epidelial cell transforming sequence 2LOXL, hypy oxidaseENT, epidelial mesnchymal iteractionmAKAP, muscle-selective A-kinase anhoring protein		GEF, guanine-nucleotide exchange factor
ARID1A, AT-rich interactive domain-containing protein 1AGhb2, growth factor receptor-bound protein 2BMK1/Erk5, big MAP kinaseGK3β, glycogen synthase kinase 3βBMP, bone morphogenic proteinHCC, hepatocellular carcinoma cellBNP, BCL2/adenovirus ELB 19 kDa protein-interacting proteinHIF, hypoxia-induclibe factorβPIX, p21-activated protein kinase-exchange factor βHIK, hexokinaseCAF, cancer-associated fibroblastHIF, hypoxia-responsive elementCaMK2, Ca <sup>2+</sup> /calmodulin-dependent kinase 2IAP, integrin-associated proteinCaMK42, Ca <sup>2+</sup> /calmodulin-dependent kinase 2IAP, integrin-associated proteinCRB, casein kinase 1IGF-18, naciln-like growth factor-1CK1, casein kinase 1IGF-18, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alphaCLASP1, cytoplasmic linker associated protein 1ILK, interferonCLASP1, cytoplasmic linker associated protein 1ILK, interferonCLSP1, cacher stem cell-likeJag2, jagged-2CSL, ake named CBPIQGAP1, IQ motif-containing GTPase activating protein 1CSC-clike, cancer stem cell-likeJag2, jagged-2CSL, the transcriptional repressor OF Isuppressor of hairless/Lag-11JaK2, janus kinase 2DTC, circulating tumor cellINK Jun N-terninal kinaseCTGC, connective tissue growth factorLATS1/2, large tumor suppressor kinase 1/2DU1, DiaheelledLDTHA, lactate dehydrogenase AECGP, epithelial cell transforming sequence 2LOX, lyvyl oxidaseECGP, epithelial cell transforming sequence 2LOX, lyvyl oxidaseECGP, epithelial cell tran		GLUT, glucose transporter
BMK1/Erk5, big MAP kinaseGSK3β, glycogen synthase kinase 3βBMP, bone morphogenic proteinHCC, hepatocellular carcinoma cellBNIP, BCL2/adenovirus E1B 19 kDa protein-interacting proteinHIF, hypoxia-inducible factor(PDK, p21-activated protein kinase-exchange factor βHIF, hypoxia-inducible factorCAK2, Ca*7/calmodulin-dependent kinase 2HRE, hypoxia-inducible factorCaMKA2, Ca*7/calmodulin-dependent kinase 2IAP, integrin-associated proteinCaMK4, Caseri kinase 1IGF-1, insulin-like growth factor-1CK1, casein kinase 1IGF-1, insulin-like growth factor-1CLASP1, cyclic adenosine monophosphate response element-binding protein 1ILF, interferonCLASP1, cyclic adenosine monophosphate response element-binding protein in-binding protein, also named CBPIGF-1, insulin-like growth factor-1CLSP1, cAP-GLY domain-containing linker protein 1IL, interleukinCREBBP, cyclic adenosine monophosphate response element-binding protein-binding protein, also named CBPIQGAP1, IQ motif-containing GTPase activating protein 1CLSC-like, cancer stem cellIQGAP1, IQ motif-containing GTPase activating protein 1CSC, cancer stem cell-likeJaZ2, Jagged-2CSC, cancer stem cell-likeIJaZ4, Jaux kinase 2CTGF, connective tissue growth factorKIBRA, kidney and brain expressed protein 1DII, Delta-like 1LATS1/2, large tumor suppressor kinase 1/2DVL, DishevelledLDHA, lactate dehydrogenase AECC, excluating tumor celIDVA, lycly oxidaseFCGF, epidermal growth factor (GCF)LDXL, IOX, like enzymesDNL, Dishevelled		Grb2, growth factor receptor-bound protein 2
BMP, bone morphogenic proteinHCC, hepatocellular carcinoma cellBNIP, BCL2/adenovirus E1B 19 kDa protein-interacting proteinHIF, hypoxia-inducible factorβPIX, p21-activated protein kinase-exchange factor βHIF, hypoxia-inducible factorCAF, cancer-associated fibroblastHIF, hypoxia-responsive elementCaMK2, Ca <sup>2+</sup> /calmodulin-dependent kinase 2IAP, integrin-associated proteinCaMK42, Ca <sup>2+</sup> /calmodulin-dependent kinase 2IAP, integrin-associated proteinCBP, cyclic adenosine monophosphate response element-binding protein, also named CREB-binding protein (CREBBP)IGF-1R, IGF-1 receptorCK1, casein kinase 1IGF-2, inverted formin-2CLASP1, cytoplasmic linker associated protein 1LLK, integrin-linked kinaseCLIP1, CAP-GIY domain-containing linker protein 1LK, integrin-linked kinaseCREBBBP, cyclic adenosine monophosphate response element-binding protein, also named CBPIQGAP1, IQ motif-containing GTPase activating protein 1CLIP1, CAP-GIY domain-containing linker protein 1LK, integrin-linked kinaseCRC2, cancer stem cell-likeIg42, jagged-2CSC-like, cancer stem cell-likeIg42, jagged-2CSC, dicter stem cell-like 1IATS1/2, large tumor suppressor kinase 1/2DII1, Delta-like 1Keap1, kiche-like ECH-associated protein 1DII4, betta-like 4LATS1/2, large tumor suppressor kinase 1/2DVI, joishevelledLDHA, lactate dehytogenase AECM, extracellular matrixLMW-PTP, low molecular weight protein tyrosine phosphataseECM, extracellular matrixLOX, lysi oxidaseECM, epithelial-mesenchymal interaction		<b>GSK3</b> $\beta$ , glycogen synthase kinase 3 $\beta$
BNIP, BCL2/adenovirus E1B 19 kDa protein-interacting proteinHIF, hypoxia-inducible factorβPIX, p21-activated protein kinase-exchange factor βHK, hexokinaseCAF, cancer-associated fibroblastHPH, HIF prolyl hydroxylasesCaMK2, Ca <sup>2+</sup> /calmodulin-dependent kinase 2IAP, integrin-associated proteinCaMKP, caMK phosphataseIAP, integrin-associated proteinCBP, cyclic adenosine monophosphate response element-binding proteinIFN, integrin-associated proteinCK1, casein kinase 1IGF-1, insulin-like growth factor-1CK2, casein kinase 2IrsBa, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alphaCLIP1, CAP-GLY domain-containing linker protein 1LLK, integrin-linked kinaseCSC, caseir stem cellIQGAP1, 1Q motif-containing GTPase activating protein 1CSC, circulating tumor cellJAK2, janged-2CSL, circulating tumor cellJAK2, janged-2CTGF, connective tissue growth factorKBRA, kidhey and brain expressed protein 1DII1, Detta-like 1LATS1/2, large tumor suppressor kinase 1/2DVL, bishevelledLATS1/2, large tumor suppressor kinase 1/2CVL, bishevelledLATS1/2, large tumor suppressor kinase 1/2DVL, bishevelledIOXL, LOX-like enzymesECA, ertracellular matrixLMW-PTP, low molecular weight protein tyrosine phosphataseEC2, epidermal growth factor (EGF)IOXL, LOX-like enzymesEM1, epithelial-mesenchymal interactionMAP4K, mitogen-activated protein kinase kinase<	-	HCC, hepatocellular carcinoma cell
βPIX, p21-activated protein kinase-exchange factor βHK, hesokinaseCAF, cancer-associated fibroblastHPH, HIF prol/hydroxylasesCaMK2, Ca <sup>2*</sup> /calmodulin-dependent kinase 2HRE, hypoxia-responsive elementCaMKP, CaMK phosphataseIAP, integrin-associated proteinCBP, cyclic adenosine monophosphate response element-binding protein binding protein, also named CREB-binding protein (CREBBP)IGF-1 , insulin-like growth factor-1CK1, casein kinase 1IGF-1 , insulin-like growth factor-1CK2, casein kinase 2IkBa, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alphaCL1P1, CAP-GLY domain-containing linker protein 1I.K, integrin-linked kinaseCSC, cascer stem cellIQGAP1, 1Q motif-containing GTPase activating protein 1CSC, circulating tumor cellJag2, Jagged-2CSL, circulating tumor cellJNK, Jun N-terminal kinaseDI1, Delta-like 1Keap1, kelch-like ECH-associated protein 1DI1, Delta-like 1LGT12, largut mor suppressor for factorDI1, Delta-like 1LGT13, largut mor suppressor kinase 1/2DVL, DishevelledLDHA, lactate dehydrogenase AECM, extracellular matrixLMW-PTP, low molecular weight protein tyrosine phosphataseEAG, epithelial-mesenchymal interactionmAKAP, muscle-selective A-kinase anchoring protein		HIF, hypoxia-inducible factor
CAF, cancer-associated fibroblastHPH, HIF prolyl hydroxylasesCaMK2, Ca <sup>3+</sup> /calmodulin-dependent kinase 2HRE, hypoxia-responsive elementCaMKP, CaMK phosphataseIAP, integrin-associated proteinCBP, cyclic adenosine monophosphate response element-binding proteinIFN, instalin-associated proteinbinding protein, also named CREB-binding protein (CREBBP)IGF-1, insulin-like growth factor-1CK1, casein kinase 1IGF-1, k, IGF-1 receptorCK2, casein kinase 2IRBs, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alphaCLISP1, CAP-GLY domain-containing linker protein 1IL, interleukinCREBBP, cyclic adenosine monophosphate response element-binding protein-binding protein, also named CBPIQGAP1, IQ motif-containing GTPase activating protein 1CSC, cancer stem cellIQGAP1, IQ motif-containing GTPase activating protein 1CSC, circulating tumor cellJNK, Jun N-terminal kinaseCTGF, concucitive tissue growth factorKIBRA, kidney and brain expressed protein 1DII, belta-like 1Keap1, kelch-like ECH-associated protein 1DII, belta-like 4LATSI/2, large tumor suppressor kinase 1/2DVL, bishevelledIDHA, lactate dehydrogenase AECM, extracellular matrixLMW-PTP, low molecular weight protein tyrosine phosphataseEct2, epithelial-mesenchymal interactionmAKAP, muscle-selective A-kinase anchoring proteinEMT, epithelial-mesenchymal transitionMAP4K, mitogen-activated protein kinase kinase kinase kinase kinase		HK, hexokinase
CaMK2, Ca <sup>2+</sup> /calmodulin-dependent kinase 2HRE, hypoxia-responsive elementCaMKP, CaMK phosphataseIAP, integrin-associated proteinCBP, cyclic adenosine monophosphate response element-binding proteinIFN, instelfronbinding protein, also named CREB-binding protein (CREBBP)IGF-1, insulin-like growth factor-1CK1, casein kinase 1IGF-1, insulin-like growth factor-1CK2, casein kinase 2IkBa, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alphaCLIASP1, cytoplasmic linker associated protein 1II, interleukinCLIP1, CAP-GLY domain-containing linker protein 1ILK, integrin-linked kinaseCREBBP, cyclic adenosine monophosphate response element-binding protein-binding protein, also named CBPINF-2, inverted formin-2CSC, cancer stem cellIQGAP1, IQ motif-containing GTPase activating protein 1CSC-like, cancer stem cell-likeJag2, Jagged-2CSL, the transcriptional repressor CBF1/suppressor of hairless/Lag-1JAK2, Janus kinase 2CTGF, connective tissue growth factorKIBRA, kidney and brain expressed protein 1DIIL, Delta-like 1Keap1, kelch-like ECH-associated protein 1DIIL, betta-like 4LATSI/2, Jarge tumor suppressor kinase 1/2DVL, bishevelledLDHA, lactat dehydrogenase AECM, extracellular matrixLMW-PTP, low molecular weight protein tyrosine phosphataseEct2, epithelial cell transforming sequence 2LOX1, loX-like enzymesEGF, epidermal growth factor (EGF)LOX1, LOX-like enzymesEMI, epithelial-mesenchymal interactionMAP4K, muisce-selective A-kinase anchoring protein	•	HPH, HIF prolyl hydroxylases
CaMKP, CaMK phosphataseIAP, integrin-associated proteinCBP, cyclic adenosine monophosphate response element-binding protein binding protein, also named CREB-binding protein (CREBBP)IFN, interferonCKI, casein kinase 1IGF-1R, IGF-1 receptorCKZ, casein kinase 2IABG, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alphaCLASP1, cytoplasmic linker associated protein 1IL, interleukinCREBBBP, cyclic adenosine monophosphate response element-binding protein-binding protein, also named CBPIQGAP1, IQ motif-containing GTPase activating protein 1CSC-like, cancer stem cellIQGAP1, IQ motif-containing GTPase activating protein 1CSC-like, cancer stem cell-likeJag2, Jagged-2CSL, the transcriptional repressor CBF1/suppressor of hairless/Lag-1JKX, Jun N-terminal kinaseCTGF, connective tissue growth factorKIBRA, kidney and brain expressed protein 1DII1, Delta-like 1Keap1, Kelch-like ECH-associated protein 1DII2, beta-like 4LATS1/2, large tumor suppressor kinase 1/2DVL, DishevelledLDHA, lactate dehydrogenase AECM, extracellular matrixLMW-PTP, low molecular weight protein tyrosine phosphataseEct2, epithelial cell transforming sequence 2LOX, loX-like enzymesEMI, epithelial-mesenchymal interactionmAKAP, muscle-selective A-kinase anchoring protein		HRE, hypoxia-responsive element
CBP, cyclic adenosine monophosphate response element-binding protein binding protein, also named CREB-binding protein (CREBBP)IFN, interferonCK1, casein kinase 1IGF-1, insulin-like growth factor-1CK2, casein kinase 2IkBa, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alphaCLASP1, cytoplasmic linker associated protein 1IL, interleukinCKEBBP, cyclic adenosine monophosphate response element-binding protein-binding protein, also named CBPIKK, integrin-linked kinaseCSC, cancer stem cellIQGAP1, IQ motif-containing GTPase activating protein 1CSC-like, cancer stem cell-likeJag2, Jagged-2CSL, the transcriptional repressor CBF1/suppressor of hairless/Lag-1JAK2, Janus kinase 2DTL, black-like 4LATS1/2, large tumor suppressor kinase 1/2DV1, black-like 4LATS1/2, large tumor suppressor kinase 1/2DV1, black-like 4LDHA, lactate dehydrogenase AECCM, extracellular matrixLMW-PTP, low molecular weight protein tyrosine phosphataseEK12, epithelial cell transforming sequence 2LOX1, JOX-like enzymesEM1, epithelial-mesenchymal transitionMAP4K, mitogen-activated protein kinase	-	IAP, integrin-associated protein
CK1, casein kinase 1IGF-1R, IGF-1 receptorCK2, casein kinase 2IkBG, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alphaCLASP1, cytoplasmic linker associated protein 1IL, interleukinCLIP1, CAP-GLY domain-containing linker protein 1ILK, integrin-linked kinaseCREBBP, cyclic adenosine monophosphate response element-binding protein-binding protein, also named CBPIQGAP1, IQ motif-containing GTPase activating protein 1CSC, cancer stem cellIQGAP1, IQ motif-containing GTPase activating protein 1CSC-like, cancer stem cellJag2, Jagged-2CSL, ik transcriptional repressor CBF1/suppressor of hairless/Lag-1JaK2, Janus kinase 2CTC, circulating tumor cellJNK, Jun N-terminal kinaseCTGF, connective tissue growth factorKIBRA, kidney and brain expressed protein 1DII, Delta-like 1LATS1/2, large tumor suppressor kinase 1/2DVL, DishevelledLDHA, lactate dehydrogenase AECM, extracellular matrixLMW-PTP, low molecular weight protein tyrosine phosphataseEct2, epithelial cell transforming sequence 2LOX, lysyl oxidaseEMI, epithelial-mesenchymal interactionmAKAP, muscle-selective A-kinase anchoring proteinEMT, epithelial-mesenchymal transitionMAP4K, mitogen-activated protein kinase kinase kinase kinase		IFN, interferon
CK2, casein kinase 2IKBG, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alphaCLASP1, cytoplasmic linker associated protein 1IL, interleukinCLIP1, CAP-GLY domain-containing linker protein 1IL, interleukinCREBBP, cyclic adenosine monophosphate response element-binding protein-binding protein, also named CBPIQGAP1, IQ motif-containing GTPase activating protein 1CSC, cancer stem cellIQGAP1, IQ motif-containing GTPase activating protein 1CSC-like, cancer stem cell-likeJag2, Jagged-2CSL, the transcriptional repressor CBF1/suppressor of hairless/Lag-1JaK2, Janus kinase 2CTC, circulating tumor cellJNK, Jun N-terminal kinaseCTGF, connective tissue growth factorKIBRA, kidney and brain expressed protein 1DI1, Delta-like 1LATS1/2, large tumor suppressor kinase 1/2DVL, DishevelledIDHA, lactate dehydrogenase AECM, extracellular matrixLOX, lysyl oxidaseEct2, epithelial cell transforming sequence 2LOXI, LOX-like enzymesEMI, epithelial-mesenchymal interactionmAKAP, muscle-selective A-kinase anchoring proteinEMT, epithelial-mesenchymal transitionMAP4K, mitogen-activated protein kinase k	binding protein, also named CREB-binding protein (CREBBP)	<b>IGF-1,</b> insulin-like growth factor-1
CLASP1, cytoplasmic linker associated protein 1inhibitor, alphaCLIP1, CAP-GLY domain-containing linker protein 1IL, interleukinCREBBP, cyclic adenosine monophosphate response element-binding protein-binding protein, also named CBPILK, integrin-linked kinaseCSC, cancer stem cellIQGAP1, IQ motif-containing GTPase activating protein 1CSC-like, cancer stem cell-likeJag2, Jagged-2CSL, the transcriptional repressor CBF1/suppressor of hairless/Lag-1JaK2, Janus kinase 2CTC, circulating tumor cellJNK, Jun N-terminal kinaseCTGF, connective tissue growth factorKIBRA, kidney and brain expressed protein 1DII1, Delta-like 1Keap1, Kelch-like ECH-associated protein 1DII4, Delta-like 4LATS1/2, large tumor suppressor kinase 1/2DVL, DishevelledLDHA, lactate dehydrogenase AECCA, extracellular matrixLMW-PTP, low molecular weight protein tyrosine phosphataseECF, epithelial cell transforming sequence 2LOX, lysyl oxidaseEMI, epithelial-mesenchymal interactionmAKAP, muscle-selective A-kinase anchoring proteinEMI, epithelial-mesenchymal transitionMAP4K, mitogen-activated protein kinase kinase kinase kinase kinase	CK1, casein kinase 1	IGF-1R, IGF-1 receptor
CLIP1, CAP-GLY domain-containing linker protein 1IL, interleukinCREBBP, cyclic adenosine monophosphate response element-binding protein-binding protein, also named CBPILK, integrin-linked kinaseCSC, cancer stem cellIQGAP1, 1Q motif-containing GTPase activating protein 1CSC-like, cancer stem cell-likeJag2, Jagged-2CSL, the transcriptional repressor CBF1/suppressor of hairless/Lag-1JaK2, Janus kinase 2CTC, circulating tumor cellJNK, Jun N-terminal kinaseCTGF, connective tissue growth factorKIBRA, kidney and brain expressed protein 1DI1, Delta-like 1Keap1, Kelch-like ECH-associated protein 1DI4, Delta-like 4LATS1/2, large tumor suppressor kinase 1/2DVL, DishevelledLDHA, lactate dehydrogenase AECCM, extracellular matrixLMW-PTP, low molecular weight protein tyrosine phosphataseEcCJ, epithelial cell transforming sequence 2LOXL, LOX-like enzymesEMI, epithelial-mesenchymal interactionmAKAP, muscle-selective A-kinase anchoring proteinEMT, epithelial-mesenchymal transitionMAP4K, mitogen-activated protein function tip motion		
CREBBP, cyclic adenosine monophosphate response element-binding protein-binding protein, also named CBPILK, integrin-linked kinaseCSC, cancer stem cellIQGAP1, IQ motif-containing GTPase activating protein 1CSC, cancer stem cellJag2, Jagged-2CSL, the transcriptional repressor CBF1/suppressor of hairless/Lag-1JaK2, Janus kinase 2CTC, circulating tumor cellJNK, Jun N-terminal kinaseCTGF, connective tissue growth factorKIBRA, kidney and brain expressed protein 1DII1, Delta-like 1Keap1, Kelch-like ECH-associated protein 1DIVL, DishevelledLATS1/2, large tumor suppressor kinase 1/2ECC, extracellular matrixLMW-PTP, low molecular weight protein tyrosine phosphataseEcC2, epithelial cell transforming sequence 2LOX1, loX-like enzymesEGF, epidermal growth factor (EGF)LOXL, LOX-like enzymesEMI, epithelial-mesenchymal interactionmAKAP, muscle-selective A-kinase anchoring protein		
protein-binding protein, also named CBPINF-2, inverted formin-2CSC, cancer stem cellIQGAP1, IQ motif-containing GTPase activating protein 1CSC-like, cancer stem cell-likeJag2, Jagged-2CSL, the transcriptional repressor CBF1/suppressor of hairless/Lag-1JaK2, Janus kinase 2CTC, circulating tumor cellJNK, Jun N-terminal kinaseCTGF, connective tissue growth factorKIBRA, kidney and brain expressed proteinDll1, Delta-like 1Keap1, Kelch-like ECH-associated protein 1Dll4, Delta-like 4LATS1/2, large tumor suppressor kinase 1/2DVL, DishevelledLDHA, lactate dehydrogenase AECCM, extracellular matrixLMW-PTP, low molecular weight protein tyrosine phosphataseEct2, epithelial cell transforming sequence 2LOXI, loX-like enzymesEMI, epithelial-mesenchymal interactionmAKAP, muscle-selective A-kinase anchoring proteinKAP4K, mitogen-activated protein kinase kinase kinase kinaseMAP44K, mitogen-activated protein kinase kinase kinase		ILK, integrin-linked kinase
CSC, cancer stem cellIQGAP1, IQ motif-containing GTPase activating protein 1CSC-like, cancer stem cell-likeJag2, Jagged-2CSL, the transcriptional repressor CBF1/suppressor of hairless/Lag-1JaK2, Janus kinase 2CTC, circulating tumor cellJNK, Jun N-terminal kinaseCTGF, connective tissue growth factorKIBRA, kidney and brain expressed proteinDIl1, Delta-like 1Keap1, Kelch-like ECH-associated protein 1DIl4, Delta-like 4LATS1/2, large tumor suppressor kinase 1/2DVL, DishevelledLDHA, lactate dehydrogenase AECCM, extracellular matrixLOX, lysyl oxidaseEGF, epidermal growth factor (EGF)LOXL, LOX-like enzymesEMI, epithelial-mesenchymal interactionMAP4K, mitogen-activated protein kinase kinase kinase		<b>INF-2,</b> inverted formin-2
CSC-like, cancer stem cell-likeJag2, Jagged-2CSL, the transcriptional repressor CBF1/suppressor of hairless/Lag-1JaK2, Janus kinase 2CTC, circulating tumor cellJNK, Jun N-terminal kinaseCTGF, connective tissue growth factorKIBRA, kidney and brain expressed proteinDIl1, Delta-like 1Keap1, Kelch-like ECH-associated protein 1DIl4, Delta-like 4LATS1/2, large tumor suppressor kinase 1/2DVL, DishevelledLDHA, lactate dehydrogenase AECM, extracellular matrixLMW-PTP, low molecular weight protein tyrosine phosphataseEGF, epidermal growth factor (EGF)LOXL, LOX-like enzymesEMI, epithelial-mesenchymal interactionmAKAP, muscle-selective A-kinase anchoring protein		IQGAP1, IQ motif-containing GTPase activating protein 1
CTC, circulating tumor cellJNK, Jun N-terminal kinaseCTGF, connective tissue growth factorKIBRA, kidney and brain expressed proteinDll1, Delta-like 1Keap1, Kelch-like ECH-associated protein 1Dll4, Delta-like 4LATS1/2, large tumor suppressor kinase 1/2DVL, DishevelledLDHA, lactate dehydrogenase AECM, extracellular matrixLMW-PTP, low molecular weight protein tyrosine phosphataseEct2, epithelial cell transforming sequence 2LOXL, loX, lysyl oxidaseEGF, epidermal growth factor (EGF)LOXL, LOX-like enzymesEMI, epithelial-mesenchymal interactionMAP4K, mitogen-activated protein kinase kinase kinase		Jag2, Jagged-2
CTGF, connective tissue growth factorKIBRA, kidney and brain expressed proteinDll1, Delta-like 1Keap1, Kelch-like ECH-associated protein 1Dll4, Delta-like 4LATS1/2, large tumor suppressor kinase 1/2DVL, DishevelledLDHA, lactate dehydrogenase AECM, extracellular matrixLMW-PTP, low molecular weight protein tyrosine phosphataseEct2, epithelial cell transforming sequence 2LOX, lysyl oxidaseEGF, epidermal growth factor (EGF)LOXL, LOX-like enzymesEMI, epithelial-mesenchymal interactionMAP4K, mitogen-activated protein kinase kinase kinase	CSL, the transcriptional repressor CBF1/suppressor of hairless/Lag-1	<b>JaK2,</b> Janus kinase 2
Dill1, Delta-like 1Keap1, Kelch-like ECH-associated protein 1Dill4, Delta-like 4LATS1/2, large tumor suppressor kinase 1/2DVL, DishevelledLDHA, lactate dehydrogenase AECM, extracellular matrixLMW-PTP, low molecular weight protein tyrosine phosphataseEct2, epithelial cell transforming sequence 2LOX, lysyl oxidaseEGF, epidermal growth factor (EGF)LOXL, LOX-like enzymesEMI, epithelial-mesenchymal interactionmAKAP, muscle-selective A-kinase anchoring proteinEMT, epithelial-mesenchymal transitionMAP4K, mitogen-activated protein kinase kinase kinase	CTC, circulating tumor cell	<b>JNK,</b> Jun N-terminal kinase
Dil4, Delta-like 4LATS1/2, large tumor suppressor kinase 1/2DVL, DishevelledLDHA, lactate dehydrogenase AECM, extracellular matrixLMW-PTP, low molecular weight protein tyrosine phosphataseEct2, epithelial cell transforming sequence 2LOX, lysyl oxidaseEGF, epidermal growth factor (EGF)LOXL, LOX-like enzymesEMI, epithelial-mesenchymal interactionmAKAP, muscle-selective A-kinase anchoring proteinEMT, epithelial-mesenchymal transitionMAP4K, mitogen-activated protein kinase kinase kinase	CTGF, connective tissue growth factor	KIBRA, kidney and brain expressed protein
DVL, DishevelledLDHA, lactate dehydrogenase AECM, extracellular matrixLMW-PTP, low molecular weight protein tyrosine phosphataseEct2, epithelial cell transforming sequence 2LOX, lysyl oxidaseEGF, epidermal growth factor (EGF)LOXL, LOX-like enzymesEMI, epithelial-mesenchymal interactionmAKAP, muscle-selective A-kinase anchoring proteinEMT, epithelial-mesenchymal transitionMAP4K, mitogen-activated protein kinase kinase kinase	Dll1, Delta-like 1	Keap1, Kelch-like ECH-associated protein 1
ECM, extracellular matrixLMW-PTP, low molecular weight protein tyrosine phosphataseEct2, epithelial cell transforming sequence 2LOX, lysyl oxidaseEGF, epidermal growth factor (EGF)LOXL, LOX-like enzymesEMI, epithelial-mesenchymal interactionmAKAP, muscle-selective A-kinase anchoring proteinEMT, epithelial-mesenchymal transitionMAP4K, mitogen-activated protein kinase kinase kinase	Dll4, Delta-like 4	LATS1/2, large tumor suppressor kinase 1/2
Ect2, epithelial cell transforming sequence 2LOX, lysyl oxidaseEGF, epidermal growth factor (EGF)LOXL, LOX-like enzymesEMI, epithelial-mesenchymal interactionmAKAP, muscle-selective A-kinase anchoring proteinEMT, epithelial-mesenchymal transitionMAP4K, mitogen-activated protein kinase kinase kinase	DVL, Dishevelled	LDHA, lactate dehydrogenase A
EGF, epidermal growth factor (EGF)LOXL, LOX-like enzymesEMI, epithelial-mesenchymal interactionmAKAP, muscle-selective A-kinase anchoring proteinEMT, epithelial-mesenchymal transitionMAP4K, mitogen-activated protein kinase kinase kinase	ECM, extracellular matrix	LMW-PTP, low molecular weight protein tyrosine phosphatase
EMI, epithelial-mesenchymal interactionmAKAP, muscle-selective A-kinase anchoring proteinEMT, epithelial-mesenchymal transitionMAP4K, mitogen-activated protein kinase kinase kinase	Ect2, epithelial cell transforming sequence 2	LOX, lysyl oxidase
EMT, epithelial-mesenchymal transition MAP4K, mitogen-activated protein kinase kinase kinase	EGF, epidermal growth factor (EGF)	LOXL, LOX-like enzymes
	EMI, epithelial-mesenchymal interaction	mAKAP, muscle-selective A-kinase anchoring protein
ENaC, epithelial sodium channels MAPK, mitogen-activated protein kinase	EMT, epithelial-mesenchymal transition	MAP4K, mitogen-activated protein kinase kinase kinase kinase
	ENaC, epithelial sodium channels	MAPK, mitogen-activated protein kinase

MDSC, myeloid-derived suppressor cell Merlin, moesin/ezrin/radixin-like protein Mito, mitochondria MLC, myosin light chain MOB1, Mps one binder (MOB) kinase activator-like 1 MSC, mesenchymal stem cell MST1/2, mammalian Ste20-like protein kinase 1/2 MVB, multi-vesicular body MYPT1, myosin phosphatase target subunit 1 NAD<sup>+</sup>, nicotinamide adenine dinucleotide **NADP<sup>+</sup>**, nicotinamide adenine dinucleotide phosphate NADPH, the reduced form of nicotinamide adenine dinucleotide phosphate NCX, sodium-calcium exchanger NEDD4, neural precursor cell expressed developmentally downregulated protein 4 NES, nuclear export signal NF2, neurofibromatosis type 2 NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells NICD, Notch intracellular domain NLK, Nemo-like kinase NLS, nuclear localization signal NOS, nitric oxide synthase NOX, NADPH oxidases Nrf2, nuclear factor erythroid-derived 2-related factor 2 NRX, nucleoredoxin NSCLC, non-small cell lung cancer p300, E1A binding protein p300 **PA**, phosphatidic acid PAK, P21-activated protein kinase PALS1, protein associated with Caenorhabditis elegans Lin-7 protein 1 PAR3, partition-defective 3 **PAR6** $\beta$ , partition-defective 6 $\beta$ PATJ, PALS1-associated tight junction protein PD-1, programmed death-1 PDE, phosphodiesterase PDGF, platelet-derived growth factor PDK, pyruvate dehydrogenase kinase (PDK) PD-L1, programmed death ligand-1 PDZ, Post-synaptic density 95, Discs large, and Zonula occludens-1 PHD prolyl hydroxylase domain-containing proteins PID, protein interaction domain PI3K, phosphatidyl-inositol-3-kinase PIP<sub>2</sub>, phosphatidylinositol (4,5)-bisphosphate

PIP<sub>3</sub>, phosphatidylinositol (3,4,5)-trisphosphate PIX, p21-activated protein kinase exchange factor **PKA**, cAMP-dependent protein kinase PKB, protein kinase B PKC, protein kinase C PKG, cGMP-dependent protein kinase PKM2, pyruvate kinase isozymes M2 **Poldip2**, polymerase  $\delta$ -interacting protein 2 POPX2, partner of PIX 2, also known as protein phosphatase 2C-like domain-containing metal-dependent protein phosphatase (PPM), PPM1F, or CaMK phosphatase (CaMKP) PP2AC, PP2A catalytic subunit PPM, protein phosphatase 2C-like domain-containing metal-dependent protein phosphatase **PPM1A**, protein phosphatase, Mg<sup>2+</sup>/Mn<sup>2+</sup>-dependent 1A **PPM1F**, protein phosphatase, Mg<sup>2+</sup>/Mn<sup>2+</sup>-dependent 1F PPP, protein serine/threonine phosphatases PTEN, phosphatase and tensin homolog PTK protein tyrosine kinase PTM, post-translational modification PTP, protein tyrosine phosphatases PTPN14, protein tyrosine phosphatase non-receptor type 14 PX, pbox consensus sequence **Pyk2**, proline-rich tyrosine kinase 2 Rac1, Ras-related C3 botulinum toxin substrate 1 RASSF, Ras-association domain family **RBPJ**, recombination signal-binding protein for immunoglobulin KJ region **Ref-1**, redox factor-1 RhoA, Ras homolog family member A ROCK, Rho-associated protein kinase RyR, ryanodine receptor SARAH, SAV/RASSF/HPO SAV1, Salvador family WW domain-containing protein 1 SCF, Skp1-Cullin-1-F-box protein  $SCF^{\beta\text{-}TrCP}$  , SCF type of E3 ubiquitin ligase SCLC, small cell lung cancer SH2, Src homology 2 SHP, SH2 domain-containing protein tyrosine phosphatase SHPS-1, SHP substrate-1 SIAH1/2, seven in absentia homolog 1/2 SLMAP, sarcolemmal membrane-associated protein Smad3, mothers against decapentaplegic homolog 3 SNF, sucrose non-fermentable

SR, sarcoplasmic reticulum

Src, steroid receptor coactivator	TME, tumor microenvironment
SrcFK, Src family kinase	TNF, tumor necrosis factor
STAT3, signal transducer and activator of transcription 3	TRAF4, TNF receptor-associated factor 4
STK25, serine/threonine kinase 25	
STRIP1/2, STRN-interacting protein 1/2	TRP, transient receptor potential
STRIPAK, STRN-interacting phosphatase and kinase	<b>VEGF,</b> vascular EGF
STRN, striatin	VEGFR, VEGF receptor
SWH, Salvador-Warts-Hippo	VHL, von Hippel-Lindau tumor suppressor protein E3 ubiquitin ligase
SWI, switch	WASP, Wiskott-Aldrich syndrome protein
TAZ, transcriptional coactivator with PDZ-binding motif	
TE, trophectoderm	WAVE1, WASP family verprolin homologous protein 1
TEAD, the transcriptional enhancer factor TEF-1, TEC1, and AbaA (TEA)	WWC, WW domain and C2 domain-containing protein
domain	<b>WWTR1,</b> WW domain-containing transcription regulator 1
<b>TGF</b> $\beta$ , transforming growth factor- $\beta$	X-ROS, NOX-derived ROS
$TGF\beta R$ , transforming growth factor- $\beta$ receptor	YAP, Yes-associated protein
TJ, tight junction	${\bf Yes},~{\rm Src}$ family, non-receptor proto-oncogene tyrosine-protein kinase.

43